Antigen binding protein that binds BCMA

By developing whole-human anti-BCMA antibodies or antigen binding fragments with specific amino acid sequences, the treatment problem of BCMA overexpression in multiple myeloma was solved, and efficient binding and inhibition of BCMA protein was achieved, which significantly improved the therapeutic effect.

CN113874082BInactive Publication Date: 2024-12-06SORRENTO THERAPEUTICS INC
View PDF 19 Cites 0 Cited by

Patent Information

Application Number
CN202080031584.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2019-02-27
Filing Date
2020-02-25
Publication Date
2024-12-06
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Existing treatments for multiple myeloma (MM) are difficult to effectively target and inhibit cells with overexpression of BCMA, resulting in poor treatment effects.

Method used

A whole-human anti-BCMA antibody or antigen-binding fragment thereof has been developed, containing a specific amino acid sequence, capable of efficiently binding to BCMA protein and blocking the binding of APRIL to BCMA for the treatment of multiple myeloma.

Benefits of technology

This antibody can efficiently bind BCMA protein, inhibit its expression, and significantly reduce the growth and proliferation of multiple myeloma cells, providing a new effective method for the treatment of multiple myeloma.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN113874082B_ABST
    Figure CN113874082B_ABST
Patent Text Reader

Abstract

The present disclosure provides BCMA binding proteins that specifically bind to BCMA, in particular anti-BCMA antibodies or antigen binding portions thereof, and uses thereof. In one embodiment, the anti-BCMA antibody comprises an antigen binding portion that binds to a human BCMA epitope and blocks the binding of human APRIL and / or human BAFF to a human BCMA epitope (e.g., inhibits binding). Various aspects of anti-BCMA antibodies relate to antibody fragments, single-chain antibodies, pharmaceutical compositions, nucleic acids, recombinant expression vectors, host cells, and methods for preparing and using such anti-BCMA antibodies. Methods of using anti-BCMA antibodies include in vitro and in vivo methods for binding to BCMA, detecting BCMA, and treating diseases associated with BCMA overexpression.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims priority under 35 U.S.C. §119 to U.S. Provisional Application No. 62 / 810,771, filed on February 26, 2019, and U.S. Provisional Application No. 62 / 811,431, filed on February 27, 2019. The disclosures of all of the above applications are incorporated by reference in their entirety.

[0003] Throughout this application, various publications, patents and / or patent applications are cited. The disclosures of the publications, patents and / or patent applications are hereby incorporated into this application by reference in their entirety to more fully describe the current state of the art to which the present disclosure relates. Technical Field

[0004] The present disclosure provides an antigen-binding protein that specifically binds to B-cell maturation antigen (BCMA), a nucleic acid encoding the antigen-binding protein, a vector comprising the nucleic acid, a host cell carrying the vector, and methods of using the same. Background Art

[0005] B cell maturation antigen (BCMA), also known as TNFRSF17 and CD269 (UniProt Q02223), is a member of the tumor necrosis receptor superfamily. BCMA is a non-glycosylated type III transmembrane protein expressed on differentiated plasma cells (Laabi et al., 1992 The EMBO Journal 11 (11): 3897-3904; Laabi et al., 1994 Nucleic Acids Research 22 (7): 1147-1154; Madry et al., 1998 International Immunology 10 (11): 1693-1702), and is a cell surface receptor involved in B cell development and survival.

[0006] BCMA is one of the two ligands of TNF superfamily, APRIL (proliferation-inducing ligand, A PR oliferation- I nducing LAPRIL and BAFF are cell surface receptors for BCMA, BCMA-ligand, and BAFF. APRIL and BAFF are high-affinity and low-affinity ligands for BCMA, respectively. APRIL is a proliferation-inducing ligand and BAFF is a B lymphocyte stimulator. TACI is a negative regulator that binds APRIL and BAFF. The synergistic binding of APRIL and BAFF with BCMA and / or TACI induces the transcription of the factor NF-κB, increases the expression of pro-survival Bcl-2 family members, and downregulates the expression of pro-apoptotic factors, thereby promoting survival and inhibiting apoptosis. This complex interaction promotes B cell differentiation, proliferation, survival, and antibody production (Rickert 2011 Immunology Review 244(1):115-133). BCMA is known to support the growth and survival of malignant human B cells, and it has been reported that BCMA and TACI are upregulated in malignant human B cells, including multiple myeloma (MM) cells (see Mackay et al., "BAFF and APRIL: a tutorial on B cell survival", 2004 Annual Review Immunology 21: 231-264). In addition, BCMA, APRIL and BAFF signaling have been reported to activate NFκB in B cell tumors and multiple myeloma.

[0007] Multiple myeloma is a clonal B-cell lymphoma that arises in multiple sites of the bone marrow and then spreads through the circulation. BCMA is expressed at significantly higher levels in multiple myeloma cells than in normal tissues, making BCMA a good target antigen for immunotherapy. Therefore, BCMA is an attractive antibody-targeted antigen. The present disclosure provides BCMA-binding proteins that specifically bind to BCMA, particularly anti-BCMA antibodies or antigen-binding portions thereof, and uses thereof. Summary of the invention

[0008] The present disclosure provides a fully human anti-BCMA antibody or an antigen-binding fragment thereof, which comprises a heavy chain and a light chain, wherein (a) the heavy chain comprises: a heavy chain complementary determining region 1 (CDR1) having an amino acid sequence of SEQ ID NO: 29, a heavy chain CDR2 having an amino acid sequence of SEQ ID NO: 30, and a heavy chain CDR3 having an amino acid sequence of SEQ ID NO: 31; and the light chain comprises: a light chain CDR1 having an amino acid sequence of SEQ ID NO: 32, a light chain CDR2 having an amino acid sequence of SEQ ID NO: 33, and a light chain CDR3 having an amino acid sequence of SEQ ID NO: 34; wherein (b) the heavy chain comprises: a heavy chain CDR1 having an amino acid sequence of SEQ ID NO: 35, a heavy chain CDR2 having an amino acid sequence of SEQ ID NO: 36, and a heavy chain CDR3 having an amino acid sequence of SEQ ID NO: 37; and the light chain comprises: a light chain CDR1 having an amino acid sequence of SEQ ID NO: 38, a light chain CDR2 having an amino acid sequence of SEQ ID NO: 39, and a light chain CDR3 having an amino acid sequence of SEQ ID NO: wherein (c) the heavy chain comprises: a heavy chain CDR1 having an amino acid sequence of SEQ ID NO:41, a heavy chain CDR2 having an amino acid sequence of SEQ ID NO:42, a heavy chain CDR3 having an amino acid sequence of SEQ ID NO:43; and the light chain comprises: a light chain CDR1 having an amino acid sequence of SEQ ID NO:44, a light chain CDR2 having an amino acid sequence of SEQ ID NO:45, and a light chain CDR3 having an amino acid sequence of SEQ ID NO:46; wherein (d) the heavy chain comprises: a heavy chain CDR1 having an amino acid sequence of SEQ ID NO:47, a heavy chain CDR2 having an amino acid sequence of SEQ ID NO:48, a heavy chain CDR3 having an amino acid sequence of SEQ ID NO:49; and the light chain comprises: a light chain CDR1 having an amino acid sequence of SEQ ID NO:50, a light chain CDR2 having an amino acid sequence of SEQ ID NO:51, and a light chain CDR3 having an amino acid sequence of SEQ ID NO:52. NO:52; wherein (e) the heavy chain comprises: a heavy chain CDR1 having an amino acid sequence of SEQ ID NO:53, a heavy chain CDR2 having an amino acid sequence of SEQ ID NO:54, and a heavy chain CDR3 having an amino acid sequence of SEQ ID NO:55; and the light chain comprises: a light chain CDR1 having an amino acid sequence of SEQ ID NO:56, a light chain CDR2 having an amino acid sequence of SEQ ID NO:57, and a light chain CDR3 having an amino acid sequence of SEQ ID NO:58;wherein (f) the heavy chain comprises: a heavy chain CDR1 having an amino acid sequence of SEQ ID NO: 59, a heavy chain CDR2 having an amino acid sequence of SEQ ID NO: 60, and a heavy chain CDR3 having an amino acid sequence of SEQ ID NO: 61; and the light chain comprises: a light chain CDR1 having an amino acid sequence of SEQ ID NO: 62, a light chain CDR2 having an amino acid sequence of SEQ ID NO: 63, and a light chain CDR3 having an amino acid sequence of SEQ ID NO: 64; wherein (g) the heavy chain comprises: a heavy chain CDR1 having an amino acid sequence of SEQ ID NO: 65, a heavy chain CDR2 having an amino acid sequence of SEQ ID NO: 66, and a heavy chain CDR3 having an amino acid sequence of SEQ ID NO: 67; and the light chain comprises: a light chain CDR1 having an amino acid sequence of SEQ ID NO: 68, a light chain CDR2 having an amino acid sequence of SEQ ID NO: 69, and a light chain CDR3 having an amino acid sequence of SEQ ID NO: 70; wherein (h) the heavy chain comprises: a light chain CDR1 having an amino acid sequence of SEQ ID NO: 69, and a light chain CDR3 having an amino acid sequence of SEQ ID NO: 71. NO:71, a heavy chain CDR1 having an amino acid sequence of SEQ ID NO:72, a heavy chain CDR3 having an amino acid sequence of SEQ ID NO:73; and the light chain comprises: a light chain CDR1 having an amino acid sequence of SEQ ID NO:74, a light chain CDR2 having an amino acid sequence of SEQ ID NO:75, and a light chain CDR3 having an amino acid sequence of SEQ ID NO:76; wherein (i) the heavy chain comprises: a heavy chain CDR1 having an amino acid sequence of SEQ ID NO:77, a heavy chain CDR2 having an amino acid sequence of SEQ ID NO:78, and a heavy chain CDR3 having an amino acid sequence of SEQ ID NO:79; and the light chain comprises: a light chain CDR1 having an amino acid sequence of SEQ ID NO:80, a light chain CDR2 having an amino acid sequence of SEQ ID NO:81, and a light chain CDR3 having an amino acid sequence of SEQ ID NO:82; wherein (j) the heavy chain comprises: a light chain CDR1 having an amino acid sequence of SEQ ID NO:82 NO:83, a heavy chain CDR1 having an amino acid sequence of SEQ ID NO:84, a heavy chain CDR2 having an amino acid sequence of SEQ ID NO:85, and a heavy chain CDR3 having an amino acid sequence of SEQ ID NO:86; and the light chain comprises: a light chain CDR1 having an amino acid sequence of SEQ ID NO:87, a light chain CDR2 having an amino acid sequence of SEQ ID NO:88, and a light chain CDR3 having an amino acid sequence of SEQ ID NO:89;or wherein (k) the heavy chain comprises: a heavy chain CDR1 having an amino acid sequence of SEQ ID NO: 53, a heavy chain CDR2 having an amino acid sequence of SEQ ID NO: 54, a heavy chain CDR3 having an amino acid sequence of SEQ ID NO: 55; and the light chain comprises: a lambda light chain CDR1 having an amino acid sequence of SEQ ID NO: 89, a lambda light chain CDR2 having an amino acid sequence of SEQ ID NO: 90, and a lambda light chain CDR3 having an amino acid sequence of SEQ ID NO: 91. ;

[0009] The present disclosure provides a fully human anti-BCMA antibody or an antigen-binding fragment thereof, comprising a heavy chain and a light chain, wherein the heavy chain comprises a heavy chain variable region having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 8, 10, 12, 14 or 22; and the light chain comprises a light chain variable region having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 9, 11, 13, 15, 16, 17, 18, 19, 20, 21 or 23.

[0010] The present disclosure provides a fully human anti-BCMA antibody or an antigen-binding fragment thereof, comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region and the light chain variable region comprise SEQ ID NOs: 8 and 9 (e.g., referred to herein as BCA7); SEQ ID NOs: 10 and 11 (e.g., referred to herein as BC4C9); SEQ ID NOs: 12 and 13 (e.g., referred to herein as CD5C4); SEQ ID NOs: 14 and 15 (e.g., referred to herein as BC6G8); SEQ ID NOs: 8 and 16 (e.g., referred to herein as BCA7-2C5); SEQ ID NOs: 8 and 17 (e.g., referred to herein as BCA7-2E1); SEQ ID NOs: 8 and 18 (e.g., referred to herein as BCA7-2D11); SEQ ID NOs: 8 and 19 (e.g., referred to herein as BCA7-2G2); SEQ ID NOs: 8 and 20 (e.g., referred to herein as BCA7-2D8); SEQ ID NOs: 8 and 21 (e.g., referred to herein as BCA7-2C5); or SEQ ID NOs: 8 and 21 (eg, referred to herein as BCA7-2E8); or SEQ ID NOs: 22 and 23 (eg, referred to herein as BCA7-2C5 with a lambda light chain).

[0011] The present disclosure provides a fully human anti-BCMA antibody or an antigen-binding fragment thereof, wherein the antigen-binding fragment is a Fab fragment, which comprises a variable domain region from a heavy chain and a variable domain region from a light chain, wherein (a) the variable domain region from the heavy chain comprises: a heavy chain complementary determining region 1 (CDR1) having an amino acid sequence of SEQ ID NO: 29, a heavy chain CDR2 having an amino acid sequence of SEQ ID NO: 30, and a heavy chain CDR3 having an amino acid sequence of SEQ ID NO: 31; and the variable domain region from the light chain comprises: a light chain CDR1 having an amino acid sequence of SEQ ID NO: 32, a light chain CDR2 having an amino acid sequence of SEQ ID NO: 33, and a light chain CDR3 having an amino acid sequence of SEQ ID NO: 34; wherein (b) the variable domain region from the heavy chain comprises: a heavy chain CDR1 having an amino acid sequence of SEQ ID NO: 35, a heavy chain CDR2 having an amino acid sequence of SEQ ID NO: 36, and a light chain CDR3 having an amino acid sequence of SEQ ID NO: 37. NO:37; and the variable domain region from the light chain comprises: a light chain CDR1 having an amino acid sequence of SEQ ID NO:38, a light chain CDR2 having an amino acid sequence of SEQ ID NO:39, and a light chain CDR3 having an amino acid sequence of SEQ ID NO:40; wherein (c) the variable domain region from the heavy chain comprises: a heavy chain CDR1 having an amino acid sequence of SEQ ID NO:41, a heavy chain CDR2 having an amino acid sequence of SEQ ID NO:42, and a heavy chain CDR3 having an amino acid sequence of SEQ ID NO:43; and the variable domain region from the light chain comprises: a light chain CDR1 having an amino acid sequence of SEQ ID NO:44, a light chain CDR2 having an amino acid sequence of SEQ ID NO:45, and a light chain CDR3 having an amino acid sequence of SEQ ID NO:46; wherein (d) the variable domain region from the heavy chain comprises: a heavy chain CDR1 having an amino acid sequence of SEQ ID NO:47, a heavy chain CDR2 having an amino acid sequence of SEQ ID NO:48, and a light chain CDR3 having an amino acid sequence of SEQ ID NO:49. NO:48, a heavy chain CDR2 having an amino acid sequence of SEQ ID NO:49, a heavy chain CDR3 having an amino acid sequence of SEQ ID NO:49; and the variable domain region from the light chain comprises: a light chain CDR1 having an amino acid sequence of SEQ ID NO:50, a light chain CDR2 having an amino acid sequence of SEQ ID NO:51, and a light chain CDR3 having an amino acid sequence of SEQ ID NO:52; wherein (e) the variable domain region from the heavy chain comprises: a heavy chain CDR1 having an amino acid sequence of SEQ ID NO:53, a heavy chain CDR2 having an amino acid sequence of SEQ ID NO:54, and a heavy chain CDR3 having an amino acid sequence of SEQ ID NO:55;and the variable domain region from the light chain comprises: a light chain CDR1 having an amino acid sequence of SEQ ID NO: 56, a light chain CDR2 having an amino acid sequence of SEQ ID NO: 57, and a light chain CDR3 having an amino acid sequence of SEQ ID NO: 58; wherein (f) the variable domain region from the heavy chain comprises: a heavy chain CDR1 having an amino acid sequence of SEQ ID NO: 59, a heavy chain CDR2 having an amino acid sequence of SEQ ID NO: 60, and a heavy chain CDR3 having an amino acid sequence of SEQ ID NO: 61; and the variable domain region from the light chain comprises: a light chain CDR1 having an amino acid sequence of SEQ ID NO: 62, a light chain CDR2 having an amino acid sequence of SEQ ID NO: 63, and a light chain CDR3 having an amino acid sequence of SEQ ID NO: 64; wherein (g) the variable domain region from the heavy chain comprises: a heavy chain CDR1 having an amino acid sequence of SEQ ID NO: 65, a heavy chain CDR2 having an amino acid sequence of SEQ ID NO: 66, and a light chain CDR3 having an amino acid sequence of SEQ ID NO: NO:67; and the variable domain region from the light chain comprises: a light chain CDR1 having an amino acid sequence of SEQ ID NO:68, a light chain CDR2 having an amino acid sequence of SEQ ID NO:69, and a light chain CDR3 having an amino acid sequence of SEQ ID NO:70; wherein (h) the variable domain region from the heavy chain comprises: a heavy chain CDR1 having an amino acid sequence of SEQ ID NO:71, a heavy chain CDR2 having an amino acid sequence of SEQ ID NO:72, and a heavy chain CDR3 having an amino acid sequence of SEQ ID NO:73; and the variable domain region from the light chain comprises: a light chain CDR1 having an amino acid sequence of SEQ ID NO:74, a light chain CDR2 having an amino acid sequence of SEQ ID NO:75, and a light chain CDR3 having an amino acid sequence of SEQ ID NO:76; wherein (i) the variable domain region from the heavy chain comprises: a heavy chain CDR1 having an amino acid sequence of SEQ ID NO:77, a heavy chain CDR2 having an amino acid sequence of SEQ ID NO:78, and a light chain CDR3 having an amino acid sequence of SEQ ID NO:79. NO:78, a heavy chain CDR2 having an amino acid sequence of SEQ ID NO:79, and a heavy chain CDR3 having an amino acid sequence of SEQ ID NO:79; and the variable domain region from the light chain comprises: a light chain CDR1 having an amino acid sequence of SEQ ID NO:80, a light chain CDR2 having an amino acid sequence of SEQ ID NO:81, and a light chain CDR3 having an amino acid sequence of SEQ ID NO:82;wherein (j) the variable domain region from the heavy chain comprises: a heavy chain CDR1 having an amino acid sequence of SEQ ID NO: 83, a heavy chain CDR2 having an amino acid sequence of SEQ ID NO: 84, a heavy chain CDR3 having an amino acid sequence of SEQ ID NO: 85; and the variable domain region from the light chain comprises: a light chain CDR1 having an amino acid sequence of SEQ ID NO: 86, a light chain CDR2 having an amino acid sequence of SEQ ID NO: 87, and a light chain CDR3 having an amino acid sequence of SEQ ID NO: 88; or wherein (k) the variable domain region from the heavy chain comprises: a heavy chain CDR1 having an amino acid sequence of SEQ ID NO: 53, a heavy chain CDR2 having an amino acid sequence of SEQ ID NO: 54, a heavy chain CDR3 having an amino acid sequence of SEQ ID NO: 55; and the variable domain region from the light chain comprises: a lambda light chain CDR1 having an amino acid sequence of SEQ ID NO: 89, a lambda light chain CDR2 having an amino acid sequence of SEQ ID NO: 90, and a light chain CDR3 having an amino acid sequence of SEQ ID NO: λ light chain CDR3 of the amino acid sequence of NO:91.;

[0012] The present disclosure provides a fully human anti-BCMA antibody or an antigen-binding fragment thereof, wherein the antigen-binding fragment is a Fab fragment comprising a variable domain region from a heavy chain and a variable domain region from a light chain, wherein the variable domain region from the heavy chain comprises a sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 8, 10, 12, 14 or 22, and wherein the variable domain region from the light chain comprises a sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 9, 11, 13, 15, 16, 17, 18, 19, 20, 21 or 23.

[0013] The present disclosure provides a fully human anti-BCMA antibody or an antigen-binding fragment thereof, wherein the antigen-binding fragment is a Fab fragment comprising a variable domain region from a heavy chain and a variable domain region from a light chain, wherein the variable domain region from the heavy chain and the variable domain region from the light chain are SEQ ID NOs: 8 and 9 (e.g., referred to herein as BCA7); SEQ ID NOs: 10 and 11 (e.g., referred to herein as BC4C9); SEQ ID NOs: 12 and 13 (e.g., referred to herein as CD5C4); SEQ ID NOs: 14 and 15 (e.g., referred to herein as BC6G8); SEQ ID NOs: 8 and 16 (e.g., referred to herein as BCA7-2C5); SEQ ID NOs: 8 and 17 (e.g., referred to herein as BCA7-2E1); SEQ ID NOs: 8 and 18 (e.g., referred to herein as BCA7-2D11); SEQ ID NOs: 8 and 19 (e.g., referred to herein as BCA7-2G2); SEQ ID NOs: 10 and 11 (e.g., referred to herein as BC4C9); SEQ ID NOs: 12 and 13 (e.g., referred to herein as CD5C4); SEQ ID NOs: 14 and 15 (e.g., referred to herein as BC6G8); SEQ ID NOs: 8 and 20 (eg, referred to herein as BCA7-2D8); SEQ ID NOs: 8 and 21 (eg, referred to herein as BCA7-2E8); or SEQ ID NOs: 22 and 23 (eg, referred to herein as BCA7-2C5 with a lambda light chain).

[0014] The present disclosure provides a fully human anti-BCMA antibody or an antigen-binding fragment thereof, wherein the antigen-binding fragment is a single-chain antibody, which comprises a variable domain region from a heavy chain and a variable domain region from a light chain connected together by a peptide linker, wherein (a) the variable domain region from the heavy chain comprises: a heavy chain complementary determining region 1 (CDR1) having an amino acid sequence of SEQ ID NO: 29, a heavy chain CDR2 having an amino acid sequence of SEQ ID NO: 30, and a heavy chain CDR3 having an amino acid sequence of SEQ ID NO: 31; and the variable domain region from the light chain comprises: a light chain CDR1 having an amino acid sequence of SEQ ID NO: 32, a light chain CDR2 having an amino acid sequence of SEQ ID NO: 33, and a light chain CDR3 having an amino acid sequence of SEQ ID NO: 34; wherein (b) the variable domain region from the heavy chain comprises: a heavy chain CDR1 having an amino acid sequence of SEQ ID NO: 35, a heavy chain CDR2 having an amino acid sequence of SEQ ID NO: 36, and a light chain CDR3 having an amino acid sequence of SEQ ID NO: 37. NO:37; and the variable domain region from the light chain comprises: a light chain CDR1 having an amino acid sequence of SEQ ID NO:38, a light chain CDR2 having an amino acid sequence of SEQ ID NO:39, and a light chain CDR3 having an amino acid sequence of SEQ ID NO:40; wherein (c) the variable domain region from the heavy chain comprises: a heavy chain CDR1 having an amino acid sequence of SEQ ID NO:41, a heavy chain CDR2 having an amino acid sequence of SEQ ID NO:42, and a heavy chain CDR3 having an amino acid sequence of SEQ ID NO:43; and the variable domain region from the light chain comprises: a light chain CDR1 having an amino acid sequence of SEQ ID NO:44, a light chain CDR2 having an amino acid sequence of SEQ ID NO:45, and a light chain CDR3 having an amino acid sequence of SEQ ID NO:46; wherein (d) the variable domain region from the heavy chain comprises: a heavy chain CDR1 having an amino acid sequence of SEQ ID NO:47, a heavy chain CDR2 having an amino acid sequence of SEQ ID NO:48, and a light chain CDR3 having an amino acid sequence of SEQ ID NO:49. NO:48, a heavy chain CDR2 having an amino acid sequence of SEQ ID NO:49, a heavy chain CDR3 having an amino acid sequence of SEQ ID NO:49; and the variable domain region from the light chain comprises: a light chain CDR1 having an amino acid sequence of SEQ ID NO:50, a light chain CDR2 having an amino acid sequence of SEQ ID NO:51, and a light chain CDR3 having an amino acid sequence of SEQ ID NO:52; wherein (e) the variable domain region from the heavy chain comprises: a heavy chain CDR1 having an amino acid sequence of SEQ ID NO:53, a heavy chain CDR2 having an amino acid sequence of SEQ ID NO:54, and a heavy chain CDR3 having an amino acid sequence of SEQ ID NO:55;and the variable domain region from the light chain comprises: a light chain CDR1 having an amino acid sequence of SEQ ID NO: 56, a light chain CDR2 having an amino acid sequence of SEQ ID NO: 57, and a light chain CDR3 having an amino acid sequence of SEQ ID NO: 58; wherein (f) the variable domain region from the heavy chain comprises: a heavy chain CDR1 having an amino acid sequence of SEQ ID NO: 59, a heavy chain CDR2 having an amino acid sequence of SEQ ID NO: 60, and a heavy chain CDR3 having an amino acid sequence of SEQ ID NO: 61; and the variable domain region from the light chain comprises: a light chain CDR1 having an amino acid sequence of SEQ ID NO: 62, a light chain CDR2 having an amino acid sequence of SEQ ID NO: 63, and a light chain CDR3 having an amino acid sequence of SEQ ID NO: 64; wherein (g) the variable domain region from the heavy chain comprises: a heavy chain CDR1 having an amino acid sequence of SEQ ID NO: 65, a heavy chain CDR2 having an amino acid sequence of SEQ ID NO: 66, and a light chain CDR3 having an amino acid sequence of SEQ ID NO: NO:67; and the variable domain region from the light chain comprises: a light chain CDR1 having an amino acid sequence of SEQ ID NO:68, a light chain CDR2 having an amino acid sequence of SEQ ID NO:69, and a light chain CDR3 having an amino acid sequence of SEQ ID NO:70; wherein (h) the variable domain region from the heavy chain comprises: a heavy chain CDR1 having an amino acid sequence of SEQ ID NO:71, a heavy chain CDR2 having an amino acid sequence of SEQ ID NO:72, and a heavy chain CDR3 having an amino acid sequence of SEQ ID NO:73; and the variable domain region from the light chain comprises: a light chain CDR1 having an amino acid sequence of SEQ ID NO:74, a light chain CDR2 having an amino acid sequence of SEQ ID NO:75, and a light chain CDR3 having an amino acid sequence of SEQ ID NO:76; wherein (i) the variable domain region from the heavy chain comprises: a heavy chain CDR1 having an amino acid sequence of SEQ ID NO:77, a heavy chain CDR2 having an amino acid sequence of SEQ ID NO:78, and a light chain CDR3 having an amino acid sequence of SEQ ID NO:79. NO:78, a heavy chain CDR2 having an amino acid sequence of SEQ ID NO:79, and a heavy chain CDR3 having an amino acid sequence of SEQ ID NO:79; and the variable domain region from the light chain comprises: a light chain CDR1 having an amino acid sequence of SEQ ID NO:80, a light chain CDR2 having an amino acid sequence of SEQ ID NO:81, and a light chain CDR3 having an amino acid sequence of SEQ ID NO:82;wherein (j) the variable domain region from the heavy chain comprises: a heavy chain CDR1 having an amino acid sequence of SEQ ID NO: 83, a heavy chain CDR2 having an amino acid sequence of SEQ ID NO: 84, a heavy chain CDR3 having an amino acid sequence of SEQ ID NO: 85; and the variable domain region from the light chain comprises: a light chain CDR1 having an amino acid sequence of SEQ ID NO: 86, a light chain CDR2 having an amino acid sequence of SEQ ID NO: 87, and a light chain CDR3 having an amino acid sequence of SEQ ID NO: 88; or wherein (k) the variable domain region from the heavy chain comprises: a heavy chain CDR1 having an amino acid sequence of SEQ ID NO: 53, a heavy chain CDR2 having an amino acid sequence of SEQ ID NO: 54, a heavy chain CDR3 having an amino acid sequence of SEQ ID NO: 55; and the variable domain region from the light chain comprises: a lambda light chain CDR1 having an amino acid sequence of SEQ ID NO: 89, a lambda light chain CDR2 having an amino acid sequence of SEQ ID NO: 90, and a light chain CDR3 having an amino acid sequence of SEQ ID NO: λ light chain CDR3 of the amino acid sequence of NO:91.;

[0015] The present disclosure provides a fully human anti-BCMA antibody or an antigen-binding fragment thereof, wherein the antigen-binding fragment is a single-chain antibody comprising a variable domain region from a heavy chain and a variable domain region from a light chain connected together by a peptide linker, wherein the variable domain region from the heavy chain comprises a sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 8, 10, 12, 14 or 22, and wherein the variable domain region from the light chain comprises a sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 9, 11, 13, 15, 16, 17, 18, 19, 20, 21 or 23.

[0016] The present disclosure provides a fully human anti-BCMA antibody or an antigen-binding fragment thereof, wherein the antigen-binding fragment is a single-chain antibody comprising a variable domain region from a heavy chain and a variable domain region from a light chain connected together by a peptide linker, wherein the variable domain region from the heavy chain and the variable domain region from the light chain are SEQ ID NOs: 8 and 9 (e.g., referred to herein as BCA7); SEQ ID NOs: 10 and 11 (e.g., referred to herein as BC4C9); SEQ ID NOs: 12 and 13 (e.g., referred to herein as CD5C4); SEQ ID NOs: 14 and 15 (e.g., referred to herein as BC6G8); SEQ ID NOs: 8 and 16 (e.g., referred to herein as BCA7-2C5); SEQ ID NOs: 8 and 17 (e.g., referred to herein as BCA7-2E1); SEQ ID NOs: 8 and 18 (e.g., referred to herein as BCA7-2D11); SEQ ID NOs: 8 and 19 (e.g., referred to herein as BCA7-2G2); SEQ ID NOs: 10 and 11 (e.g., referred to herein as BC4C9); SEQ ID NOs: 12 and 13 (e.g., referred to herein as CD5C4); SEQ ID NOs: 14 and 15 (e.g., referred to herein as BC6G8); SEQ ID NOs: 8 and 20 (eg, referred to herein as BCA7-2D8); SEQ ID NOs: 8 and 21 (eg, referred to herein as BCA7-2E8); or SEQ ID NOs: 22 and 23 (eg, referred to herein as BCA7-2C5 with a lambda light chain).

[0017] In one embodiment, any fully human anti-BCMA antibody disclosed herein, or any antigen-binding fragment thereof, comprises an IgG1, IgG2, IgG3, or IgG4 antibody.

[0018] In one embodiment, any fully human anti-BCMA antibody disclosed herein, or any antigen-binding fragment thereof, comprises an antibody of the IgG1 or IgG4 isotype.

[0019] In one embodiment, any fully human anti-BCMA antibody disclosed herein or any antigen-binding fragment thereof can block the binding of human APRIL (proliferation-inducing ligand; also known as TNF13 and CD256) protein to human BCMA protein.

[0020] In one embodiment, any fully human anti-BCMA antibody disclosed herein or any antigen-binding fragment thereof binds to human BCMA protein and cross-reacts with BCMA protein from mouse and cynomolgus monkey.

[0021] In one embodiment, any fully human anti-BCMA antibody disclosed herein or any antigen-binding fragment thereof binds to human BCMA protein and does not cross-react with mouse or cynomolgus monkey BCMA protein.

[0022] In one embodiment, any fully human anti-BCMA antibody disclosed herein or any antigen-binding fragment thereof binds to a human BCMA protein by a K D For 10-8 M or smaller.

[0023] In one embodiment, any fully human anti-BCMA antibody disclosed herein or any antigen-binding fragment thereof binds to the K-terminus of cynomolgus macaque BCMA protein. D For 10 -7 M or smaller.

[0024] In one embodiment, any fully human anti-BCMA antibody disclosed herein or any antigen-binding fragment thereof binds to the K of mouse BCMA protein. D For 10 -5 M or smaller.

[0025] In one embodiment, any fully human anti-BCMA antibody disclosed herein, or any antigen-binding fragment thereof, binds to cells expressing BCMA protein, including, for example, to human myeloma cells expressing BCMA protein.

[0026] The present disclosure provides a pharmaceutical composition comprising any one of the disclosed human anti-BCMA antibodies or any antigen-binding fragment thereof and a pharmaceutically acceptable excipient.

[0027] The present disclosure provides a kit comprising any one of the disclosed human anti-BCMA antibodies or any antigen-binding fragment thereof.

[0028] The present disclosure provides a first nucleic acid encoding a first polypeptide comprising an antibody heavy chain variable region, the antibody heavy chain variable region having a heavy chain complementary determining region (CDR) of any one of the disclosed human anti-BCMA antibodies, including (a) a heavy chain CDR1 having an amino acid sequence of SEQ ID NO: 29, a heavy chain CDR2 having an amino acid sequence of SEQ ID NO: 30, and a heavy chain CDR3 having an amino acid sequence of SEQ ID NO: 31; or (b) a heavy chain CDR1 having an amino acid sequence of SEQ ID NO: 35, a heavy chain CDR2 having an amino acid sequence of SEQ ID NO: 36, and a heavy chain CDR3 having an amino acid sequence of SEQ ID NO: 37; or (c) a heavy chain CDR1 having an amino acid sequence of SEQ ID NO: 41, a heavy chain CDR2 having an amino acid sequence of SEQ ID NO: 42, and a heavy chain CDR3 having an amino acid sequence of SEQ ID NO: 43; or (d) a heavy chain CDR1 having an amino acid sequence of SEQ ID NO: 47, a heavy chain CDR2 having an amino acid sequence of SEQ ID NO: 48, and a heavy chain CDR3 having an amino acid sequence of SEQ ID NO: 49. NO:48, and a heavy chain CDR2 having an amino acid sequence of SEQ ID NO:49; or (e) a heavy chain CDR1 having an amino acid sequence of SEQ ID NO:53, a heavy chain CDR2 having an amino acid sequence of SEQ ID NO:54, and a heavy chain CDR3 having an amino acid sequence of SEQ ID NO:55; or (f) a heavy chain CDR1 having an amino acid sequence of SEQ ID NO:59, a heavy chain CDR2 having an amino acid sequence of SEQ ID NO:60, and a heavy chain CDR3 having an amino acid sequence of SEQ ID NO:61; or (g) a heavy chain CDR1 having an amino acid sequence of SEQ ID NO:65, a heavy chain CDR2 having an amino acid sequence of SEQ ID NO:66, and a heavy chain CDR3 having an amino acid sequence of SEQ ID NO:67; or (h) a heavy chain CDR1 having an amino acid sequence of SEQ ID NO:71, a heavy chain CDR2 having an amino acid sequence of SEQ ID NO:72, and a heavy chain CDR3 having an amino acid sequence of SEQ ID NO:73. NO:73; or (i) a heavy chain CDR1 having the amino acid sequence of SEQ ID NO:77, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO:78, and a heavy chain CDR3 having the amino acid sequence of SEQ ID NO:79; or (j) a heavy chain CDR1 having the amino acid sequence of SEQ ID NO:83, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO:84, and a heavy chain CDR3 having the amino acid sequence of SEQ ID NO:85.

[0029] The present disclosure provides a first vector operably linked to a first nucleic acid encoding a first polypeptide comprising an antibody heavy chain variable region having CDRs 1, 2, and 3 of any one of the human anti-BCMA antibodies disclosed herein.

[0030] The present disclosure provides a first host cell carrying a first vector operably linked to a first nucleic acid, the first nucleic acid encoding a first polypeptide comprising an antibody heavy chain variable region having CDRs 1, 2, and 3 of any one of the human anti-BCMA antibodies disclosed herein. In one embodiment, the first vector comprises a first expression vector. In one embodiment, the first host cell expresses a first polypeptide comprising an antibody heavy chain variable region having CDRs 1, 2, and 3 of any one of the human anti-BCMA antibodies disclosed herein.

[0031] The present disclosure provides a method for preparing a first polypeptide having an antibody heavy chain variable region comprising CDRs 1, 2, and 3, the method comprising: culturing a population (e.g., multiple) of first host cells carrying a first expression vector under conditions suitable for expressing the first polypeptide having an antibody heavy chain variable region comprising CDRs 1, 2, and 3. In one embodiment, the method further comprises: recovering the expressed first polypeptide having an antibody heavy chain variable region comprising CDRs 1, 2, and 3 from the population of the first host cells.

[0032] The present disclosure provides a first nucleic acid encoding a first polypeptide comprising an antibody heavy chain variable region, wherein the antibody heavy chain variable region has at least 95% sequence identity with the amino acid sequence of SEQ ID NO: 8, 10, 12, 14 or 22.

[0033] The present disclosure provides a first vector operably linked to a first nucleic acid, wherein the first nucleic acid encodes a first polypeptide comprising an antibody heavy chain variable region, wherein the antibody heavy chain variable region has at least 95% sequence identity with the amino acid sequence of SEQ ID NO: 8, 10, 12, 14 or 22.

[0034] The present invention provides a first host cell carrying a first vector operably linked to a first nucleic acid, wherein the first nucleic acid encodes a first polypeptide comprising an antibody heavy chain variable region, wherein the antibody heavy chain variable region has at least 95% sequence identity with the amino acid sequence of SEQ ID NO: 8, 10, 12, 14 or 22. In one embodiment, the first vector comprises a first expression vector. In one embodiment, the first host cell expresses a first polypeptide comprising an antibody heavy chain variable region, wherein the antibody heavy chain variable region has at least 95% sequence identity with the amino acid sequence of SEQ ID NO: 8, 10, 12, 14 or 22.

[0035] The present disclosure provides a method for preparing a first polypeptide having an antibody heavy chain variable region, the method comprising: culturing a population (e.g., a plurality) of first host cells carrying a first expression vector under conditions suitable for expressing a first polypeptide having an antibody heavy chain variable region, wherein the antibody heavy chain variable region has at least 95% sequence identity with an amino acid sequence of SEQ ID NO: 8, 10, 12, 14, or 22. In one embodiment, the method further comprises: recovering the expressed first polypeptide having at least 95% sequence identity with an amino acid sequence of SEQ ID NO: 8, 10, 12, 14, or 22 from the population of the first host cells.

[0036] The present disclosure provides a second nucleic acid encoding a polypeptide comprising an antibody light chain variable region, the antibody light chain variable region having a light chain complementary determining region (CDR) of any one of the disclosed human anti-BCMA antibodies, including (a) a light chain CDR1 having an amino acid sequence of SEQ ID NO: 32, a light chain CDR2 having an amino acid sequence of SEQ ID NO: 33, and a light chain CDR3 having an amino acid sequence of SEQ ID NO: 34; or (b) a light chain CDR1 having an amino acid sequence of SEQ ID NO: 38, a light chain CDR2 having an amino acid sequence of SEQ ID NO: 39, and a light chain CDR3 having an amino acid sequence of SEQ ID NO: 40; or (c) a light chain CDR1 having an amino acid sequence of SEQ ID NO: 44, a light chain CDR2 having an amino acid sequence of SEQ ID NO: 45, and a light chain CDR3 having an amino acid sequence of SEQ ID NO: 46; or (d) a light chain CDR1 having an amino acid sequence of SEQ ID NO: 50, a light chain CDR2 having an amino acid sequence of SEQ ID NO: 51, and a light chain CDR3 having an amino acid sequence of SEQ ID NO: 52. NO:51, and a light chain CDR2 having an amino acid sequence of SEQ ID NO:52; or (e) a light chain CDR1 having an amino acid sequence of SEQ ID NO:56, a light chain CDR2 having an amino acid sequence of SEQ ID NO:57, and a light chain CDR3 having an amino acid sequence of SEQ ID NO:58; or (f) a light chain CDR1 having an amino acid sequence of SEQ ID NO:62, a light chain CDR2 having an amino acid sequence of SEQ ID NO:63, and a light chain CDR3 having an amino acid sequence of SEQ ID NO:64; or (g) a light chain CDR1 having an amino acid sequence of SEQ ID NO:68, a light chain CDR2 having an amino acid sequence of SEQ ID NO:69, and a light chain CDR3 having an amino acid sequence of SEQ ID NO:70; or (h) a light chain CDR1 having an amino acid sequence of SEQ ID NO:74, a light chain CDR2 having an amino acid sequence of SEQ ID NO:75, and a light chain CDR3 having an amino acid sequence of SEQ ID NO:76. NO:76; or (i) a light chain CDR1 having an amino acid sequence of SEQ ID NO:80, a light chain CDR2 having an amino acid sequence of SEQ ID NO:81, and a light chain CDR3 having an amino acid sequence of SEQ ID NO:82; or (j) a light chain CDR1 having an amino acid sequence of SEQ ID NO:86, a light chain CDR2 having an amino acid sequence of SEQ ID NO:87, and a light chain CDR3 having an amino acid sequence of SEQ ID NO:88;or (k) a lambda light chain CDR1 having the amino acid sequence of SEQ ID NO: 89, a lambda light chain CDR2 having the amino acid sequence of SEQ ID NO: 90, and a lambda light chain CDR3 having the amino acid sequence of SEQ ID NO: 91. ;

[0037] The present disclosure provides a second vector operably linked to a second nucleic acid encoding a second polypeptide comprising an antibody light chain variable region having CDRs 1, 2, and 3 of any one of the human anti-BCMA antibodies disclosed herein.

[0038] The present disclosure provides a second host cell carrying a second vector operably linked to a second nucleic acid, the second nucleic acid encoding a second polypeptide comprising an antibody light chain variable region having CDRs 1, 2, and 3 of any one of the human anti-BCMA antibodies disclosed herein. In one embodiment, the second vector comprises a second expression vector. In one embodiment, the second host cell expresses a second polypeptide comprising an antibody light chain variable region having CDRs 1, 2, and 3 of any one of the human anti-BCMA antibodies disclosed herein.

[0039] The present disclosure provides a method for preparing a second polypeptide having an antibody light chain variable region comprising CDRs 1, 2, and 3, the method comprising: culturing a population (e.g., multiple) of second host cells carrying a second expression vector under conditions suitable for expressing the second polypeptide having an antibody light chain variable region comprising CDRs 1, 2, and 3. In one embodiment, the method further comprises: recovering the expressed second polypeptide having an antibody light chain variable region comprising CDRs 1, 2, and 3 from the population of second host cells.

[0040] The present disclosure provides a second nucleic acid encoding a second polypeptide comprising an antibody light chain variable region, wherein the antibody light chain variable region has at least 95% sequence identity with the amino acid sequence of SEQ ID NO:9, 11, 13, 15, 16, 17, 18, 19, 20, 21 or 23.

[0041] The present disclosure provides a second vector operably linked to a second nucleic acid, wherein the second nucleic acid encodes a second polypeptide comprising an antibody light chain variable region, wherein the antibody light chain variable region has at least 95% sequence identity with the amino acid sequence of SEQ ID NO:9, 11, 13, 15, 16, 17, 18, 19, 20, 21 or 23.

[0042] The present invention provides a second host cell carrying a second vector operably linked to a second nucleic acid, wherein the second nucleic acid encodes a second polypeptide comprising an antibody light chain variable region, wherein the antibody light chain variable region has at least 95% sequence identity with the amino acid sequence of SEQ ID NO: 9, 11, 13, 15, 16, 17, 18, 19, 20, 21 or 23. In one embodiment, the second vector comprises a second expression vector. In one embodiment, the second host cell expresses a second polypeptide comprising an antibody light chain variable region, wherein the antibody light chain variable region has at least 95% sequence identity with the amino acid sequence of SEQ ID NO: 9, 11, 13, 15, 16, 17, 18, 19, 20, 21 or 23.

[0043] The present disclosure provides a method for preparing a second polypeptide having an antibody light chain variable region, the method comprising: culturing a population (e.g., a plurality) of second host cells carrying a second expression vector under conditions suitable for expressing a second polypeptide having an antibody light chain variable region, wherein the antibody light chain variable region has at least 95% sequence identity with an amino acid sequence of SEQ ID NO: 9, 11, 13, 15, 16, 17, 18, 19, 20, 21, or 23. In one embodiment, the method further comprises: recovering the expressed second polypeptide having at least 95% sequence identity with an amino acid sequence of SEQ ID NO: 8, 10, 12, 14, or 22 from the population of the second host cells.

[0044] The present disclosure provides a first nucleic acid encoding a first polypeptide comprising an antibody heavy chain variable region having a heavy chain complementary determining region (HC-CDR 1, 2, and 3) of any one of the disclosed human anti-BCMA antibodies, and a second nucleic acid encoding a second polypeptide comprising a light chain variable region of the antibody, wherein (a) the heavy chain CDR 1, 2, and 3 regions comprise the amino acid sequences of SEQ ID NOs: 29, 30, and 31, respectively, and the light chain CDR 1, 2, and 3 regions comprise the amino acid sequences of SEQ ID NOs: 32, 33, and 34, respectively; or (b) the heavy chain CDR 1, 2, and 3 regions comprise the amino acid sequences of SEQ ID NOs: 35, 36, and 37, respectively, and the light chain CDR 1, 2, and 3 regions comprise the amino acid sequences of SEQ ID NOs: 38, 39, and 40, respectively; or (c) the heavy chain CDR 1, 2, and 3 regions comprise the amino acid sequences of SEQ ID NOs: 39, 40, and 41, respectively. NO:41, 42 and 43, and the light chain CDR 1, 2 and 3 regions comprise the amino acid sequences of SEQ ID NO:44, 45 and 46, respectively; or (d) the heavy chain CDR 1, 2 and 3 regions comprise the amino acid sequences of SEQ ID NO:47, 48 and 49, respectively, and the light chain CDR 1, 2 and 3 regions comprise the amino acid sequences of SEQ ID NO:50, 51 and 52, respectively; or (e) the heavy chain CDR 1, 2 and 3 regions comprise the amino acid sequences of SEQ ID NO:53, 54 and 55, respectively, and the light chain CDR 1, 2 and 3 regions comprise the amino acid sequences of SEQ ID NO:56, 57 and 58, respectively; or (f) the heavy chain CDR 1, 2 and 3 regions comprise the amino acid sequences of SEQ ID NO:59, 60 and 61, respectively, and the light chain CDR 1, 2 and 3 regions comprise the amino acid sequences of SEQ ID NO:62, 63 and 64, respectively; or (g) the heavy chain CDR (h) the heavy chain CDR1, 2 and 3 regions comprise the amino acid sequences of SEQ ID NOs: 71, 72 and 73, respectively, and the light chain CDR1, 2 and 3 regions comprise the amino acid sequences of SEQ ID NOs: 74, 75 and 76, respectively; or (i) the heavy chain CDR1, 2 and 3 regions comprise the amino acid sequences of SEQ ID NOs: 77, 78 and 79, respectively, and the light chain CDR1, 2 and 3 regions comprise the amino acid sequences of SEQ ID NOs: 80, 81 and 82, respectively;or (j) the heavy chain CDR 1, 2 and 3 regions comprise the amino acid sequences of SEQ ID NOs: 83, 84 and 85, respectively, and the light chain CDR 1, 2 and 3 regions comprise the amino acid sequences of SEQ ID NOs: 86, 87 and 88, respectively; or (k) the heavy chain CDR 1, 2 and 3 regions comprise the amino acid sequences of SEQ ID NOs: 53, 54 and 55, respectively, and the light chain CDR 1, 2 and 3 regions comprise the amino acid sequences of SEQ ID NOs: 89, 90 and 91, respectively.;

[0045] The present disclosure provides a vector operably linked to a first nucleic acid encoding a first polypeptide comprising an antibody heavy chain variable region having heavy chain complementary determining regions (HC-CDRs 1, 2, and 3) of any one of the disclosed human anti-BCMA antibodies, and the vector is operably linked to a second nucleic acid encoding a second polypeptide comprising an antibody light chain variable region having light chain complementary determining regions (LC-CDRs 1, 2, and 3) of any one of the disclosed human anti-BCMA antibodies.

[0046] The present disclosure provides a host cell carrying a vector, wherein the vector is operably linked to a first nucleic acid encoding a first polypeptide and a second nucleic acid encoding a second polypeptide, wherein the first polypeptide comprises a heavy chain complementary determining region (HC-CDR 1, 2, and 3) of any one of the disclosed human anti-BCMA antibodies, and the second polypeptide comprises a light chain complementary determining region (LC-CDR 1, 2, and 3) of any one of the disclosed human anti-BCMA antibodies. In one embodiment, the vector comprises an expression vector. In one embodiment, the host cell expresses a first polypeptide comprising a heavy chain complementary determining region (HC-CDR 1, 2, and 3) of any one of the disclosed human anti-BCMA antibodies and a second polypeptide comprising a light chain complementary determining region (LC-CDR 1, 2, and 3) of any one of the disclosed human anti-BCMA antibodies.

[0047] The present disclosure provides a method for preparing a first and a second polypeptide, the method comprising: culturing a population (e.g., a plurality) of host cells carrying an expression vector under conditions suitable for expressing a first polypeptide and a second polypeptide, wherein the first polypeptide comprises a heavy chain complementary determining region (HC-CDR 1, 2, and 3) of any one of the disclosed human anti-BCMA antibodies, and the second polypeptide comprises a light chain complementary determining region (LC-CDR 1, 2, and 3) of any one of the disclosed human anti-BCMA antibodies. In one embodiment, the method further comprises: recovering the expressed first and second polypeptides from the population of host cells.

[0048] The present disclosure provides a first nucleic acid encoding a first polypeptide comprising an antibody heavy chain variable region and a second nucleic acid encoding a second polypeptide comprising an antibody light chain variable region, wherein the antibody heavy chain variable region has at least 95% sequence identity with the amino acid sequence of SEQ ID NO: 8, 10, 12, 14 or 22, and the antibody light chain variable region has at least 95% sequence identity with the amino acid sequence of SEQ ID NO: 9, 11, 13, 15, 16, 17, 18, 19, 20, 21 or 23.

[0049] The present disclosure provides a vector operably linked to a first nucleic acid encoding a first polypeptide comprising an antibody heavy chain variable region, wherein the antibody heavy chain variable region has at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 8, 10, 12, 14 or 22, and the vector is operably linked to a second nucleic acid encoding a second polypeptide comprising an antibody light chain variable region, wherein the antibody light chain variable region has at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 9, 11, 13, 15, 16, 17, 18, 19, 20, 21 or 23.

[0050] The present invention provides a host cell carrying a vector operably linked to a first nucleic acid encoding a first polypeptide comprising an antibody heavy chain variable region, the antibody heavy chain variable region having at least 95% sequence identity to an amino acid sequence of SEQ ID NO: 8, 10, 12, 14 or 22, and the vector operably linked to a second nucleic acid encoding a second polypeptide comprising an antibody light chain variable region, the antibody light chain variable region having at least 95% sequence identity to an amino acid sequence of SEQ ID NO: 9, 11, 13, 15, 16, 17, 18, 19, 20, 21 or 23. In one embodiment, the vector comprises an expression vector. In one embodiment, the host cell expresses a first polypeptide comprising an antibody heavy chain variable region, wherein the antibody heavy chain variable region has at least 95% sequence identity with the amino acid sequence of SEQ ID NO:8, 10, 12, 14 or 22, and the host cell expresses a second polypeptide comprising an antibody light chain variable region, wherein the antibody light chain variable region has at least 95% sequence identity with the amino acid sequence of SEQ ID NO:9, 11, 13, 15, 16, 17, 18, 19, 20, 21 or 23.

[0051] The present disclosure provides a method for preparing a first polypeptide having an antibody heavy chain variable region and a second polypeptide having an antibody light chain variable region, the method comprising: culturing a population (e.g., a plurality) of host cells carrying an expression vector under conditions suitable for expressing a first polypeptide comprising an antibody heavy chain variable region and expressing a second polypeptide having an antibody light chain variable region, wherein the antibody heavy chain variable region has at least 95% sequence identity with an amino acid sequence of SEQ ID NO: 8, 10, 12, 14 or 22, and the antibody light chain variable region has at least 95% sequence identity with an amino acid sequence of SEQ ID NO: 9, 11, 13, 15, 16, 17, 18, 19, 20, 21 or 23. In one embodiment, the method further comprises: recovering from the host cell population an expressed first polypeptide comprising an antibody heavy chain variable region and an expressed second polypeptide, wherein the antibody heavy chain variable region has at least 95% sequence identity with the amino acid sequence of SEQ ID NO: 8, 10, 12, 14 or 22, and the second polypeptide has at least 95% sequence identity with the amino acid sequence of SEQ ID NO: 8, 10, 12, 14 or 22.

[0052] The present disclosure provides a first nucleic acid encoding a first polypeptide comprising an antibody heavy chain variable region having a heavy chain complementary determining region (HC-CDR 1, 2, and 3) of any one of the disclosed human anti-BCMA antibodies, and a second nucleic acid encoding a second polypeptide comprising a light chain variable region of the antibody, wherein (a) the heavy chain CDR 1, 2, and 3 regions comprise the amino acid sequences of SEQ ID NOs: 29, 30, and 31, respectively, and the light chain CDR 1, 2, and 3 regions comprise the amino acid sequences of SEQ ID NOs: 32, 33, and 34, respectively; or (b) the heavy chain CDR 1, 2, and 3 regions comprise the amino acid sequences of SEQ ID NOs: 35, 36, and 37, respectively, and the light chain CDR 1, 2, and 3 regions comprise the amino acid sequences of SEQ ID NOs: 38, 39, and 40, respectively; or (c) the heavy chain CDR 1, 2, and 3 regions comprise the amino acid sequences of SEQ ID NOs: 39, 40, and 41, respectively. NO:41, 42 and 43, and the light chain CDR 1, 2 and 3 regions comprise the amino acid sequences of SEQ ID NO:44, 45 and 46, respectively; or (d) the heavy chain CDR 1, 2 and 3 regions comprise the amino acid sequences of SEQ ID NO:47, 48 and 49, respectively, and the light chain CDR 1, 2 and 3 regions comprise the amino acid sequences of SEQ ID NO:50, 51 and 52, respectively; or (e) the heavy chain CDR 1, 2 and 3 regions comprise the amino acid sequences of SEQ ID NO:53, 54 and 55, respectively, and the light chain CDR 1, 2 and 3 regions comprise the amino acid sequences of SEQ ID NO:56, 57 and 58, respectively; or (f) the heavy chain CDR 1, 2 and 3 regions comprise the amino acid sequences of SEQ ID NO:59, 60 and 61, respectively, and the light chain CDR 1, 2 and 3 regions comprise the amino acid sequences of SEQ ID NO:62, 63 and 64, respectively; or (g) the heavy chain CDR (h) the heavy chain CDR1, 2 and 3 regions comprise the amino acid sequences of SEQ ID NOs: 71, 72 and 73, respectively, and the light chain CDR1, 2 and 3 regions comprise the amino acid sequences of SEQ ID NOs: 74, 75 and 76, respectively; or (i) the heavy chain CDR1, 2 and 3 regions comprise the amino acid sequences of SEQ ID NOs: 77, 78 and 79, respectively, and the light chain CDR1, 2 and 3 regions comprise the amino acid sequences of SEQ ID NOs: 80, 81 and 82, respectively;or (j) the heavy chain CDR 1, 2 and 3 regions comprise the amino acid sequences of SEQ ID NOs: 83, 84 and 85, respectively, and the light chain CDR 1, 2 and 3 regions comprise the amino acid sequences of SEQ ID NOs: 86, 87 and 88, respectively; or (k) the heavy chain CDR 1, 2 and 3 regions comprise the amino acid sequences of SEQ ID NOs: 53, 54 and 55, respectively, and the light chain CDR 1, 2 and 3 regions comprise the amino acid sequences of SEQ ID NOs: 89, 90 and 91, respectively.;

[0053] The present disclosure provides a first vector operably linked to a first nucleic acid encoding a first polypeptide comprising an antibody heavy chain variable region having the heavy chain complementary determining regions (HC-CDRs 1, 2, and 3) of any one of the disclosed human anti-BCMA antibodies and a second vector operably linked to a second nucleic acid encoding a second polypeptide comprising an antibody light chain variable region having the light chain complementary determining regions (LC-CDRs 1, 2, and 3) of any one of the disclosed human anti-BCMA antibodies.

[0054] The present disclosure provides a host cell carrying a first vector, the first vector is operably linked to a first nucleic acid encoding a first polypeptide, the first polypeptide comprising the heavy chain complementary determining region (HC-CDR 1, 2 and 3) of any one of the disclosed human anti-BCMA antibodies, and the host cell carries a second vector, which is operably linked to a second nucleic acid encoding a second polypeptide, the second polypeptide comprising the light chain complementary determining region (LC-CDR 1, 2 and 3) of any one of the disclosed human anti-BCMA antibodies. In one embodiment, the first and second vectors are first and second expression vectors, respectively. In one embodiment, the host cell expresses a first polypeptide comprising the heavy chain complementary determining region (HC-CDR 1, 2 and 3) of any one of the disclosed human anti-BCMA antibodies, and the host cell expresses a second polypeptide comprising the light chain complementary determining region (LC-CDR 1, 2 and 3) of any one of the disclosed human anti-BCMA antibodies.

[0055] The present disclosure provides a method for preparing a first and a second polypeptide, the method comprising: culturing a population (e.g., a plurality) of host cells carrying a first and a second expression vector under conditions suitable for expressing a first polypeptide and a second polypeptide, wherein the first polypeptide comprises a heavy chain complementary determining region (HC-CDR 1, 2, and 3) of any one of the disclosed human anti-BCMA antibodies, and the second polypeptide comprises a light chain complementary determining region (LC-CDR 1, 2, and 3) of any one of the disclosed human anti-BCMA antibodies. In one embodiment, the method further comprises: recovering the expressed first and second polypeptides from the population of host cells.

[0056] The present disclosure provides a first nucleic acid encoding a first polypeptide comprising an antibody heavy chain variable region and a second nucleic acid encoding a second polypeptide comprising an antibody light chain variable region, wherein the antibody heavy chain variable region has at least 95% sequence identity with the amino acid sequence of SEQ ID NO: 8, 10, 12, 14 or 22, and the antibody light chain variable region has at least 95% sequence identity with the amino acid sequence of SEQ ID NO: 9, 11, 13, 15, 16, 17, 18, 19, 20, 21 or 23.

[0057] The present disclosure provides a first vector operably linked to a first nucleic acid encoding a first polypeptide comprising an antibody heavy chain variable region, wherein the antibody heavy chain variable region has at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 8, 10, 12, 14 or 22, and a second vector operably linked to a second nucleic acid encoding a second polypeptide comprising an antibody light chain variable region, wherein the antibody light chain variable region has at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 9, 11, 13, 15, 16, 17, 18, 19, 20, 21 or 23.

[0058] The present invention provides a host cell carrying a first vector operably linked to a first nucleic acid encoding a first polypeptide comprising an antibody heavy chain variable region, wherein the antibody heavy chain variable region has at least 95% sequence identity with an amino acid sequence of SEQ ID NO: 8, 10, 12, 14 or 22, and the host cell carrying a second vector operably linked to a second nucleic acid encoding a second polypeptide comprising an antibody light chain variable region, wherein the antibody light chain variable region has at least 95% sequence identity with an amino acid sequence of SEQ ID NO: 9, 11, 13, 15, 16, 17, 18, 19, 20, 21 or 23. In one embodiment, the first and second vectors comprise first and second expression vectors, respectively. In one embodiment, the host cell expresses a first polypeptide comprising an antibody heavy chain variable region, wherein the antibody heavy chain variable region has at least 95% sequence identity with the amino acid sequence of SEQ ID NO:8, 10, 12, 14 or 22, and the host cell expresses a second polypeptide comprising an antibody light chain variable region, wherein the antibody light chain variable region has at least 95% sequence identity with the amino acid sequence of SEQ ID NO:9, 11, 13, 15, 16, 17, 18, 19, 20, 21 or 23.

[0059] The present disclosure provides a method for preparing a first polypeptide having an antibody heavy chain variable region and a second polypeptide having an antibody light chain variable region, the method comprising: culturing a population (e.g., a plurality) of host cells carrying a first and a second expression vector under conditions suitable for expressing a first polypeptide comprising an antibody heavy chain variable region and expressing a second polypeptide having an antibody light chain variable region, wherein the antibody heavy chain variable region has at least 95% sequence identity with an amino acid sequence of SEQ ID NO: 8, 10, 12, 14 or 22, and the antibody light chain variable region has at least 95% sequence identity with an amino acid sequence of SEQ ID NO: 9, 11, 13, 15, 16, 17, 18, 19, 20, 21 or 23. In one embodiment, the method further comprises: recovering from the host cell population an expressed first polypeptide comprising an antibody heavy chain variable region and an expressed second polypeptide, wherein the antibody heavy chain variable region has at least 95% sequence identity with the amino acid sequence of SEQ ID NO: 8, 10, 12, 14 or 22, and the second polypeptide has at least 95% sequence identity with the amino acid sequence of SEQ ID NO: 8, 10, 12, 14 or 22.

[0060] The present disclosure provides a nucleic acid encoding a polypeptide (e.g., a single-chain antibody including an scFv) comprising an antibody heavy chain variable region and an antibody light chain variable region, wherein the antibody heavy chain variable region has a heavy chain complementary determining region (HC-CDR 1, 2, and 3) of any one of the disclosed human anti-BCMA antibodies, and the antibody light chain variable region has a light chain complementary determining region (LC-CDR 1, 2, and 3) of any one of the disclosed human anti-BCMA antibodies, wherein (a) the heavy chain CDR 1, 2, and 3 regions comprise the amino acid sequences of SEQ ID NOs: 29, 30, and 31, respectively, and the light chain CDR 1, 2, and 3 regions comprise the amino acid sequences of SEQ ID NOs: 32, 33, and 34, respectively; or (b) the heavy chain CDR 1, 2, and 3 regions comprise the amino acid sequences of SEQ ID NOs: 35, 36, and 37, respectively, and the light chain CDR 1, 2, and 3 regions comprise the amino acid sequences of SEQ ID NOs: 38, 39, and 40, respectively; or (c) the heavy chain CDR or (e) the heavy chain CDR 1, 2 and 3 regions comprise the amino acid sequences of SEQ ID NOs: 53, 54 and 55, respectively, and the light chain CDR 1, 2 and 3 regions comprise the amino acid sequences of SEQ ID NOs: 56, 57 and 58, respectively; or (f) the heavy chain CDR 1, 2 and 3 regions comprise the amino acid sequences of SEQ ID NOs: 59, 60 and 61, respectively, and the light chain CDR 1, 2 and 3 regions comprise the amino acid sequences of SEQ ID NOs: 61, 62 and 63, respectively; NO:62, 63 and 64 amino acid sequences; or (g) the heavy chain CDR 1, 2 and 3 regions comprise the amino acid sequences of SEQ ID NO:65, 66 and 67, respectively, and the light chain CDR 1, 2 and 3 regions comprise the amino acid sequences of SEQ ID NO:68, 69 and 70, respectively; or (h) the heavy chain CDR 1, 2 and 3 regions comprise the amino acid sequences of SEQ ID NO:71, 72 and 73, respectively, and the light chain CDR 1, 2 and 3 regions comprise the amino acid sequences of SEQ ID NO:74, 75 and 76, respectively; or (i) the heavy chain CDR 1, 2 and 3 regions comprise the amino acid sequences of SEQ ID NO:77, 78 and 79, respectively, and the light chain CDR 1, 2 and 3 regions comprise the amino acid sequences of SEQ ID NO:80, 81 and 82, respectively;or (j) the heavy chain CDR 1, 2 and 3 regions comprise the amino acid sequences of SEQ ID NOs: 83, 84 and 85, respectively, and the light chain CDR 1, 2 and 3 regions comprise the amino acid sequences of SEQ ID NOs: 86, 87 and 88, respectively; or (k) the heavy chain CDR 1, 2 and 3 regions comprise the amino acid sequences of SEQ ID NOs: 53, 54 and 55, respectively, and the light chain CDR 1, 2 and 3 regions comprise the amino acid sequences of SEQ ID NOs: 89, 90 and 91, respectively.;

[0061] The present disclosure provides a vector operably linked to a nucleic acid encoding a polypeptide (e.g., a single-chain antibody including an scFv) comprising an antibody heavy chain variable region having a heavy chain complementarity determining region (HC-CDR 1, 2, and 3) of any one of the disclosed human anti-BCMA antibodies and an antibody light chain variable region having a light chain complementarity determining region (LC-CDR 1, 2, and 3) of any one of the disclosed human anti-BCMA antibodies.

[0062] The present disclosure provides a host cell carrying a vector, wherein the vector is operably linked to a nucleic acid encoding a polypeptide comprising an antibody heavy chain variable region and an antibody light chain variable region (e.g., a single-chain antibody including an scFv), wherein the antibody heavy chain variable region has a heavy chain complementary determining region (HC-CDR 1, 2, and 3) of any one of the disclosed human anti-BCMA antibodies, and the antibody light chain variable region has a light chain complementary determining region (LC-CDR 1, 2, and 3) of any one of the disclosed human anti-BCMA antibodies. In one embodiment, the vector includes an expression vector. In one embodiment, the host cell expresses a polypeptide comprising an antibody heavy chain variable region and an antibody light chain variable region, wherein the antibody heavy chain variable region has a heavy chain complementary determining region (HC-CDR 1, 2, and 3) of any one of the disclosed human anti-BCMA antibodies, and the antibody light chain variable region has a light chain complementary determining region (LC-CDR 1, 2, and 3) of any one of the disclosed human anti-BCMA antibodies.

[0063] The present disclosure provides a method for preparing a polypeptide, the method comprising: culturing a population (e.g., multiple) of host cells carrying an expression vector under conditions suitable for expressing a polypeptide comprising an antibody heavy chain variable region and an antibody light chain variable region, wherein the antibody heavy chain variable region has a heavy chain complementary determining region (HC-CDR 1, 2, and 3) of any one of the disclosed human anti-BCMA antibodies, and the antibody light chain variable region has a light chain complementary determining region (LC-CDR 1, 2, and 3) of any one of the disclosed human anti-BCMA antibodies. In one embodiment, the method further comprises: recovering the expressed polypeptide from the population of host cells.

[0064] The present disclosure provides a nucleic acid encoding a polypeptide (e.g., a single-chain antibody including an scFv) comprising an antibody heavy chain variable region and an antibody light chain variable region, wherein the antibody heavy chain variable region has at least 95% sequence identity with the amino acid sequence of SEQ ID NO: 8, 10, 12, 14 or 22, and the antibody light chain variable region has at least 95% sequence identity with the amino acid sequence of SEQ ID NO: 9, 11, 13, 15, 16, 17, 18, 19, 20, 21 or 23.

[0065] The present disclosure provides a vector operably linked to a nucleic acid encoding a polypeptide (e.g., a single-chain antibody including an scFv) comprising an antibody heavy chain variable region and an antibody light chain variable region, wherein the antibody heavy chain variable region has at least 95% sequence identity with the amino acid sequence of SEQ ID NO: 8, 10, 12, 14 or 22, and the antibody light chain variable region has at least 95% sequence identity with the amino acid sequence of SEQ ID NO: 9, 11, 13, 15, 16, 17, 18, 19, 20, 21 or 23.

[0066] The present invention provides a host cell carrying a vector operably linked to a nucleic acid encoding a polypeptide comprising an antibody heavy chain variable region and an antibody light chain variable region (e.g., a single chain antibody including an scFv), wherein the antibody heavy chain variable region has at least 95% sequence identity with the amino acid sequence of SEQ ID NO: 8, 10, 12, 14 or 22, and the antibody light chain variable region has at least 95% sequence identity with the amino acid sequence of SEQ ID NO: 9, 11, 13, 15, 16, 17, 18, 19, 20, 21 or 23. In one embodiment, the vector comprises an expression vector. In one embodiment, the host cell expresses a polypeptide comprising an antibody heavy chain variable region and an antibody light chain variable region (e.g., a single chain antibody including an scFv), wherein the antibody heavy chain variable region has at least 95% sequence identity with the amino acid sequence of SEQ ID NO: 8, 10, 12, 14 or 22, and the antibody light chain variable region has at least 95% sequence identity with the amino acid sequence of SEQ ID NO: 9, 11, 13, 15, 16, 17, 18, 19, 20, 21 or 23.

[0067] The present disclosure provides a method for preparing a polypeptide (e.g., a single-chain antibody including an scFv), the method comprising: culturing a population (e.g., a plurality) of host cells carrying an expression vector under conditions suitable for expressing the polypeptide (e.g., a single-chain antibody including an scFv), the polypeptide comprising an antibody heavy chain variable region and an antibody light chain variable region, the antibody heavy chain variable region having at least 95% sequence identity with the amino acid sequence of SEQ ID NO: 8, 10, 12, 14 or 22, and the antibody light chain variable region having at least 95% sequence identity with the amino acid sequence of SEQ ID NO: 9, 11, 13, 15, 16, 17, 18, 19, 20, 21 or 23. In one embodiment, the method further comprises: recovering expressed polypeptides (e.g., single-chain antibodies including scFv) from the host cell population, wherein the polypeptide comprises an antibody heavy chain variable region and an antibody light chain variable region, wherein the antibody heavy chain variable region has at least 95% sequence identity with the amino acid sequence of SEQ ID NO: 8, 10, 12, 14 or 22, and the antibody light chain variable region has at least 95% sequence identity with the amino acid sequence of SEQ ID NO: 9, 11, 13, 15, 16, 17, 18, 19, 20, 21 or 23.

[0068] The present disclosure provides a method (e.g., an in vitro method) for inhibiting the growth or proliferation of cells expressing BCMA, comprising: contacting (i) a population (e.g., multiple) of effector cells with (ii) a population (e.g., multiple) of target cells expressing BCMA (iii) in the presence of any one or any combination of 2-3 of the human anti-BCMA antibodies described herein under conditions suitable for inhibiting the growth or proliferation of cells expressing BCMA. In one embodiment, the population of effector cells includes PBMCs or NK cells. In one embodiment, the population of target cells includes multiple myeloma (MM) cells expressing BCMA or transgenic cells expressing BCMA. In one embodiment, the ratio of effector cells to target cells is 1: 1, 2: 1, 3: 1, 4: 1, or 5: 1. In one embodiment, the ratio of effector cells to target cells is 5-10: 1, 10-20: 1, or 20-30: 1.

[0069] The present disclosure provides a method (e.g., an in vitro method) for killing cells expressing BCMA, comprising: contacting (i) a population (e.g., multiple) of effector cells with (ii) a population (e.g., multiple) of target cells expressing BCMA (iii) in the presence of any one or any combination of 2-3 of the human anti-BCMA antibodies described herein under conditions suitable for killing cells expressing BCMA. In one embodiment, the population of effector cells includes PBMCs or NK cells. In one embodiment, the population of target cells includes multiple myeloma (MM) cells expressing BCMA or transgenic cells expressing BCMA. In one embodiment, the ratio of effector cells to target cells is 1: 1, 2: 1, 3: 1, 4: 1, or 5: 1. In one embodiment, the ratio of effector cells to target cells is 5-10: 1, 10-20: 1, or 20-30: 1.

[0070] The present disclosure provides a method for treating a subject suffering from a disease associated with BCMA overexpression, the method comprising: administering to the subject an effective amount of a therapeutic composition comprising any one or any combination of 2-3 of the human anti-BCMA antibodies described herein. In one embodiment, the disease associated with BCMA overexpression includes: B cell leukemia, B cell lymphoma or B cell myeloma. In one embodiment, the disease associated with BCMA overexpression is selected from the group consisting of: multiple myeloma (MM), non-Hodgkin's lymphoma (NHL) including Burkitt's lymphoma (BL), B chronic lymphocytic leukemia (B-CLL), systemic lupus erythematosus (SLE), B and T acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma, chronic myeloid leukemia (CML), hairy cell leukemia (HCL), follicular lymphoma, Waldenstrom's Macroglobulinemia, mantle cell lymphoma, Hodgkin's lymphoma (Hodgkin's Lymphoma (HL), plasma cell myeloma, precursor B-cell lymphoblastic leukemia / lymphoma, plasma cell neoplasm, giant cell myeloma, plasma cell myeloma, heavy chain myeloma, light chain or Bence-Jones myeloma, lymphomatoid granulomatosis, post-transplant lymphoproliferative disorder, immunomodulatory disorder, rheumatoid arthritis, myasthenia gravis, idiopathic thrombocytopenic purpura, antiphospholipid syndrome, Chagas' disease, Grave's disease, Wegener's granulomatosis, polyarteritis nodosa, Sjogren's syndrome, pemphigus vulgaris, scleroderma, multiple sclerosis, antiphospholipid syndrome, ANCA-associated vasculitis, Goodpasture's disease, Kawasaki disease disease), autoimmune hemolytic anemia and rapidly progressive glomerulonephritis, heavy chain disease, primary or immune cell-associated amyloidosis, and monoclonal gammopathy of undetermined significance. BRIEF DESCRIPTION OF THE DRAWINGS

[0071] Figure 1 SPR sensorgrams showing the binding kinetics of the BCA7 antibody.

[0072] Figure 2SPR sensorgrams showing the binding kinetics of the GSK J6M0 antibody.

[0073] Figure 3 SPR sensorgrams showing the binding kinetics of the BC4C9 antibody.

[0074] Figure 4 SPR sensorgrams showing the binding kinetics of the BC5C5 antibody.

[0075] Figure 5 SPR sensorgrams showing the binding kinetics of the BCA7-2C5 antibody.

[0076] Figure 6 SPR sensorgrams showing the binding kinetics of the BCA7-2D11 antibody.

[0077] Figure 7 SPR sensorgrams showing the binding kinetics of the BCA7-2G2 antibody.

[0078] Figure 8 SPR sensorgrams showing the binding kinetics of the BCA7-2E1 antibody.

[0079] Fig. 9 SPR sensorgrams showing the binding kinetics of the BCA7-2D8 antibody.

[0080] Fig.10 SPR sensorgrams showing the binding kinetics of the BCA7-2E81 antibody.

[0081] Fig.11A SPR sensorgrams showing the binding kinetics of the BCA7-2C5 antibody to human BCMA protein.

[0082] Fig. 11B SPR sensorgrams showing the binding kinetics of BCA7-2E1 antibody to human BCMA protein.

[0083] Fig. 12A SPR sensorgrams showing the binding kinetics of the BCA7-2C5 antibody to cynomolgus macaque BCMA protein.

[0084] Fig. 12B SPR sensorgrams showing the binding kinetics of the BCA7-2E1 antibody to cynomolgus macaque BCMA protein.

[0085] Fig.13A SPR sensorgrams showing the binding kinetics of the BCA7-2C5 antibody to mouse BCMA protein.

[0086] Fig. 13BSPR sensorgrams showing the binding kinetics of BCA7-2E1 antibody to mouse BCMA protein.

[0087] Fig.14 It is a bar graph showing the results of ELISA analysis of the cross-reactivity of various anti-BCMA antibodies with mouse, cynomolgus monkey or human BCMA protein. The vertical axis shows absorbance.

[0088] Fig.15 is a graph showing the results of binding of various anti-BCMA antibodies to the MM1R cell line by flow cytometry.

[0089] Fig.16 It is a bar graph showing the results of epitope mapping analysis using a sandwich ELISA procedure. The vertical axis shows absorbance.

[0090] Fig.17 The ribbon diagram presented by BCMA protein is shown.

[0091] Fig.18 is a diagram showing the results of protein-protein binding analysis using bio-layer interferometry.

[0092] Fig.19 is a diagram showing the results of protein-protein binding analysis using bio-layer interferometry.

[0093] Fig. 20 is a bar graph showing the results of epitope mapping analysis using biolayer interferometry.

[0094] Fig.21 Results of protein binding blockade analysis using biolayer interferometry are shown.

[0095] Fig. 22 Results of antibody-protein binding analysis using bio-layer interferometry are shown. DETAILED DESCRIPTION

[0096] definition:

[0097] Unless otherwise defined, the technical and scientific terms used herein have the meanings commonly understood by those of ordinary skill in the art. In general, the terms related to cell and tissue culture, molecular biology, immunology, microbiology, genetics, transgenic cell production, protein chemistry and nucleic acid chemistry and hybridization techniques as described herein are well-known and commonly used in the art. Unless otherwise specified, the methods and techniques provided herein are usually carried out according to the conventional procedures described in the various general and more specific references well-known in the art and cited and discussed herein. See, for example, Sambrook et al. Molecular cloning: Laboratory Manual (Molecular Cloning: A Laboratory Manual), 2nd edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (1989) and Ausubel et al., Current Protocols in Molecular Biology, Greene Publishing Associates (1992).Many basic texts describe standard antibody production procedures, including Borrebaeck (ed.) Antibody Engineering, 2nd ed. Freeman and Company, NY, 1995; McCafferty et al. Antibody Engineering, A Practical Approach IRLat Oxford Press, Oxford, England, 1996; and Paul (1995) Antibody Engineering Protocols Humana Press, Towata, NJ, 1995; Paul (ed.), Fundamental Immunology, Raven Press, NY, 1993; Coligan (1991) Current Protocols in Immunology Wiley / Greene, NY; Harlow and Lane (1989) Antibodies: A Laboratory Manual Cold Spring Harbor Press, NY; Stites et al. (eds.) Basic and Clinical Immunology (4th ed.) Lange & Rowe Press, NY, 1996. Medical Publications, Los Altos, Calif. and references cited therein; Coding Monoclonal Antibodies: Principles and Practice (2nd Edition) Academic Press, New York, NY, 1986 and Kohler and Milstein Nature 256:495-497, 1975. All references cited herein are incorporated herein by reference in their entirety. Enzymatic reactions and enrichment / purification techniques are also well known and performed according to the manufacturer's instructions, as is commonly accomplished in the art or as described herein. Terms and laboratory procedures and techniques related to analytical chemistry, synthetic organic chemistry, and drug and pharmaceutical chemistry as described herein are all well known and commonly used in the art. Standard techniques can be used for chemical synthesis, chemical analysis, drug preparation, formulation and delivery, and treatment of patients.

[0098] The headings provided herein are not limitations of the various aspects of the disclosure, which can be understood by reference to the specification as a whole.

[0099] Unless otherwise required by context, singular terms shall include pluralities and plural terms shall include the singular. The singular forms "a", "an" and "the" and any word used in the singular include plural referents unless expressly and unequivocally limited to one referent.

[0100] It should be understood that alternative words (such as "or") used herein mean one or two of the alternatives or any combination thereof.

[0101] As used herein, the term "and / or" means the specific disclosure of each particular feature or component, whether or not there are other features or components. For example, the term "and / or" as used herein in a phrase such as "A and / or B" is intended to include "A and B," "A or B," "A" (alone), and "B" (alone). Similarly, the term "and / or" as used in a phrase such as "A, B, and / or C" is intended to cover the following: A, B, and C; A, B or C; A or C; A or B; B or C; A and C; A and B; B and C; A (alone); B (alone); and C (alone).

[0102] As used herein, the terms "comprises," "including," "having," and "containing," and their grammatical variations are intended to be non-limiting, such that one or more items in a list do not exclude other items that can be substituted or added to the listed items. It should be understood that wherever aspects are described herein with "comprising" language, other similar aspects described as "consisting of" and / or "consisting essentially of" are also provided.

[0103] As used herein, the term "about" refers to a value or composition within an acceptable error range of a particular value or composition determined by a person of ordinary skill in the art, which will depend in part on how to measure or determine the value or composition, i.e., the limitations of the measurement system. For example, "about" or "substantially including" can mean within one or more than one standard deviation according to the practice of the art. Alternatively, "about" or "substantially including" can mean a range of up to 10% (i.e., ± 10%) or more, depending on the limitations of the measurement system. For example, about 5 mg can include any number between 4.5 mg and 5.5 mg. In addition, particularly with respect to biological systems or processes, the term can mean a value of up to an order of magnitude or up to 5 times. When a specific value or composition is provided in the present disclosure, unless otherwise stated, the meaning of "about" or "substantially including" should be assumed to be within an acceptable error range of the specific value or composition.

[0104] The terms "peptide", "polypeptide" and "protein" and other related terms used herein are used interchangeably and refer to polymers of amino acids and are not limited to any particular length. Polypeptides may comprise natural and non-natural amino acids. Polypeptides include recombinant or chemically synthesized forms. These terms encompass native and artificial proteins, protein fragments and polypeptide analogs of protein sequences (such as mutants, variants, chimeric proteins and fusion proteins), and proteins that are post-translationally or otherwise covalently or non-covalently modified. Described herein are polypeptides comprising the amino acid sequence of a binding protein that binds to BCMA prepared using a recombinant procedure (e.g., an anti-BCMA antibody or an antigen-binding portion thereof).

[0105] The terms "nucleic acid", "polynucleotide" and "oligonucleotide", as well as other related terms used herein, are used interchangeably and refer to polymers of nucleotides and are not limited to any particular length. Nucleic acids include recombinant and chemically synthesized forms. Nucleic acids include DNA molecules (cDNA or genomic DNA), RNA molecules (e.g., mRNA), analogs of DNA or RNA generated using nucleotide analogs (e.g., peptide nucleic acids and non-naturally occurring nucleotide analogs), and hybrids thereof. Nucleic acid molecules may be single-stranded or double-stranded. In one embodiment, the nucleic acid molecules of the present disclosure include a continuous open reading frame encoding an antibody or fragment thereof or scFv, derivative, mutein or variant. In one embodiment, the nucleic acid includes a mixture of one type of polynucleotide or two or more different types of polynucleotides. Nucleic acids encoding anti-BCMA antibodies or antigen-binding portions thereof are described herein.

[0106] The term "recover / recovery / recovering" and other related terms refer to obtaining a protein (e.g., an antibody or its antigen-binding portion thereof) from a host cell culture medium or from a host cell lysate or from a host cell membrane. In one embodiment, the protein is expressed by a host cell as a recombinant protein fused to a secretion signal peptide sequence, which mediates the secretion of the expressed protein. The secreted protein can be recovered from the host cell culture medium. In one embodiment, the protein is expressed by a host cell as a recombinant protein lacking a secretion signal peptide sequence, which can be recovered from a host cell lysate. In one embodiment, the protein is expressed by a host cell as a membrane-bound protein, which can be recovered by releasing the expressed protein from the host cell membrane using a detergent. In one embodiment, no matter which method is used to recover the protein, the protein can be subjected to a procedure for removing cell debris from the recovered protein. For example, the recovered protein can be subjected to chromatography, gel electrophoresis and / or dialysis. In one embodiment, chromatography includes any one or any combination or two or more procedures, including affinity chromatography, hydroxyapatite chromatography, ion exchange chromatography, reverse phase chromatography and / or silica gel chromatography. In one embodiment, the affinity chromatography includes Protein A or G (cell wall components from Staphylococcus aureus).

[0107] The term "isolated" refers to a protein (e.g., an antibody or an antigen-binding portion thereof) or polynucleotide that is substantially free of other cellular material. The protein can be isolated using protein purification techniques well known in the art so that it is substantially free of naturally associated components (or components associated with a cell expression system or a chemical synthesis method for producing antibodies). The term isolated in some embodiments also refers to a protein or polynucleotide that is substantially free of other molecules of the same species, such as other proteins or polynucleotides having different amino acid or nucleotide sequences, respectively. The purity uniformity of the desired molecule can be analyzed using techniques well known in the art, including low-resolution methods such as gel electrophoresis and high-resolution methods such as HPLC or mass spectrometry. In one embodiment, any anti-BCMA antibody or antigen-binding protein thereof is isolated.

[0108] As used herein, "antigen binding protein" and related terms refer to a protein comprising a portion that binds to an antigen and a scaffold or framework portion, optionally, the scaffold or framework portion allows the antigen binding portion to adopt a conformation that promotes the binding of the antigen binding protein to the antigen. Examples of antigen binding proteins include antibodies, antibody fragments (e.g., antigen binding portions of antibodies), antibody derivatives, and antibody analogs. The antigen binding protein may comprise, for example, an alternative protein scaffold or an artificial scaffold with a transplanted CDR or CDR derivative. Such scaffolds include, but are not limited to, antibody-derived scaffolds that include mutations introduced to, for example, stabilize the three-dimensional structure of the antigen binding protein; and fully synthetic scaffolds that include, for example, biocompatible polymers. See, for example, Korndorfer et al., 2003, Proteins: Structure, Function, and Bioinformatics, Vol. 53, No. 1: 121-129; Roque et al., 2004, Biotechnol. Prog. 20: 639-654. Additionally, peptide antibody mimetics ("PAMs") can also be used, as well as scaffolds based on antibody mimetics utilizing fibronectin components as scaffolds.Antigen binding proteins that bind BCMA are described herein.

[0109] Antigen binding proteins can have the structure of, for example, immunoglobulins. In one embodiment, an "immunoglobulin" refers to a tetrameric molecule consisting of two pairs of identical polypeptide chains, each pair having a "light" chain (about 25 kDa) and a "heavy" chain (about 50-70 kDa). The amino terminal portion of each chain includes a variable region of about 100 to 110 or more amino acids, which is primarily responsible for antigen recognition. The carboxyl terminal portion of each chain defines a constant region primarily responsible for effector function. Human light chains are classified as κ or λ light chains. Heavy chains are classified as μ, δ, γ, α or ε, and the isotypes of antibodies are defined as IgM, IgD, IgG, IgA and IgE, respectively. Within the light and heavy chains, the variable and constant regions are connected by a "J" region of about 12 or more amino acids, and the heavy chain also includes a "D" region of about 10 amino acids. See generally Fundamental Immunology, Chapter 7 (Paul, W., ed., 2nd ed. Raven Press, NY (1989)) (incorporated by reference in its entirety for all purposes). The variable regions of each light / heavy chain pair form an antibody binding site, such that a complete immunoglobulin has two antigen binding sites. In one embodiment, the antigen binding protein can be a synthetic molecule that is structurally different from a tetrameric immunoglobulin molecule but still capable of binding to a target antigen or binding to two or more target antigens. For example, a synthetic antigen binding protein can include an antibody fragment, 1-6 or more polypeptide chains, an asymmetric assembly of polypeptides, or other synthetic molecules. Antigen binding proteins having immunoglobulin-like properties that specifically bind to BCMA are described herein.

[0110] The variable regions of immunoglobulin chains exhibit the same general structure of a relatively conserved framework region (FR) connected by three hypervariable regions, also called complementarity determining regions or CDRs. From N-terminus to C-terminus, both light and heavy chains comprise the domains FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4.

[0111] One or more CDRs can be covalently or non-covalently incorporated into a molecule to make it an antigen binding protein. Antigen binding proteins can incorporate CDRs as part of a larger polypeptide chain, can covalently link CDRs to another polypeptide chain, or can incorporate CDRs non-covalently. CDRs allow antigen binding proteins to specifically bind to a particular antigen of interest.

[0112] The amino acid assignments for each domain conform to the definitions of Kabat et al. in Sequences of Proteins of Immunological Interest, 5th Edition, U.S. Department of Health and Human Services, PHS, NIH, NIH Publication No. 91-3242, 1991. Other numbering systems for amino acids in immunoglobulin chains include IMGT.RTM. (International Immunogenetics Information System; Lefranc et al., Dev. Comp. Immunol. 29: 185-203; 2005) and AHo (Honegger and Pluckthun, J. Mol. Biol. 309(3): 657-670; 2001); Chothia (Al-Lazikani et al., 1997 Journal of Molecular Biology 273: 927-948; Contact (Maccallum et al., 1996 Journal of Molecular Biology 262: 732-745 and Aho (Honegger and Pluckthun 2001 Journal of Molecular Biology 309: 657-670).

[0113] As used herein, "antibody" and related terms refer to a complete immunoglobulin or an antigen-binding portion thereof (or an antigen-binding fragment thereof) that specifically binds to an antigen. The antigen-binding portion (or antigen-binding fragment) can be produced by recombinant DNA technology or by enzymatic or chemical cleavage of a complete antibody. The antigen-binding portion (or antigen-binding fragment) particularly includes Fab, Fab', F(ab')2, Fv, domain antibodies (dAb) and complementary determining region (CDR) fragments, single-chain antibodies (scFv), chimeric antibodies, bifunctional antibodies, trifunctional antibodies, tetrafunctional antibodies, and polypeptides containing at least a portion of an immunoglobulin, at least a portion of which is sufficient to confer specific antigen binding to the polypeptide.

[0114] Antibodies include recombinantly produced antibodies and antigen-binding portions. Antibodies include non-human antibodies, chimeric antibodies, humanized antibodies and fully human antibodies. Antibodies include monospecific, multispecific (e.g., bispecific, trispecific and high-order specific). Antibodies include tetrameric antibodies, light chain monomers, heavy chain monomers, light chain dimers, heavy chain dimers. Antibodies include F(ab')2 fragments, Fab' fragments and Fab fragments. Antibodies include single domain antibodies, monovalent antibodies, single chain antibodies, single chain variable fragments (scFv), camelized antibodies, affinity antibodies, disulfide bond-linked Fv (sdFv), anti-idiotypic antibodies (anti-Id), mini antibodies. Antibodies include monoclonal and polyclonal populations. Anti-BCMA antibodies are described herein.

[0115] As used herein, "antigen binding domain," "antigen binding region," or "antigen binding site" and other related terms refer to a portion of an antigen binding protein that contains the amino acid residues (or other moieties) that interact with an antigen and contribute to the specificity and affinity of the antigen binding protein for the antigen. For an antibody that specifically binds to its antigen, this will include at least a portion of at least one of its CDR domains. Antigen binding domains of anti-BCMA antibodies are described herein.

[0116] As used herein in the context of antibodies or antigen-binding proteins or antibody fragments, the term "specific binding", "specifically binds", "specifically binding" and other related terms refer to non-covalent or covalent preferential binding to an antigen relative to other molecules or moieties (e.g., an antibody specifically binds to a specific antigen relative to other available antigens). In one embodiment, if the dissociation constant K of the antibody binding to the antigen is D For 10 -5 M or smaller, or 10 -6 M or smaller, or 10 -7 M or smaller, or 10 -8 M or smaller, or 10 -9 M or smaller, or 10 -10 M or less, the antibody specifically binds to the target antigen. Anti-BCMA antibodies that specifically bind to BCMA are described herein.

[0117] In one embodiment, the dissociation constant (K D) can be measured using BIACORE surface plasmon resonance (SPR) analysis. Surface plasmon resonance refers to an optical phenomenon that can be used to analyze real-time interactions by detecting changes in protein concentration within a biosensor matrix, such as using the BIACORE system (Biacore Life Sciences division of GE Healthcare, Piscataway, NJ).

[0118] As used herein, "epitope" and related terms refer to the portion of an antigen that is bound by an antigen binding protein (e.g., by an antibody or its antigen binding portion). An epitope may comprise portions of two or more antigens that are bound by an antigen binding protein. An epitope may comprise non-continuous portions of one antigen or two or more antigens (e.g., amino acid residues that are not continuous in the primary sequence of an antigen, but in the case of the tertiary and quaternary structures of the antigen, they are close to each other and are sufficient to be bound by an antigen binding protein). In general, the variable regions of an antibody, particularly the CDRs, interact with an epitope. Anti-BCMA antibodies and antigen binding proteins thereof that bind to an epitope of a BCMA polypeptide are described herein.

[0119] As used herein, "antibody fragment," "antibody portion," "antigen-binding fragment of an antibody," or "antigen-binding portion of an antibody," and other related terms refer to molecules other than intact antibodies that contain a portion of an intact antibody that binds to the antigen to which the intact antibody binds. Examples of antibody fragments include, but are not limited to, Fv, Fab, Fab', Fab'-SH, F(ab')2; Fd; and Fv fragments, as well as dAbs; bifunctional antibodies; linear antibodies; single-chain antibody molecules (e.g., scFv); polypeptides containing at least a portion of an antibody sufficient to confer specific antigen binding to the polypeptide. Antigen-binding portions of antibodies can be produced by recombinant DNA techniques or by enzymatic or chemical cleavage of intact antibodies. Antigen-binding portions include, among others, Fab, Fab', F(ab')2, Fv, domain antibodies (dAbs), and complementarity determining region (CDR) fragments, chimeric antibodies, bifunctional antibodies, trifunctional antibodies, tetrafunctional antibodies, and polypeptides containing at least a portion of an immunoglobulin sufficient to confer antigen-binding properties to the antibody fragment. Antigen-binding fragments of anti-BCMA antibodies are described herein.

[0120] The terms "Fab", "Fab fragment" and other related terms refer to the fragment containing the variable light chain region (V L ), constant light chain region (C L ), variable heavy chain region (V H ) and the first constant region (C H1) is a monovalent fragment. Fab is able to bind to antigen. The F(ab')2 fragment is a bivalent fragment containing two Fab fragments connected by a disulfide bond in the hinge region. F(Ab')2 has antigen binding ability. The Fd fragment contains V H and C H1 The Fv fragment contains V L and V H region. Fv can bind to antigen. dAb fragment has V H Domain, V L Domain or V H Antigen-binding fragments of the VL domain or VL domain (U.S. Pat. Nos. 6,846,634 and 6,696,245; U.S. Published Application Nos. 2002 / 02512, 2004 / 0202995, 2004 / 0038291, 2004 / 0009507, 2003 / 0039958; and Ward et al., Nature 341:544-546, 1989). Fab fragments comprising an antigen-binding portion of an anti-BCMA antibody are described herein.

[0121] Single chain antibody (scFv) is a V L and V H The regions are connected by a linker (e.g., a synthetic sequence of amino acid residues) to form an antibody of a continuous protein chain. Preferably, the linker is long enough to allow the protein chain to fold back on itself and form a monovalent antigen binding site (see, e.g., Bird et al., 1988, Science 242:423-26 and Huston et al., 1988, Proc. Natl. Acad. Sci. USA 85:5879-83). Single-chain antibodies comprising an antigen-binding portion of an anti-BCMA antibody are described herein.

[0122] Diabodies are bivalent antibodies composed of two polypeptide chains, each of which contains a V H and V LDomains, the linker is too short to pair between the two domains on the same chain, thus allowing each domain to pair with the complementary domain on the other polypeptide chain (see, e.g., Holliger et al., 1993, Proc. Natl. Acad. Sci. USA 90: 6444-48 and Poljak et al., 1994, Structure 2: 1121-23). ​​If the two polypeptide chains of the double-chain antibody are identical, the double-chain antibody produced by their pairing will have two identical antigen-binding sites. Polypeptide chains with different sequences can be used to make double-chain antibodies with two different antigen-binding sites. Similarly, three-chain antibodies and four-chain antibodies are antibodies comprising three and four polypeptide chains, respectively, and forming three and four antigen-binding sites, respectively, which may be the same or different. Double-chain antibodies, three-chain antibodies and four-chain antibody constructs can be prepared using the antigen-binding portion of any anti-BCMA antibody described herein.

[0123] The term "human antibody" refers to an antibody having one or more variable and constant regions derived from human immunoglobulin sequences. In one embodiment, all variable and constant domains are derived from human immunoglobulin sequences (e.g., fully human antibodies). These antibodies can be prepared in a variety of ways, examples of which are described below, including by recombinant methods or by immunizing with an antigen of interest in a mouse, the mouse being genetically modified to express antibodies derived from human heavy and / or light chain encoding genes. Fully human anti-BCMA antibodies and antigen-binding proteins thereof are described herein.

[0124] "Humanized" antibody refers to an antibody whose sequence is different from the sequence of an antibody derived from a non-human species by one or more amino acid substitutions, deletions and / or additions, so that the humanized antibody is less likely to induce an immune response when applied to a human subject than the non-human species antibody, and / or induces a less severe immune response. In one embodiment, certain amino acid mutations in the framework and constant domain of the heavy chain and / or light chain of the non-human species antibody are used to produce a humanized antibody. In another embodiment, the constant domain of a human antibody is fused with the variable domain of a non-human species. In another embodiment, one or more amino acid residues in one or more CDR sequences of a non-human antibody are changed to reduce the possible immunogenicity of the non-human antibody when applied to a human subject, wherein the amino acid residues changed are not critical for the immunospecific binding of the antibody to its antigen, or the changes made to the amino acid sequence are conservative changes, so that the binding of the humanized antibody to the antigen will not be significantly worse than the binding of the non-human antibody to the antigen. Examples of how to make humanized antibodies can be found in US Pat. Nos. 6,054,297, 5,886,152, and 5,877,293.

[0125] The term "chimeric antibody" and related terms used herein refer to an antibody containing one or more regions from a first antibody and one or more regions from one or more other antibodies. In one embodiment, one or more CDRs are derived from human antibodies. In another embodiment, all CDRs are derived from human antibodies. In another embodiment, CDRs from more than one human antibody are mixed and matched in a chimeric antibody. For example, a chimeric antibody can include CDR1 from a first human antibody light chain, CDR2 and CDR3 from a second human antibody light chain, and CDRs from a third antibody heavy chain. In another example, CDRs are derived from different species, such as humans and mice, or humans and rabbits, or humans and goats. It will be appreciated by those skilled in the art that other combinations are also possible.

[0126] In addition, the framework region may be derived from one of the same antibodies, from one or more different antibodies, such as human antibodies, or from a humanized antibody. In one example of a chimeric antibody, a portion of the heavy and / or light chain is identical, homologous, or derived from an antibody from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain is identical, homologous, or derived from an antibody from another species or belonging to another antibody class or subclass. Also included are fragments of such antibodies that exhibit the desired biological activity (i.e., the ability to specifically bind to a target antigen). Chimeric antibodies can be prepared from portions of any anti-BCMA antibody described herein.

[0127] As used herein, the terms "variant" polypeptide and "variant" of a polypeptide refer to a polypeptide comprising an amino acid sequence having one or more amino acid residues inserted into, deleted from, and / or substituted into an amino acid sequence relative to a reference polypeptide sequence. Polypeptide variants include fusion proteins. Similarly, a variant polynucleotide comprises a nucleotide sequence having one or more nucleotides inserted into, deleted from, and / or substituted into a nucleotide sequence relative to another polynucleotide sequence. Polynucleotide variants include fusion polynucleotides.

[0128] As used herein, the term "derivative" of a polypeptide is a polypeptide (e.g., an antibody) that has been chemically modified, such as by conjugation with another chemical moiety such as polyethylene glycol, albumin (e.g., human serum albumin), phosphorylation, and glycosylation. Unless otherwise indicated, the term "antibody" includes derivatives, variants, fragments, and mutant proteins thereof in addition to antibodies comprising two full-length heavy chains and two full-length light chains, examples of which are described below.

[0129] As used herein, the term "Fc" or "Fc region" refers to the portion of the constant region of an antibody heavy chain that begins in or after the hinge region and ends at the C-terminus of the heavy chain. The Fc region comprises at least a portion of the CH and CH3 regions and may or may not include a portion of the hinge region. Two polypeptide chains, each carrying half of the Fc region, can dimerize to form a complete Fc domain. The Fc domain can bind to Fc cell surface receptors and some proteins of the immune complement system. The Fc domain exhibits effector functions, including any one or any combination of two or more activities, including complement dependent cytotoxicity (CDC), antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent phagocytosis (ADP), opsonization and / or cell binding. The Fc domain can bind to Fc receptors, including FcγRI (e.g., CD64), FcγRII (e.g., CD32) and / or FcγRIII (e.g., CD16a).

[0130] As used herein, the term "labeled antibody" or related terms refers to an antibody and antigen-binding portion thereof that is unlabeled or linked to a detectable label or moiety for detection, wherein the detectable label or moiety is radioactive, colorimetric, antigenic, enzymatic, detectable beads (such as magnetic or electron-dense (such as gold) beads), biotin, streptavidin or protein A. A variety of labels can be used, including but not limited to radionuclides, fluorescent agents, enzymes, enzyme substrates, enzyme cofactors, enzyme inhibitors, and ligands (e.g., biotin, haptens). Any anti-BCMA antibody described herein can be unlabeled or can be linked to a detectable label or moiety.

[0131] " Percentage identity " or " homology percentage " and related terms used herein refer to the quantitative measurement of the similarity between two polypeptides or between two polynucleotide sequences. The percentage identity between two polypeptide sequences is a function of the number of identical amino acids shared at the alignment position between the two polypeptide sequences, taking into account the number of gaps and the length of each gap, which may need to be introduced to optimize the alignment of the two polypeptide sequences. In a similar manner, the percentage identity between two polynucleotide sequences is a function of the number of identical nucleotides shared at the alignment position between the two polynucleotide sequences, taking into account the number of gaps and the length of each gap, which may need to be introduced to optimize the alignment of the two polynucleotide sequences. The comparison of sequences and the determination of the percentage identity between two polypeptide sequences or between two polynucleotide sequences can be realized using a mathematical algorithm. For example, the " percentage identity " or " percentage homology " of two polypeptides or two polynucleotide sequences can be determined by using the GAP computer program (a part of the GCG Wisconsin Package, version 10.3 (Accelrys, San Diego, Calif.)) using its default parameters to compare sequences.

[0132] In one embodiment, the amino acid sequence of the test antibody may be similar but not identical to any amino acid sequence of the polypeptide constituting any anti-BCMA antibody or antigen-binding protein thereof described herein. The similarity between the test antibody and the polypeptide may be at least 95%, or at least 96% identical, or at least 97% identical, or at least 98% identical, or at least 99% identical to any polypeptide constituting any anti-BCMA antibody or antigen-binding protein thereof described herein. In one embodiment, the similar polypeptide may contain amino acid substitutions within the heavy chain and / or light chain. In one embodiment, the amino acid substitutions include one or more conservative amino acid substitutions. "Conservative amino acid substitution" is an amino acid residue replaced by another amino acid residue having a side chain (R group) of similar chemical properties (e.g., charge or hydrophobicity). In general, conservative amino acid substitutions do not substantially change the functional properties of the protein. In the case where two or more amino acid sequences differ from each other due to conservative substitutions, the percentage of sequence identity or degree of similarity may be adjusted upward to correct for the conservative nature of the substitution. The means for making such adjustments are well known to those skilled in the art. See, e.g., Pearson (1994) Methods Mol. Biol. 24:307-331, which is incorporated herein by reference in its entirety. Examples of groups of amino acids having side chains with similar chemical properties include (1) aliphatic side chains: glycine, alanine, valine, leucine, and isoleucine; (2) aliphatic hydroxyl side chains: serine and threonine; (3) amide-containing side chains: asparagine and glutamine; (4) aromatic side chains: phenylalanine, tyrosine, and tryptophan; (5) basic side chains: lysine, arginine, and histidine; (6) acidic side chains: aspartic acid and glutamic acid, and (7) sulfur-containing side chains: cysteine ​​and methionine.

[0133] Antibodies can be obtained from sources such as serum or plasma containing immunoglobulins of different antigen specificities. If such antibodies are affinity purified, they can be enriched for specific antigen specificity. Such enriched antibody preparations are usually made of less than about 10% antibodies with specific binding activity to a specific antigen. Several rounds of affinity purification of these preparations can increase the proportion of antibodies with specific binding activity to the antigen. Antibodies prepared in this way are generally referred to as "monospecific". Monospecific antibody preparations can be composed of about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 99% or 99.9% antibodies with specific binding activity to a specific antigen. Antibodies can be produced using recombinant nucleic acid technology as described below.

[0134] As used herein, "vector" and related terms refer to a nucleic acid molecule (e.g., DNA or RNA) that can be operably linked to foreign genetic material (e.g., a nucleic acid transgene). A vector can be used as a vehicle for introducing foreign genetic material into a cell (e.g., a host cell). A vector may include at least one restriction endonuclease recognition sequence for inserting a transgene into the vector. A vector may include at least one gene sequence that confers antibiotic resistance or selectable characteristics to aid in the selection of host cells carrying a vector-transgene construct. A vector may be a single-stranded or double-stranded nucleic acid molecule. A vector may be a linear or circular nucleic acid molecule. One type of vector is a "plasmid," which refers to a linear or circular double-stranded extrachromosomal DNA molecule that can be linked to a transgene and is capable of replicating in a host cell, as well as transcribing and / or translating the transgene. Viral vectors typically contain a viral RNA or DNA backbone sequence that can be linked to a transgene. The viral backbone sequence may be modified to render the infection ineffective, but retain the viral backbone and the co-linked transgene inserted into the host cell genome. Examples of viral vectors include retroviruses, slow viruses, adenoviruses, adeno-associated viruses, baculoviruses, papovaviruses, vaccinia viruses, herpes simplex viruses, and Epstein-Barr virus vectors. Some vectors can replicate autonomously in the host cell into which they are introduced (e.g., bacterial vectors and additional mammalian vectors comprising bacterial replication origins). Other vectors (e.g., non-additional mammalian vectors) are integrated into the genome of the host cell after introducing the host cell, thereby replicating together with the host genome.

[0135] An "expression vector" is a type of vector that may contain one or more regulatory sequences such as inducible and / or constitutive promoters and enhancers. An expression vector may include a ribosome binding site and / or a polyadenylation site. The regulatory sequence directs the transcription or transcription and translation of a transgene that is linked to an expression vector transduced into a host cell. The regulatory sequence may control the level, timing, and / or location of expression of the transgene. For example, a regulatory sequence may exert its influence on the transgene directly or through the action of one or more other molecules (e.g., a polypeptide that binds to a regulatory sequence and / or nucleic acid). The regulatory sequence may be part of a vector. Other examples of regulatory sequences are described, for example, in Goeddel, 1990, Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, Calif. and Baron et al., 1995, Nucleic Acids Res. 23: 3605-3606. The expression vector may contain at least a portion of any anti-BCMA antibody described herein.

[0136] A transgene is "operably linked" to a vector when the relationship between the transgene and the vector allows the transgene sequences contained in the vector to function or be expressed. In one embodiment, a transgene is "operably linked" to a regulatory sequence when the regulatory sequence affects the expression of the transgene (e.g., the level, timing, or location of expression).

[0137] The terms "transfection" or "transformation" or "transduction" or other related terms used herein refer to the process of transferring or introducing exogenous nucleic acids (e.g., transgenes) into host cells. A "transfected" or "transformed" or "transduced" host cell is a host cell that has been transfected, transformed, or transduced with an exogenous nucleic acid (transgene). Host cells include primary subject cells and their progeny. Exogenous nucleic acids encoding at least a portion of any anti-BCMA antibody described herein can be introduced into host cells. An expression vector comprising at least a portion of any anti-BCMA antibody described herein can be introduced into a host cell, and the host cell can express a polypeptide comprising at least a portion of the anti-BCMA antibody.

[0138] As used herein, the term "host cell" or "or a population of host cells" or related terms refers to a cell (or a population or multiple host cells) into which an exogenous (exogenous or transgenic) nucleic acid has been introduced. The exogenous nucleic acid may include an expression vector operably linked to a transgene, and the host cell may be used to express nucleic acids and / or polypeptides encoded by the exogenous nucleic acid (transgene). The host cell (or its population) may be a cultured cell or may be extracted from a subject. The host cell (or its population) includes primary subject cells and their progeny, regardless of the number of passages. Compared to the parent cell, the progeny cell may or may not contain the same genetic material. The host cell encompasses progeny cells. In one embodiment, the host cell describes any cell (including its progeny) that is modified, transfected, transduced, transformed and / or manipulated in any way to express an antibody as disclosed herein. In one example, a host cell (or its population) may be introduced into an expression vector operably linked to a nucleic acid encoding a desired antibody or antigen-binding portion thereof as described herein. The host cell and its population may carry an expression vector stably integrated into the host genome or may carry an extrachromosomal expression vector. In one embodiment, host cells and populations thereof may carry an extrachromosomal vector that persists after several cell divisions, or persists transiently and disappears after several cell divisions.

[0139] The host cell can be a prokaryotic organism, such as E. coli, or can be a eukaryotic organism, such as a unicellular eukaryotic organism (e.g., yeast or other fungi), a plant cell (e.g., a tobacco or tomato plant cell), a mammalian cell (e.g., a human cell, a monkey cell, a hamster cell, a rat cell, a mouse cell, or an insect cell), or a hybridoma. In one embodiment, the host cell can introduce an expression vector operably linked to a nucleic acid encoding a desired antibody, thereby producing a transfected / transformed host cell, which is cultured under conditions suitable for the transfected / transformed host cell to express the antibody, and the antibody can be optionally recovered from the transfected / transformed host cell (e.g., recovered from a host cell lysate) or recovered from the culture medium. In one embodiment, the host cell includes non-human cells, including CHO, BHK, NS0, SP2 / 0, and YB2 / 0. In one embodiment, the host cell includes human cells, including HEK293, HT-1080, Huh-7, and PER.C6. Examples of host cells include the COS-7 line of monkey kidney cells (ATCC CRL 1651) (see Gluzman et al., 1981, Cell 23:175), L cells, C127 cells, 3T3 cells (ATCC CCL 163), Chinese hamster ovary (CHO) cells or derivatives thereof, such as Veggie CHO and related cell lines grown in serum-free medium (see Rasmussen et al., 1998, Cytotechnology 28:31) or the CHO strain DX-B 11 lacking DHFR (see Urlaub et al., 1980, Proc. Natl. Acad. Sci. USA 77:4216-20), HeLa cells, BHK (ATCC CRL 10) cell line, CV1 / EBNA cell line derived from the African green monkey kidney cell line CV1 (ATCC CCL 70) (see McMahan et al., 1991, EMBO J.10:2821), human embryonic kidney cells such as 293, 293EBNA or MSR 293, human epidermal A431 cells, human Colo 205 cells, other transformed primate cell lines, normal diploid cells, cell lines obtained from in vitro culture of primary tissues, primary explants, HL-60, U937, HaK or Jurkat cells. In one embodiment, the host cell comprises a lymphocyte, such as Y0, NS0 or Sp20. In one embodiment, the host cell is a mammalian host cell, but not a human host cell. Typically, the host cell is a cultured cell that can be transformed or transfected with a nucleic acid encoding a polypeptide, which can then be expressed in the host cell. The phrase "transgenic host cell" or "recombinant host cell" can be used to refer to a host cell that has been transformed or transfected with a nucleic acid to be expressed.Host cell can also be a cell that contains nucleic acid but does not express nucleic acid at a desired level, unless a regulatory sequence is introduced into the host cell so that it is operably connected to the nucleic acid. It should be understood that the term "host cell" refers not only to a specific subject cell, but also to the offspring or potential offspring of such cells. Because some modifications may occur in subsequent generations due to, for example, sudden changes or environmental influences, such offspring may not in fact be identical to the parent cell, but are still included in the scope of the term used herein.

[0140] The polypeptides (e.g., antibodies and antigen-binding proteins) disclosed herein can be produced using any method known in the art. In one embodiment, the polypeptide is produced by a recombinant nucleic acid method by inserting a nucleic acid sequence (e.g., DNA) encoding the polypeptide into a recombinant expression vector, introducing the recombinant expression vector into a host cell, and expressing the host cell under conditions that promote expression.

[0141] The general techniques of recombinant nucleic acid manipulation are described in, for example, Sambrook et al., Molecular Cloning: A Laboratory Manual, Vol. 1-3, Cold Spring Harbor Laboratory Press, 2nd edition, 1989 or F.Ausubel et al., Current Protocols in Molecular Biology (Green Publishing and Wiley-Interscience: New York, 1987) and regular updates, which are incorporated herein by reference in their entirety. The nucleic acid (e.g., DNA) encoding the polypeptide is operably connected to an expression vector carrying one or more suitable transcription or translation regulatory elements derived from mammalian, viral or insect genes. Such regulatory elements include transcription promoters, optional operator sequences controlling transcription, sequences encoding suitable mRNA ribosome binding sites, and sequences controlling transcription and translation termination. The expression vector may include a starting point or replication that imparts replication capability in a host cell. The expression vector may include a gene that imparts selection to promote recognition of a transgenic host cell (e.g., a transformant).

[0142] The recombinant DNA can also encode any type of protein tag sequence, which may be useful for purifying proteins. Examples of protein tags include, but are not limited to, histidine tags, FLAG tags, myc tags, HA tags, or GST tags. Suitable cloning and expression vectors for bacterial, fungal, yeast, and mammalian cell hosts can be found in Cloning Vectors: A Laboratory Manual, (Elsevier, NY, 1985).

[0143] The expression vector construct can be introduced into the host cell using a method appropriate for the host cell. Various methods for introducing nucleic acids into host cells are known in the art, including but not limited to electroporation; transfection using calcium chloride, rubidium chloride, calcium phosphate, DEAE-dextran or other substances; viral transfection; non-viral transfection; microprojectile bombardment; lipofection; and infection (e.g., when the vector is the infectious agent). Suitable host cells include prokaryotes, yeast, mammalian cells or bacterial cells.

[0144] Suitable bacteria include Gram-negative or Gram-positive organisms, such as Escherichia coli or Bacillus. Yeast, preferably from the genus Saccharomyces, such as S. cerevisiae, can also be used to produce polypeptides. Various mammalian or insect cell culture systems can also be used to express recombinant proteins. Luckow and Summers, (Bio / Technology, 6:47, 1988) reviewed the baculovirus system for producing heterologous proteins in insect cells. Examples of suitable mammalian host cell lines include endothelial cells, COS-7 monkey kidney cells, CV-1, L cells, C127, 3T3, Chinese hamster ovary (CHO), human embryonic kidney cells, HeLa, 293, 293T and BHK cell lines. Purified polypeptides are prepared by culturing a suitable host / vector system to express recombinant proteins. For many applications, the small size of many polypeptides disclosed herein will make expression in E. coli a preferred expression method. The protein is then purified from the culture medium or cell extract. Any anti-BCMA antibody or antigen-binding protein thereof can be expressed by a transgenic host cell.

[0145] Antibodies and antigen-binding proteins disclosed herein can also be produced using a cellular translation system. For such purposes, the nucleic acid encoding the polypeptide must be modified to allow in vitro transcription to produce mRNA and allow mRNA to be translated into cells in the particular cell-free system utilized (eukaryotic, such as mammalian or yeast cell-free translation systems or prokaryotes, such as bacterial cell-free translation systems).

[0146] Nucleic acids encoding any of the various polypeptides disclosed herein can be chemically synthesized. Codon usage can be selected to improve expression in cells. Such codon usage will depend on the cell type selected. Specific codon usage patterns have been developed for E. coli and other bacteria, as well as mammalian cells, plant cells, yeast cells, and insect cells. See, for example: Mayfield et al., Proc. Natl. Acad. Sci. USA. 2003 100 (2): 438-42; Sinclair et al. Protein Expr. Purif. 2002 (1): 96-105; Connell N D. Curr. Opin. Biotechnol. 2001 12 (5): 446-9; Makrides et al. Microbiol. Rev. 1996 60 (3): 512-38; and Sharp et al. Yeast. 1991 7 (7): 657-78.

[0147] The antibodies and antigen-binding proteins described herein can also be produced by chemical synthesis (e.g., by methods described in Solid Phase Peptide Synthesis, 2nd Edition, 1984, The Pierce Chemical Co., Rockford, 111.). Modifications to proteins can also be produced by chemical synthesis.

[0148] Antibodies and antigen-binding proteins described herein can be purified by separation / purification methods of proteins generally known in the field of protein chemistry. Non-limiting examples include extraction, recrystallization, salting out (e.g., with ammonium sulfate or sodium sulfate), centrifugation, dialysis, ultrafiltration, adsorption chromatography, ion exchange chromatography, hydrophobic chromatography, normal phase chromatography, reverse phase chromatography, gel filtration, gel permeation chromatography, affinity chromatography, electrophoresis, countercurrent distribution, or any combination of these. After purification, the polypeptide can be exchanged into different buffers and / or concentrated by any of a variety of methods known in the art, including but not limited to filtration and dialysis.

[0149] The purified antibodies and antigen-binding proteins described herein are preferably at least 65% pure, at least 75% pure, at least 85% pure, more preferably at least 95% pure, and most preferably at least 98% pure. Regardless of the exact numerical value of purity, the polypeptide is sufficiently pure for use as a pharmaceutical product. Any anti-BCMA antibody or antigen-binding protein thereof described herein can be expressed by a transgenic host cell and then purified to a purity of about 65-98% or a higher level of purity using any method known in the art.

[0150] In certain embodiments, the antibodies and antigen-binding proteins herein may also include post-translational modifications. Exemplary post-translational protein modifications include phosphorylation, acetylation, methylation, ADP-ribosylation, ubiquitination, glycosylation, carbonylation, sumoylation, biotinylation, or addition of polypeptide side chains or hydrophobic groups. Thus, the modified polypeptide may contain non-amino acid elements, such as lipids, polysaccharides or monosaccharides and phosphates. A preferred form of glycosylation is sialylation, which conjugates one or more sialic acid moieties to the polypeptide. The sialic acid moiety improves solubility and serum half-life, while also reducing the possible immunogenicity of the protein. See Raju et al. Biochemistry. 2001 31; 40(30): 8868-76.

[0151] In one embodiment, the antibodies and antigen-binding proteins described herein can be modified into soluble polypeptides, which includes connecting the antibodies and antigen-binding proteins to non-protein polymers. In one embodiment, the non-protein polymer includes polyethylene glycol ("PEG"), polypropylene glycol or polyoxyalkylene, in a manner such as described in U.S. Pat. Nos. 4,640,835; 4,496,689; 4,301,144; 4,670,417; 4,791,192 or 4,179,337.

[0152] PEG is a water-soluble polymer that is commercially available or can be prepared by ring-opening polymerization of ethylene glycol according to methods well known in the art (Sandler and Karo, Polymer Synthesis, Academic Press, New York, Vol. 3, pp. 138-161). The term "PEG" is used broadly to encompass any polyethylene glycol molecule, regardless of size or modification of the PEG termini, and can be represented by the formula: XO(CH2CH2O) n -CH2CH2OH (1), wherein n is 20 to 2300 and X is H or a terminal modification, such as C 1-4Alkyl. In one embodiment, PEG is terminated with a hydroxyl or methoxy group at one end, i.e., X is H or CH3 ("methoxy PEG"). PEG may contain other chemical groups necessary for the binding reaction; produced by chemical synthesis of the molecule; or a spacer for the optimal distance between the parts of the molecule. In addition, this PEG may be composed of one or more PEG side chains, which are linked together. PEG with more than one PEG chain is referred to as multi-arm or branched PEG. For example, branched PEG can be prepared by adding polyethylene oxide to various polyols, including glycerol, pentaerythritol and sorbitol. For example, four-arm branched PEG can be prepared from pentaerythritol and ethylene oxide. Branched PEG is described in, for example, EP-A 0 473 084 and U.S. Patent No. 5,932,462. One form of PEG includes two PEG side chains (PEG2) connected by the primary amino group of lysine (Monfardini et al., Bioconjugate Chem.6 (1995) 62-69).

[0153] The serum clearance of PEG-modified polypeptides can be modulated (e.g., increased or decreased) by about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or even 90% relative to the clearance of unmodified antibodies and antigen-binding proteins binding polypeptides. PEG-modified antibodies and antigen-binding proteins can have an increased half-life (t) relative to the half-life of unmodified polypeptides. 1 / 2 ). The half-life of PEG-modified polypeptides can be increased by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 125%, 150%, 175%, 200%, 250%, 300%, 400% or 500%, or even 1000% relative to the half-life of unmodified antibodies and antigen-binding proteins. In some embodiments, protein half-life is measured in vitro, such as in a buffered saline solution or in serum. In other embodiments, protein half-life is in vivo half-life, such as the half-life of a protein in animal serum or other body fluids.

[0154] The present disclosure provides therapeutic compositions comprising any anti-BCMA antibody or antigen binding protein thereof described herein and a pharmaceutically acceptable excipient. Excipients include carriers, stabilizers and excipients. Excipients of pharmaceutically acceptable excipients include, for example, inert diluents or fillers (e.g., sucrose and sorbitol), lubricants, glidants and anti-adhesives (e.g., magnesium stearate, zinc stearate, stearic acid, silicon dioxide, hydrogenated vegetable oil or talc). Other examples include buffers, stabilizers, preservatives, nonionic detergents, antioxidants and isotonic agents.

[0155] Therapeutic compositions and methods for their preparation are well known in the art and can be found, for example, in "Remington: The Science and Practice of Pharmacy" (20th edition, ARGennaro A R. ed., 2000, Lippincott Williams & Wilkins, Philadelphia, Pa.). Therapeutic compositions can be formulated for parenteral administration and can, for example, contain excipients, sterile water, saline, polyalkylene glycols such as polyethylene glycol, oils of plant origin, or hydrogenated naphthalene. Biocompatible, biodegradable lactide polymers, lactide / glycolide copolymers, or polyoxyethylene-polyoxypropylene copolymers can be used to control the release of the antibodies (or their antigen-binding proteins) described herein. Nanoparticle formulations (e.g., biodegradable nanoparticles, solid lipid nanoparticles, liposomes) can be used to control the biodistribution of antibodies (or their antigen-binding proteins). Other potentially useful parenteral delivery systems include ethylene-vinyl acetate copolymer particles, osmotic pumps, implantable infusion systems, and liposomes. The concentration of the antibody (or antigen binding protein thereof) in the formulation varies depending on a variety of factors, including the dose of the drug to be administered and the route of administration.

[0156] Any anti-BCMA antibody (or antigen-binding portion thereof) can be optionally administered in the form of a pharmaceutically acceptable salt, such as a non-toxic acid addition salt or metal complex commonly used in the pharmaceutical industry. Examples of acid addition salts include organic acids such as acetic acid, lactic acid, pamoic acid, maleic acid, citric acid, malic acid, ascorbic acid, succinic acid, benzoic acid, palmitic acid, suberic acid, salicylic acid, tartaric acid, methanesulfonic acid, toluenesulfonic acid or trifluoroacetic acid, etc.; polymeric acids such as tannic acid, carboxymethyl cellulose, etc.; and inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, etc. Metal complexes include zinc, iron, etc. In one example, the antibody (or antigen-binding portion thereof) is formulated in the presence of sodium acetate to increase thermal stability.

[0157] Any anti-BCMA antibody (or antigen-binding portion thereof) can be formulated for oral use, including tablets containing a mixture of the active ingredient and a non-toxic pharmaceutically acceptable excipient. Formulations for oral use can also be provided as chewable tablets, or hard gelatin capsules in which the active ingredient is mixed with an inert solid diluent, or soft gelatin capsules in which the active ingredient is mixed with water or an oil medium.

[0158] As used herein, the term "subject" refers to humans and non-human animals, including vertebrates, mammals and non-mammals. In one embodiment, the subject can be a human, non-human primate, a monkey, ape, mouse (e.g., mouse and rat), cow, pig, horse, dog, cat, goat, wolf, frog or fish.

[0159] The term "administering / administered" and grammatical variants refer to the physical introduction of a medicament into a subject using any of the various methods and delivery systems known to those skilled in the art. Exemplary routes of administration of the preparations disclosed herein include intravenous, intramuscular, subcutaneous, intraperitoneal, spinal or other parenteral routes of administration, such as by injection or infusion. As used herein, the phrase "parenteral administration" refers to the mode of administration other than enteral and topical administration, usually by injection, including but not limited to intravenous, intramuscular, intraarterial, intrathecal, intralymphatic, intralesional, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, intraarticular, subcapsular, subarachnoid, intraspinal, epidural and intrasternal injection and infusion, and in vivo electroporation. In some embodiments, the preparation is administered by non-parenteral routes, such as oral. Other non-parenteral routes include topical, epidermal or mucosal routes of administration, such as intranasal, vaginal, rectal, sublingual or topical. Administration can also be performed, for example, once, multiple times, and / or over one or more extended periods of time.Any anti-BCMA antibody (or antigen binding protein thereof) described herein can be administered to a subject using methods and delivery routes known in the art.

[0160] The terms "effective amount", "therapeutically effective amount" or "effective dose" or related terms are used interchangeably and refer to an amount of an antibody or antigen binding protein (e.g., any anti-BCMA antibody or antigen binding protein thereof described herein) that, when administered to a subject, is sufficient to achieve a measurable improvement or prevention of a disease or condition associated with tumor or cancer antigen expression. The therapeutically effective amount of the antibodies provided herein, when used alone or in combination, will depend on the relative activity of the antibodies and combinations (e.g., in terms of inhibiting cell growth), and on the subject being treated and the disease condition being treated, the subject's weight, age and sex, the severity of the subject's disease condition, the mode of administration, etc., all of which can be readily determined by one of ordinary skill in the art.

[0161] In one embodiment, the therapeutically effective amount will depend on certain aspects of the subject to be treated and the disease to be treated, and can be determined by those skilled in the art using known techniques. In general, the polypeptide is administered at about 0.01 g / kg to about 50 mg / kg per day, preferably 0.01 mg / kg to about 30 mg / kg per day, and most preferably 0.1 mg / kg to about 20 mg / kg per day. The polypeptide can be administered daily (e.g., once, twice, three times or four times per day) or preferably at a lower frequency (e.g., weekly, every two weeks, every three weeks, monthly or quarterly). In addition, as known in the art, it may be necessary to adjust the severity of age and body weight, general health, sex, diet, administration time, drug interactions and disease.

[0162] The present disclosure provides a method for treating a subject with a disease associated with BCMA expression. The disease includes cancer or tumor cells expressing tumor-associated antigens. In one embodiment, the cancer or tumor includes prostate cancer, breast cancer, ovarian cancer, head and neck cancer, bladder cancer, skin cancer, colorectal cancer, anal cancer, rectal cancer, pancreatic cancer, lung cancer (including non-small cell lung cancer and small cell lung cancer), leiomyoma, brain cancer, glioma, glioblastoma, esophageal cancer, liver cancer, kidney cancer, gastric cancer, colon cancer, cervical cancer, uterine cancer, endometrial cancer, vulvar cancer, laryngeal cancer, vaginal cancer, bone cancer, nasal cancer, paranasal sinus cancer, nasopharyngeal cancer, oral cancer, oropharyngeal cancer, laryngeal cancer, lower laryngeal cancer, salivary gland cancer, ureteral cancer, urethral cancer, penile cancer and testicular cancer.

[0163] In one embodiment, the cancer comprises a blood cancer, including leukemia, lymphoma, myeloma, and B cell lymphoma. Blood cancers include multiple myeloma (MM), non-Hodgkin's lymphoma (NHL) including Burkitt's lymphoma (BL), B chronic lymphocytic leukemia (B-CLL), systemic lupus erythematosus (SLE), B and T acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), diffuse large B cell lymphoma, chronic myeloid leukemia (CML), hairy cell leukemia (HCL), follicular lymphoma, Waldenstrom's macroglobulinemia, mantle cell lymphoma, Hodgkin's lymphoma (HL), plasma cell myeloma, precursor B cell lymphoblastic leukemia / lymphoma, plasma cell myeloma, giant cell myeloma, plasma cell myeloma, heavy chain myeloma, light chain or Bence Jones myeloma, lymphomatoid granulomatosis, post-transplant lymphoproliferative disorder, immunomodulatory disorders, rheumatoid arthritis, myasthenia gravis, idiopathic thrombocytopenic purpura, antiphospholipid syndrome, Chagas disease, Graves disease, Wegener's granulomatosis, polyarteritis nodosa, Sjögren's syndrome, pemphigus vulgaris, scleroderma, multiple sclerosis, antiphospholipid syndrome, ANCA-associated vasculitis, Goodpasture's disease, Kawasaki disease, autoimmune hemolytic anemia and rapidly progressive glomerulonephritis, heavy chain disease, primary or immune cell-associated amyloidosis, and monoclonal gammopathy of undetermined significance.

[0164] The present disclosure provides BCMA-binding proteins that specifically bind to BCMA, particularly anti-BCMA antibodies or antigen-binding portions thereof, and uses thereof. In one embodiment, the BCMA-binding protein binds to BCMA (an epitope of the B cell maturation antigen (BCMA). BCMA is also known as TNFRSF17 and CD269 (e.g., UniProt Q02223)). Various aspects of anti-BCMA antibodies relate to antibody fragments, single-chain antibodies, pharmaceutical compositions, nucleic acids, recombinant expression vectors, host cells, and methods for preparing and using such anti-BCMA antibodies. Methods of using anti-BCMA antibodies include in vitro and in vivo methods for binding to BCMA, detecting BCMA, and treating diseases associated with BCMA expression.

[0165] The present disclosure provides antigen binding proteins that specifically bind to BCMA polypeptides (e.g., antigen targets) or fragments of BCMA polypeptides. In one embodiment, the BCMA target antigen includes a naturally occurring polypeptide (e.g., UniProt accession number Q02223-1) having a wild-type or polymorphic or mutant amino acid sequence. The BCMA target antigen can be prepared by a recombinant method or can be chemically synthesized. The BCMA target antigen can be in a soluble form or a membrane-bound form (e.g., expressed by a cell or phage). In one embodiment, the BCMA target antigen is expressed by a cell, such as a cancer or non-cancer cell line that naturally expresses BCMA or is engineered to express BCMA, such as U2392, EJM, MMUR, U266, OPM2, H929, JJN-3, RPMI-8226, K562, NCIH929, ANBL-6, DP-6, KAS-6 / 1, KP6 or JMW. Cell lines that do not express BCMA are not expected to bind to anti-BCMA antibodies, such as K562, A549, and TC71 cell lines. The BCMA target antigen can be a fusion protein or conjugated to, for example, a detectable portion such as a fluorophore. The BCMA target antigen can bind to APRIL and / or BAFF. The BCMA target antigen can be in a mutated form, increasing or decreasing binding to APRIL and / or BAFF. In one embodiment, the human BCMA target antigen comprises an amino acid sequence of SEQ ID NO: 1 (e.g., recombinant human BCMA from LifeSpan BioSciences, catalog number LS-G5771) or SEQ ID NO: 2 (e.g., recombinant human BCMA with a his tag from AcroBioSystems, catalog number BCA-H522y-100ug). In one embodiment, the BCMA target antigen is a mutant polypeptide comprising an amino acid sequence of SEQ ID NO: 3 or 4. In one embodiment, wild-type and / or mutant human BCMA antigens can be used in an analysis to compare the binding ability of any anti-BCMA antibody described herein with a control anti-BCMA antibody, and / or in an epitope mapping analysis to compare the binding ability of any anti-BCMA antibody described herein with a control anti-BCMA antibody.

[0166] The present disclosure provides fully human antibodies of the IgG class that bind to BCMA polypeptides. In one embodiment, the anti-BCMA antibody comprises a heavy chain variable region having at least 95% sequence identity, or at least 96% sequence identity, or at least 97% sequence identity, or at least 98% sequence identity, or at least 99% sequence identity with the amino acid sequence of SEQ ID NO: 8, 10, 12, 14 or 22 or a combination thereof; and / or the anti-BCMA antibody comprises a light chain variable region having 95% sequence identity, or at least 96% sequence identity, or at least 97% sequence identity, or at least 98% sequence identity, or at least 99% sequence identity with the amino acid sequence of SEQ ID NO: 9, 11, 13, 15, 16, 17, 18, 19, 20, 21 or 23 or a combination thereof. In one embodiment, the anti-BCMA antibody comprises an IgG1, IgG2, IgG3 or IgG4 class antibody. In one embodiment, the anti-BCMA antibody comprises an IgG1 or IgG4 class antibody.

[0167] In one embodiment, an anti-BCMA antibody or fragment thereof comprises an antigen binding portion that binds to an epitope of a BCMA target antigen with a binding affinity (K D ) is 10 -6 M or smaller, 10 -7 M or smaller, 10 -8 M or smaller, 10 -9 M or smaller, or 10 -10 M or smaller (see Figure 3-10 and Tables 2 and 3). In one embodiment, the BCMA antigen comprises a cell surface BCMA antigen or a soluble BCMA antigen. In one embodiment, the BCMA antigen comprises an extracellular portion of a cell surface BCMA antigen. In one embodiment, the BCMA antigen comprises a human or non-human BCMA antigen. In one embodiment, the BCMA antigen is expressed by a human or non-human cell. In one embodiment, the anti-BCMA antibody binds to human BCMA expressed by human B cells or expressed by human multiple myeloma cells. In one embodiment, surface plasmon resonance, flow cytometry, and / or ELISA can be used to detect and measure the binding between anti-BCMA antibodies or fragments thereof.

[0168] In one embodiment, the anti-BCMA antibody or antigen-binding fragment comprises an antigen-binding portion that binds to a human BCMA epitope and blocks the binding of human APRIL and / or human BAFF to the human BCMA epitope (e.g., inhibits binding). In one embodiment, APRIL refers to human proliferation-inducing ligand (also known as TNF13, CD256), which is commercially available from R&D Systems (Catalog No. 5860-AP-010 / CF) or IBI Scientific (Catalog No. #RPH-151). In one embodiment, BAFF refers to human BAFF (e.g., UniProt Accession No. Q9Y275). In one embodiment, the anti-BCMA antibody or antigen-binding fragment blocks the binding of human APRIL and / or human BAFF to the human BCMA epitope, reducing the binding level by about 5-25%, or about 25-45%, or about 45-65%, or about 65-85%, or about 85-95% or more.

[0169] In one embodiment, the anti-BCMA antibody reduces APRIL-dependent or BAFF-dependent NF-κB activation by about 1-5% (or less than about 1%), about 5-25%, or about 25-45%, or about 45-65%, or about 65-85%, or about 85-95% or more of binding level.

[0170] The present disclosure provides an anti-BCMA antibody or antigen-binding fragment that binds to a BCMA epitope from a human, or can bind (e.g., cross-react) to a BCMA (e.g., a homologous antigen) epitope from any one or any combination of non-human animals such as mice, rats, goats, rabbits, hamsters, and / or monkeys (e.g., cynomolgus macaques). In one embodiment, the anti-BCMA antibody or antigen-binding fragment binds to mouse BCMA with a binding affinity of K D For 10 -5 M or smaller, or 10 -6 M or smaller, or 10 -7 M or smaller, or 10 -8 M or smaller, or 10 -9 M or smaller, or 10 -10 In one embodiment, the anti-BCMA antibody or antigen-binding fragment binds to cynomolgus macaque BCAM with a binding affinity of K D For 10 -5 M or smaller, or 10 -6 M or smaller, or 10 -7 M or smaller, or 10 -8 M or smaller, or 10 -9 M or smaller, or 10 -10M or less. In one embodiment, cynomolgus macaque BCMA is commercially available from ACROBiosystems (Catalog No. BCA-C52H7). In one embodiment, mouse BCMA is commercially available from ACROBiosystems (Catalog No. BCA-M52H3).

[0171] The present disclosure provides an anti-BCMA antibody or antigen-binding fragment that binds to an epitope of APRIL and / or BAFF from a human, or can bind (e.g., cross-react) to an epitope of APRIL and / or BAFF (e.g., a homologous antigen) from any one or any combination of non-human animals such as mice, rats, goats, rabbits, hamsters, and / or monkeys (e.g., cynomolgus macaques). In one embodiment, human APRIL protein is commercially available from R&D Systems (Catalog No. 5860-AP-010 / CF) or IBIScientific (Catalog No. RPH-151).

[0172] The present disclosure provides a fully human antibody comprising a heavy chain and a light chain, wherein the heavy / light chain variable region amino acid sequence has at least 95% sequence identity, or at least 96% sequence identity, or at least 97% sequence identity, or at least 98% sequence identity, or at least 99% sequence identity with any one of the following amino acid sequence groups: SEQ ID NOs: 8 and 9 (referred to herein as BCA7), SEQ ID NOs: 10 and 11 (referred to herein as BC4C9), SEQ ID NOs: 12 and 13 (referred to herein as CD5C4), SEQ ID NOs: 14 and 15 (referred to herein as BC6G8), SEQ ID NOs: 8 and 16 (referred to herein as BCA7-2C5), SEQ ID NOs: 8 and 17 (referred to herein as BCA7-2E1), SEQ ID NOs: 8 and 18 (referred to herein as BCA7-2D11), SEQ ID NOs: 8 and 19 (referred to herein as BCA7-2G2), SEQ ID NOs: 8 and 20 (referred to herein as BCA7-2D8), SEQ ID NOs: NOs: 8 and 21 (referred to herein as BCA7-2E8) or SEQ ID NOs: 22 and 23 (referred to herein as BCA7-2C5 full length).

[0173] The present disclosure provides a Fab fully human antibody fragment comprising a heavy chain variable region from a heavy chain and a variable region from a light chain, wherein the sequence of the variable region from the heavy chain is at least 95% identical to the amino acid sequence of SEQ ID NO: 8, 10, 12, 14 or 22 or a combination thereof, or at least 96% identical, or at least 97% identical, or at least 98% identical, or at least 99% identical. The sequence of the variable region from the light chain is at least 95% identical to the amino acid sequence of SEQ ID NO: 9, 11, 13, 15, 16, 17, 18, 19, 20, 21 or 23 or a combination thereof, or at least 96% identical, or at least 97% identical, or at least 98% identical, or at least 99% identical.

[0174] The present disclosure provides a Fab fully human antibody fragment, which comprises a heavy chain variable region and a light chain variable region, wherein the heavy / light chain variable region amino acid sequence is at least 95% identical, or at least 96% identical, or at least 97% identical, or at least 98% identical, or at least 99% identical to any one of the following amino acid sequence groups: SEQ ID NOs: 8 and 9 (referred to herein as BCA7), SEQ ID NOs: 10 and 11 (referred to herein as BC4C9), SEQ ID NOs: 12 and 13 (referred to herein as CD5C4), SEQ ID NOs: 14 and 15 (referred to herein as BC6G8), SEQ ID NOs: 8 and 16 (referred to herein as BCA7-2C5), SEQ ID NOs: 8 and 17 (referred to herein as BCA7-2E1), SEQ ID NOs: 8 and 18 (referred to herein as BCA7-2D11), SEQ ID NOs: 8 and 19 (referred to herein as BCA7-2G2), SEQ ID NOs: 8 and 20 (referred to herein as BCA7-2D8), SEQ ID NOs: NOs: 8 and 21 (referred to herein as BCA7-2E8) or SEQ ID NOs: 22 and 23 (referred to herein as BCA7-2C5 full length).

[0175] The present disclosure provides a single-chain fully human antibody comprising a polypeptide chain having a variable region from a fully human heavy chain and a variable region from a fully human light chain, and optionally a linker connecting the heavy chain variable region and the light chain variable region, wherein the heavy chain variable region comprises at least 95% sequence identity, or at least 96% sequence identity, or at least 97% sequence identity, or at least 98% sequence identity, or at least 99% sequence identity with the amino acid sequence of SEQ ID NO: 8, 10, 12, 14 or 22 or a combination thereof. The light chain variable region comprises at least 95% sequence identity, or at least 96% sequence identity, or at least 97% sequence identity, or at least 98% sequence identity, or at least 99% sequence identity with the amino acid sequence of SEQ ID NO: 9, 11, 13, 15, 16, 17, 18, 19, 20, 21 or 23 or a combination thereof.

[0176] The present disclosure provides a single-chain fully human antibody, which comprises a polypeptide chain having a heavy chain variable region and a light chain variable region, wherein the heavy / light chain variable region amino acid sequence group is at least 95% identical to any of the following amino acid sequence groups, or at least 96% identical, or at least 97% identical, or at least 98% identical, or at least 99% identical: SEQ ID NO: 8 and 9 (referred to herein as BCA7), SEQ ID NO: 10 and 11 (referred to herein as BC4C9), SEQ ID NO: 12 and 13 (referred to herein as CD5C4), SEQ ID NO: 14 and 15 (referred to herein as BC6G8), SEQ ID NO: 8 and 16 (referred to herein as BCA7-2C5), SEQ ID NO: 8 and 17 (referred to herein as BCA7-2E1), SEQ ID NO: 8 and 18 (referred to herein as BCA7-2D11), SEQ ID NO: 8 and 19 (referred to herein as BCA7-2G2), SEQ ID NO: 8 and 20 (referred to herein as BCA7-2D8), SEQ ID NO: 8 and 21 (referred to herein as BCA7-2D9), SEQ ID NO: 8 and 22 (referred to herein as BCA7-2D10), SEQ ID NO: 8 and 23 (referred to herein as BCA7-2D11), SEQ ID NO: 8 and 24 (referred to herein as BCA7-2D12), SEQ ID NO: 8 and 25 (referred to herein as BCA7-2D13), SEQ ID NO: 8 and 26 (referred to herein as BCA7-2D2), SEQ ID NO: 8 and 27 (referred to herein as BCA7-2D8), SEQ ID NO: 8 and 28 (referred to herein as BCA NOs: 8 and 21 (referred to herein as BCA7-2E8) or SEQ ID NOs: 22 and 23 (referred to herein as BCA7-2C5 full length).

[0177] The present disclosure provides a pharmaceutical composition comprising any anti-BCMA antibody or antigen-binding fragment described herein and a pharmaceutically acceptable excipient. Excipients include carriers and stabilizers. In one embodiment, the pharmaceutical composition comprises an anti-BCMA antibody or an antigen-binding fragment thereof, which comprises a heavy chain variable region and a light chain variable region, wherein the heavy / light chain variable region amino acid sequence is at least 95% identical, or at least 96% identical, or at least 97% identical, or at least 98% identical, or at least 99% identical to any one of the following amino acid sequence groups: SEQ ID NOs: 8 and 9 (referred to herein as BCA7), SEQ ID NOs: 10 and 11 (referred to herein as BC4C9), SEQ ID NOs: 12 and 13 (referred to herein as CD5C4), SEQ ID NOs: 14 and 15 (referred to herein as BC6G8), SEQ ID NOs: 8 and 16 (referred to herein as BCA7-2C5), SEQ ID NOs: 8 and 17 (referred to herein as BCA7-2E1), SEQ ID NOs: 8 and 18 (referred to herein as BCA7-2D11), SEQ ID NOs: 8 and 19 (referred to herein as BCA7-2G2), SEQ ID NOs: 8 and 20 (referred to herein as BCA7-2D8), SEQ ID NOs: NOs: 8 and 21 (referred to herein as BCA7-2E8) or SEQ ID NOs: 22 and 23 (referred to herein as BCA7-2C5 full length).

[0178] The present disclosure provides a kit comprising any one or any combination of two or more of the anti-BCMA antibodies or antigen-binding fragments thereof described herein. In one embodiment, the kit comprises any one or any combination of two or more anti-BCMA antibodies or antigen-binding fragments thereof, wherein the antibodies or antigen-binding fragments thereof comprise a heavy chain variable region and a light chain variable region, wherein the heavy / light chain variable region amino acid sequence is at least 95% identical, or at least 96% identical, or at least 97% identical, or at least 98% identical, or at least 99% identical to any one of the following amino acid sequence groups: SEQ ID NOs: 8 and 9 (referred to herein as BCA7), SEQ ID NOs: 10 and 11 (referred to herein as BC4C9), SEQ ID NOs: 12 and 13 (referred to herein as CD5C4), SEQ ID NOs: 14 and 15 (referred to herein as BC6G8), SEQ ID NOs: 8 and 16 (referred to herein as BCA7-2C5), SEQ ID NOs: 8 and 17 (referred to herein as BCA7-2E1), SEQ ID NOs: 8 and 18 (referred to herein as BCA7-2D11), SEQ ID NOs: 8 and 19 (referred to herein as BCA7-2G2), SEQ ID NOs: 8 and 10 (referred to herein as BCA7-2E1), SEQ ID NOs: 8 and 11 (referred to herein as BCA7-2D11), SEQ ID NOs: 8 and 19 (referred to herein as BCA7-2G2), SEQ ID NOs: 8 and 10 (referred to herein as BCA7-2E2), SEQ ID NOs: 8 and 11 (referred to herein as BCA7-2D12), SEQ ID NOs: 8 and 11 (referred to herein as BCA7-2E3), SEQ ID NOs: 8 and 12 (referred to herein as BCA7-2D13), SEQ ID NOs: NO: 8 and 20 (referred to herein as BCA7-2D8), SEQ ID NO: 8 and 21 (referred to herein as BCA7-2E8) or SEQ ID NO: 22 and 23 (referred to herein as BCA7-2C5 full length). The kit can be used to detect the presence or absence of BCMA antigen in, for example, a biological sample. The kit can be used to perform in vitro reactions, such as antigen binding analysis in the form of ELIZA, flow cytometry, or plasma surface resonance; in vitro cell activation analysis, including NF-κB activation analysis; luciferase reporter gene analysis; Western blotting and detection; and other such in vitro analysis. The kit can be used to treat subjects with BCMA-related diseases or disorders such as multiple myeloma.

[0179] The present disclosure provides a method for inhibiting the growth or proliferation of a target cell, or a method for killing a target cell, the method comprising: contacting a population of effector cells with a population of target cells (e.g., target cells expressing BCMA) in the presence of an anti-BCMA antibody (or its antibody fragment) described herein under conditions suitable for killing the target cell. In one embodiment, the population of effector cells comprises peripheral blood mononuclear cells (PBMC) or natural killer (NK) cells. PBMC may include lymphocytes, including T cells, B cells and / or NK cells. In one embodiment, the population of target cells comprises cells that naturally express BCMA, including B cells, multiple myeloma (MM) cells, or any type of B cells from subjects with a disease associated with BCMA expression. In one embodiment, the population of target cells is any type of transgenic cell engineered to express BCMA. In one embodiment, the ratio of effector cells to target cells may be about 1: 1, or about 2: 1, or about 3: 1, or about 4: 1, or about 5: 1, or about 5-10: 1, or about 10-20: 1, or about 20-30: 1.

[0180] The present disclosure provides a method for treating a subject with a disease associated with BCMA overexpression or a BCMA-positive cancer, the method comprising: administering to the subject an effective amount of a therapeutic composition comprising an anti-BCMA antibody or an antigen-binding fragment thereof as described herein, for example, selected from the group consisting of: any fully human anti-BCMA antibody described herein, any Fab fully human anti-BCMA antibody described herein, and any single-chain human anti-BCMA antibody described herein. In one embodiment, BCMA-positive cancers include: B cell leukemia, B cell lymphoma, or B cell myeloma. Also provided are methods for treating a subject having a disease associated with BCMA expression, wherein the disease associated with BCMA expression is selected from the group consisting of: multiple myeloma (MM), non-Hodgkin's lymphoma (NHL) including Burkitt's lymphoma (BL), B chronic lymphocytic leukemia (B-CLL), systemic lupus erythematosus (SLE), B and T acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma, chronic myeloid leukemia (CML), hairy cell leukemia (HCL), follicular lymphoma, Waldenstrom's macroglobulinemia, mantle cell lymphoma, Hodgkin's lymphoma (HL), plasma cell myeloma, precursor B-cell lymphoblastic leukemia / lymphoma , plasmacytoma, giant cell myeloma, plasma cell myeloma, heavy chain myeloma, light chain or Bence Jones myeloma, lymphomatoid granulomatosis, post-transplant lymphoproliferative disorder, immunomodulatory disorder, rheumatoid arthritis, myasthenia gravis, idiopathic thrombocytopenic purpura, antiphospholipid syndrome, Chagas' disease, Grave's disease, Wegener's granulomatosis, polyarteritis nodosa, Sjögren's syndrome, pemphigus vulgaris, scleroderma, multiple sclerosis, antiphospholipid syndrome, ANCA-associated vasculitis, Goodpasture's disease, Kawasaki disease, autoimmune hemolytic anemia and rapidly progressive glomerulonephritis, heavy chain disease, primary or immune cell-associated amyloidosis and monoclonal gammopathy of undetermined significance, the method comprising: administering to the subject an effective amount of a therapeutic composition comprising an antibody or antigen-binding fragment thereof described herein.

[0181] Sequence Listing:

[0182] Wild-type human BCMA protein (5-54) SEQ ID NO: 1:

[0183] AGQCSQNEYFDSLLHACIPCQLRCSSNTPPLTCQRYCNASVTNSVKGTNA.

[0184] Wild-type human BCMA protein (1-54) SEQ ID NO: 2:

[0185] MLQMAGQCSQNEYFDSLLHACIPCQLRCSSNTPPLTCQRYCNASVTNSVKGTNA.

[0186] Wild-type human BCMA protein (UniProt Q02223-1) SEQ ID NO:92

[0187] MLQMAGQCSQNEYFDSLLHACIPCQLRCSSNTPPLTCQRYCNASVTNSVKGTNAILWTCLGLSLIISLAVFVLMFLLRKINSEPLKDEFKNTGSGLLGMANIDLEKSRTGDEIILPRGLEYTVEECTCEDCIKSKPKVDSDHCFPLPAMEEGATILVTTKTNDYCKSLPAALSATEIEKSISAR.

[0188] Mutant-1 human BCMA protein SEQ ID NO:3:

[0189] MLQMAGQCSQNEYFDS GG HACIPCQLRCSSNTPPLTCQRYCNASVTNSVKGTNA.

[0190] Mutant-2 human BCMA protein SEQ ID NO:4:

[0191] MLQMAGQCSQNEYFDSLLHACIPCQLRCSSNPP G TCQRYCNASVTNSVKGTNA.

[0192] Wild-type human BCMA protein - murine Fc SEQ ID NO:5:

[0193] MLQMAGQCSQNEYFDSLLHACIPCQLRCSSNTPPLTCQRYCNASVTNSVKGTNAGLGGLVDYKDDDDKTHTCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK.

[0194] Mutant-1 Human BCMA Protein - Mouse Fc SEQ ID NO:6:

[0195] MLQMAGQCSQNEYFDSGGHACIPCQLRCSSNTPPLTCQRYCNASVTNSVKGTNAGLGGLVDYKDDDDKTHTCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK.

[0196] Mutant-2 Human BCMA Protein - Mouse Fc SEQ ID NO:7:

[0197] MLQMAGQCSQNEYFDSLLHACIPCQLRCSSNPPGTCQRYCNASVTNSVKGTNAGLGGLVDYKDDDDKTHTCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK.

[0198] Table 1:

[0199]

[0200]

[0201]

[0202] Table 2:

[0203]

[0204]

[0205]

[0206] Example

[0207] The following examples are intended to be illustrative, may be used to further understand the embodiments of the present disclosure, and should not be construed as limiting the scope of the present teachings in any way.

[0208] Example 1: Generation of anti-BCMA antibodies.

[0209] Monoclonal phage ELISA was used to select antibodies from a fully human antibody library. Standard panning procedures were used to select antibodies that bind to BCMA protein and the RPMI8226 cell line expressing BCMA. Using standard molecular biology techniques, scFvs were cloned into the STI-Fc vector, or the heavy and light chain variable regions were cloned into the STI heavy chain and lambda light chain vectors containing their respective constant regions. Plasmids containing verified insert sequences were used for transient expression in CHO-S cells, and antibodies were purified using protein A resin. Selected anti-BCMA antibodies include BCA7, BC4C9, BC5C4, and BC6G8.

[0210] Affinity maturation of BCA7 antibody clones was performed using a soft random phage library. BCA8 phagemid DNA was used as a PCR template. Six degenerate oligonucleotides were used as PCR primers to introduce mutations into six CDR regions. The PCR fragments were digested with restriction enzymes and connected to linearized phagemid vector pCGMT3 and electroporated into E. coli SS320 cells. Human BCMA protein and PRMI8226 cell lines expressing BCMA were used for panning. The anti-BCMA antibodies selected include BCA7-2C5, BCA7-2E1, BCA7-2D11, BCA7-2G2, BCA7-2D8 and BCA7-2E8.

[0211] Example 2: Measuring binding affinity using surface plasmon resonance.

[0212] The binding kinetics of anti-BCMA antibodies to human BCMA proteins with his tags (ACROBiosystems, catalog number BCA-H522y-100ug, UniProt Q02223-1, SEQ ID NO: 92) were measured using surface plasmon resonance (SPR). The kinetic interactions between antibodies and BCMA proteins with his tags were measured at 25°C using Biacore T200 surface plasmon resonance (GE Healthcare). Anti-human fragment crystallizable region (Fc region) antibodies were immobilized on a CM5 sensor chip using a standard N-hydroxysuccinimide / N-ethyl-N′-(3-dimethylaminopropyl) carbodiimide hydrochloride (NHS / EDC) coupling method to achieve approximately 8000 resonance units (RU). Anti-BCMA antibodies (2 μg / mL) were captured at a flow rate of 10 μL / min for 60 seconds. His-tagged BCMA protein was run at six different dilutions of 3.12, 6.25, 12.5, 25, 50, 100 and 200 nM in a running buffer of 0.01 M HEPES pH 7.4, 0.15 M NaCl, 3 mM EDTA, 0.05% v / v Surfactant P20 (HBS-EP+). 25 nM BCMA protein was measured twice. All measurements were performed in HBS-EP+ buffer at a flow rate of 30 μL / min. A 1:1 (Langmuir) binding model was used to fit the data. The SPR sensorgrams of anti-BCMA antibodies BCA7, GSK J6M0, BC4C9 and BC5C4 are shown in Figure 1 , 2 , 3 and 4, and their corresponding binding kinetics are listed in Table 3.

[0213] Table 3:

[0214] ka(1 / Ms) kd(1 / s) <![CDATA[K D (M)]]> <![CDATA[χ 2 (RU 2 )]]> Model BC4C9 2.08E+04 5.67E-04 2.73E-08 0.146 1:1 combination BC5C4 3.56E+06 3.30E-02 9.27E-09 0.281 1:1 combination BCA7 1.03E+03 1.80E-02 1.75E-05 0.0847 1:1 combination GSK-J6M0 1.97E+05 4.96E-04 2.52E-09 0.022 1:1 combination

[0215] The binding kinetics of the optimized anti-BCMA antibodies BCA7-2C5, BCA7-2D11, BCA7-2G2, BCA7-2E1, BCA7-2D8 and BCA7-2E8 to human BCMA protein with his tag (ACROBiosystems, catalog number BCA-H522y-100ug) were analyzed in the above manner. The sensorgrams are shown in Figure 5-10 The corresponding binding kinetics are listed in Table 4. The optimized anti-BCMA antibodies showed significantly improved binding to BCMA protein.

[0216] Table 4:

[0217] ka1(1 / Ms) kd1(1 / s) ka2(1 / s) kd2(1 / s) <![CDATA[K D (M)]]> <![CDATA[χ 2 (RU 2 )]]> BCA7 785.9 0.03493 0.004635 0.01204 3.21E-05 0.0841 2C5 1.37E+06 0.04216 8.47E-04 0.00145 1.94E-08 0.0531 2E1 2.51E+06 0.1506 0.001797 9.29E-04 2.04E-08 0.0245 2D11 1.87E+06 0.2608 0.003815 7.10E-04 2.19E-08 0.0131 2G2 3.21E+04 0.003761 0.001432 0.001209 5.37E-08 1.32 2D8 2.43E+06 1.092 0.01132 0.002598 8.38E-08 0.0682 2E8 4.87E+04 0.02023 0.01189 0.007074 1.55E-07 1.42

[0218] Example 3: Measuring binding affinity using surface plasmon resonance.

[0219] The cross-reactivity of two anti-BCMA antibodies, BCA7-2C5 and BCA7-2E1, with his-tagged human, cynomolgus monkey or mouse BCMA proteins was analyzed by SPR in the above manner. All three his-tagged BCMA proteins were obtained from ACROBiosystems: his-tagged human BCMA protein (Catalog No. BCA-H522y-100ug), his-tagged cynomolgus monkey BCMA protein (Catalog No. BCA-C52H7) and his-tagged mouse BCMA protein (Catalog No. BCA-M52H3). Sensorgrams are shown in: Fig.11A and B (2C5 and 2E1 antibodies bind to human BCMA protein, respectively); Fig. 12A and B (2C5 and 2E1 antibodies bind to cynomolgus macaque BCMA protein, respectively); and Fig.13A and B (2C5 and 2E1 bind to mouse BCMA protein, respectively).

[0220] Example 4: ELISA cross-reactivity.

[0221] The cross-reactivity of anti-BCMA antibodies with his-tagged BCMA proteins from human, cynomolgus monkey or mouse was analyzed by ELISA analysis. Ni-NTA plates were coated with 2 μg / mL his-tagged BCMA proteins (listed in Example 2 above), then reacted with 20 μg / mL anti-BCMA antibodies and reacted with anti-human Fc HRP (KPL Scientific, catalog number 5220-0279) diluted 1:2500. Fig.14 8 groups are shown, from left to right, anti-BCMA antibodies 2C5, 2E1, 4C9, 5C4, Bluebird C11D5 (BB C11D5), GSK J6M0, isotype control antibody, and Dulbecco's phosphate-buffered saline. Each group includes 5 test antigens or buffers, from left to right, negative control antigen, mouse BCMA protein with his tag, cynomolgus macaque BCMA protein with his tag, human BCMA protein with his tag, and Dulbecco's phosphate-buffered saline. Fig.14 It was shown that GSK and Bluebird antibodies bound to human and cynomolgus macaque BCMA proteins, but not to mouse BCMA proteins; 2C5 and 2E1 antibodies bound to human, cynomolgus macaque and mouse BCMA proteins; and 4C9 and 5C4 antibodies only bound to human BCMA proteins.

[0222] Example 5: Flow cytometry analysis.

[0223] Flow cytometry was used to test the binding of antibodies to the multiple myeloma cell line MM1R using various anti-BCMA antibodies (5-fold serial dilutions) and 80,000 cells per well. The secondary antibody was FITC AffiniPure FAB2 fragment goat anti-human IgG (H+L) (from Jackson Immuno Research). Fig.15 Results are shown for (A) control isotype; (B) BCA7 antibody; (C) BCA-2E1 antibody; (D) BCA7-2C5 antibody; (E) Bluebird C11D5 antibody; and (F) GSK J6M0. A BL1 detector (IntelliCyt iQue Screener Plus) was used with detection at 530 nm. Geometric means are reported.

[0224] Example 6: Epitope mapping using wild-type BCMA protein.

[0225] Epitope mapping of various anti-BCMA antibodies was performed using sandwich ELISA analysis. The primary antibody (Ab-1) was Bluebird C11D5 ( Fig.16 White strip with "BB" mark) or GSK J6M0 ( Fig.16 The black bars with "GSK" marks in the middle) (all 4 μg / mL), the antigen is human BCMA protein with a his tag (ACROBiosystems, catalog number BCA-H522y-100ug), the second antibody is one of various anti-BCMA antibodies, and the secondary antibody is anti-λ / HRP at 1:2500. Various anti-BCMA antibodies include: isotype control antibody; 2C5; 2E1; 4C9; 5C4; and 6G8. Fig.16 Results of epitope mapping are shown, where BCA7 variant antibodies (2C5, 2E1, 4C9, 5C4, and 6G8) bind to overlapping epitopes with the GSK antibody. BCA7 variant antibodies (4C9, 5C4, and 6G8) bind to overlapping epitopes with the Bluebird antibody.

[0226] Example 7: Mutant BCMA proteins for epitope mapping.

[0227] DNA fragments encoding wild-type and mutant BCMA proteins were synthesized by IDT and cloned into an STI vector with a C-terminal mouse Fc tag. The validated plasmids were used for transient expression in CHO-S cells. Wild-type and mutant BCMA proteins were purified using protein A resin. The BCMA wild-type protein comprises the amino acid sequence of SEQ ID NO: 2. The BCMA mutant-1 protein comprises the amino acid sequence of SEQ ID NO: 3. The BCMA mutant-2 protein comprises the amino acid sequence of SEQ ID NO: 4.

[0228] Fig.17 The ribbon diagram of BCMA protein presentation is shown. The asterisk indicates the region with the amino acid sequence EYFDSLLH (SEQ ID NO: 28), which is disrupted in the BCMA mutant-1 protein with two point mutations, L17G and L18G. The positions of the disulfide bridges and residues A20, I22, and N30 are also shown.

[0229] Example 8: Biolayer interferometry to measure protein-protein binding.

[0230] Biolayer interferometry was used to measure the binding between APRIL protein and wild-type BCMA protein. Wild-type human BCMA-mouse Fc protein (SEQ ID NO: 5) was loaded onto the AR2G sensor (OctetRED96e from ForteBio) and reacted with one of two different sources of human APRIL protein (from IBI Scientific, catalog number RPH-151; R&D Systems, catalog number 5860-AP-010 / CF). The results are shown in Fig.18 , showing that human BCMA protein binds to human APRIL protein from R&D Systems, but not to human APRIL from IBI Scientific.

[0231] Biolayer interferometry was also used to measure the binding between APRIL protein and wild-type or mutant BCMA protein. Human APRIL protein (R&D Systems, catalog number 5860-AP-010 / CF) was loaded onto the Ar2G sensor (OctetRET96e) and reacted with 2.5 μg / mL of one of three types of human BCMA protein, including: wild-type human BCMA-mouse Fc (SEQ ID NO: 5), mutant-1 human BCMA-mouse Fc (17G-18G; SEQ ID NO: 6), or mutant-2 human BCMA-mouse Fc (del32-35G; SEQ ID NO: 7). Fig.19 It was shown that the wild-type BCMA protein bound to APRIL, the mutant-1 BCMA protein (double point mutation 17G-18G) exhibited a loss of binding to APRIL, and the mutant-2 BCMA protein retained some binding ability to the APRIL protein.

[0232] Example 9: Biolayer interferometry for epitope mapping.

[0233] The results of the protein-protein binding analysis described in Example 8 were used to design an epitope mapping analysis using bio-layer interferometry. Various anti-BCMA antibodies (2C5, 2E1, 4C9, 6G8, Bluebird C11D5, GSK J6M0, or isotype control) (100 nM) were loaded onto the AR2G sensor and reacted with buffer or one of three types of human BCMA proteins, including: wild-type human BCMA-mouse Fc (SEQ ID NO: 5), mutant-1 human BCMA-mouse Fc (double mutation 17G-18G; SEQ ID NO: 6), or mutant-2 human BCMA-mouse Fc (mutation del32-35G; SEQ ID NO: 7). Fig. 20 It shows that antibodies 2C5, 2E1, and 4C9 bind to wild-type and mutant-2 BCMA proteins and show reduced binding to mutant-1 BCMA proteins; Bluebird C11D5 antibody binds to wild-type and two mutant BCMA proteins; GSK J6M0 antibody binds to wild-type and mutant-1 BCMA proteins and shows reduced binding to mutant-2 BCMA proteins. Antibody 6G8 shows significantly reduced binding to all forms of BCMA protein used in this analysis. This data suggests that the epitope of human BCMA protein bound by antibodies 2C5, 2E1, and 4C9 is different from the epitope bound by Bluebird and GSK antibodies.

[0234] Example 10: Biolayer interferometry for measuring APRIL blocking activity.

[0235] Biolayer interferometry was used to evaluate the ability of various anti-BCMA antibodies to bind to the human BCMA epitope and block the binding of human APRIL to the human BCMA epitope. Human APRIL protein (R&D Systems, catalog number 5860-AP-010 / CF) was loaded onto the AR2G sensor (2 μg / mL) and reacted with premixed human BCMA protein (2 μg / mL) with one of the various anti-BCMA antibodies or isotype control (25 μg / mL) for 1 hour. Fig.21 The results in the study showed that various anti-BCMA antibodies (2C5, 2E1, 4C9, 5C4, Bluebird C11D5, and GSK J6M0) blocked the binding of BCMA protein to APRIL protein.

[0236] Example 11: Biolayer interferometry for measuring cross-reactivity.

[0237] Biolayer interferometry was used to measure cross-binding between (1) two different anti-BCMA antibodies (BCA7-2C5 or BB C11D5) or a control isotype and (2) various human antigens including TACI and BAFFR.

[0238] Immobilization of antibodies was achieved by standard EDC-catalyzed amide bond formation to form covalent bonds between reactive amines on the protein and the carboxyl-terminated biosensor surface. Briefly, AR2G sensors (OctetRED96e from ForteBio) were activated by EDC-NHS for 6 min, then loaded with 5 μg / ml antibodies (BCA7-2C5 antibody, Bluebird C11D5 chimeric antibody, or human IgG isotype antibody) in 10 mM acetate buffer pH 5.0 for 6 min, followed by quenching with 1 M ethanolamine pH 8.5 for 6 min. A 3 minute baseline step removed any unbound antibody from the biosensor, followed by association of the three analytical proteins TACI (human TACI / TNFRSF13B (CD267) His tag, from Sino Biological, 1 μg / ml in PBS), BAFFR (human BAFFR / TNFRSF13C (CD268) Fc tag), from Sino Biological, 2 μg / ml in PBS), and human BCMA protein (prepared in-house with mouse Fc, 2 μg / ml in PBS) for 1.5 minutes each. The analytical steps are summarized in Table 4 below:

[0239] Table 4:

[0240] Step Number Step Name Step Time (seconds) Step Type Name 1 Baseline 1 240 Baseline 2 activation 360 activation 3 load 360 load 4 Quenching 360 Quenching 5 Baseline 2 180 Baseline 6 Association 90 Association 7 Association 90 Association 8 Association 90 Association 9 Dissociation 180 Dissociation

[0241] Fig. 22 The results in the Figure 2 showed that anti-BCMA antibodies (BCA7-2C5 and BB C11D5) bound to BCMA protein but not to TACI or BAFFR protein. Sequence Listing <110> Sorrento Pharmaceuticals Ltd. <120> Antigen binding protein that binds BCMA <130> 01223-0011-00PCT <150> US 62 / 810,771 <151> 2019-02-26 <150> US 62 / 811,431 <151> 2019-02-27 <160> 92 <170> PatentIn version 3.5 <210> 1 <211> 50 <212> PRT <213> Homo sapiens <220> <221> misc_feature <223> Wild-type human BCMA protein (5-54) <400> 1 Ala Gly Gln Cys Ser Gln Asn Glu Tyr Phe Asp Ser Leu Leu His Ala 1 5 10 15 Cys Ile Pro Cys Gln Leu Arg Cys Ser Ser Asn Thr Pro Pro Leu Thr 20 25 30 Cys Gln Arg Tyr Cys Asn Ala Ser Val Thr Asn Ser Val Lys Gly Thr 35 40 45 Asn Ala 50 <210> 2 <211> 54 <212> PRT <213> Homo sapiens <220> <221> misc_feature <223> Wild-type human BCMA protein (1-54) <400> 2 Met Leu Gln Met Ala Gly Gln Cys Ser Gln Asn Glu Tyr Phe Asp Ser 1 5 10 15 Leu Leu His Ala Cys Ile Pro Cys Gln Leu Arg Cys Ser Ser Asn Thr 20 25 30 Pro Pro Leu Thr Cys Gln Arg Tyr Cys Asn Ala Ser Val Thr Asn Ser 35 40 45 Val Lys Gly Thr Asn Ala 50 <210> 3 <211> 54 <212> PRT <213> Homo sapiens <220> <221> misc_feature <223> Mutant-1 human BCMA protein <400> 3 Met Leu Gln Met Ala Gly Gln Cys Ser Gln Asn Glu Tyr Phe Asp Ser 1 5 10 15 Gly Gly His Ala Cys Ile Pro Cys Gln Leu Arg Cys Ser Ser Asn Thr 20 25 30 Pro Pro Leu Thr Cys Gln Arg Tyr Cys Asn Ala Ser Val Thr Asn Ser 35 40 45 Val Lys Gly Thr Asn Ala 50 <210> 4 <211> 53 <212> PRT <213> Homo sapiens <220> <221> misc_feature <223> Mutant-2 human BCMA protein <400> 4 Met Leu Gln Met Ala Gly Gln Cys Ser Gln Asn Glu Tyr Phe Asp Ser 1 5 10 15 Leu Leu His Ala Cys Ile Pro Cys Gln Leu Arg Cys Ser Ser Asn Pro 20 25 30 Pro Gly Thr Cys Gln Arg Tyr Cys Asn Ala Ser Val Thr Asn Ser Val 35 40 45 Lys Gly Thr Asn Ala 50 <210> 5 <211> 295 <212> PRT <213> Artificial sequence <220> <223> Synthetic: Wild-type human BCMA protein-mouse Fc <400> 5 Met Leu Gln Met Ala Gly Gln Cys Ser Gln Asn Glu Tyr Phe Asp Ser 1 5 10 15 Leu Leu His Ala Cys Ile Pro Cys Gln Leu Arg Cys Ser Ser Asn Thr 20 25 30 Pro Pro Leu Thr Cys Gln Arg Tyr Cys Asn Ala Ser Val Thr Asn Ser 35 40 45 Val Lys Gly Thr Asn Ala Gly Leu Gly Gly Leu Val Asp Tyr Lys Asp 50 55 60 Asp Asp Asp Lys Thr His Thr Cys Pro Pro Cys Lys Cys Pro Ala Pro 65 70 75 80 Asn Leu Leu Gly Gly Pro Ser Val Phe Ile Phe Pro Pro Lys Ile Lys 85 90 95 Asp Val Leu Met Ile Ser Leu Ser Pro Ile Val Thr Cys Val Val Val 100 105 110 Asp Val Ser Glu Asp Asp Pro Asp Val Gln Ile Ser Trp Phe Val Asn 115 120 125 Asn Val Glu Val His Thr Ala Gln Thr Gln Thr His Arg Glu Asp Tyr 130 135 140 Asn Ser Thr Leu Arg Val Val Ser Ala Leu Pro Ile Gln His Gln Asp 145 150 155 160 Trp Met Ser Gly Lys Glu Phe Lys Cys Lys Val Asn Asn Lys Asp Leu 165 170 175 Pro Ala Pro Ile Glu Arg Thr Ile Ser Lys Pro Lys Gly Ser Val Arg 180 185 190 Ala Pro Gln Val Tyr Val Leu Pro Pro Pro Glu Glu Glu Met Thr Lys 195 200 205 Lys Gln Val Thr Leu Thr Cys Met Val Thr Asp Phe Met Pro Glu Asp 210 215 220 Ile Tyr Val Glu Trp Thr Asn Asn Gly Lys Thr Glu Leu Asn Tyr Lys 225 230 235 240 Asn Thr Glu Pro Val Leu Asp Ser Asp Gly Ser Tyr Phe Met Tyr Ser 245 250 255 Lys Leu Arg Val Glu Lys Lys Asn Trp Val Glu Arg Asn Ser Tyr Ser 260 265 270 Cys Ser Val Val His Glu Gly Leu His Asn His His Thr Thr Lys Ser 275 280 285 Phe Ser Arg Thr Pro Gly Lys 290 295 <210> 6 <211> 295 <212> PRT <213> Artificial sequence <220> <223> Synthesis: Mutant-1 human BCMA protein-mouse Fc <400> 6 Met Leu Gln Met Ala Gly Gln Cys Ser Gln Asn Glu Tyr Phe Asp Ser 1 5 10 15 Gly Gly His Ala Cys Ile Pro Cys Gln Leu Arg Cys Ser Ser Asn Thr 20 25 30 Pro Pro Leu Thr Cys Gln Arg Tyr Cys Asn Ala Ser Val Thr Asn Ser 35 40 45 Val Lys Gly Thr Asn Ala Gly Leu Gly Gly Leu Val Asp Tyr Lys Asp 50 55 60 Asp Asp Asp Lys Thr His Thr Cys Pro Pro Cys Lys Cys Pro Ala Pro 65 70 75 80 Asn Leu Leu Gly Gly Pro Ser Val Phe Ile Phe Pro Pro Lys Ile Lys 85 90 95 Asp Val Leu Met Ile Ser Leu Ser Pro Ile Val Thr Cys Val Val Val 100 105 110 Asp Val Ser Glu Asp Asp Pro Asp Val Gln Ile Ser Trp Phe Val Asn 115 120 125 Asn Val Glu Val His Thr Ala Gln Thr Gln Thr His Arg Glu Asp Tyr 130 135 140 Asn Ser Thr Leu Arg Val Val Ser Ala Leu Pro Ile Gln His Gln Asp 145 150 155 160 Trp Met Ser Gly Lys Glu Phe Lys Cys Lys Val Asn Asn Lys Asp Leu 165 170 175 Pro Ala Pro Ile Glu Arg Thr Ile Ser Lys Pro Lys Gly Ser Val Arg 180 185 190 Ala Pro Gln Val Tyr Val Leu Pro Pro Pro Glu Glu Glu Met Thr Lys 195 200 205 Lys Gln Val Thr Leu Thr Cys Met Val Thr Asp Phe Met Pro Glu Asp 210 215 220 Ile Tyr Val Glu Trp Thr Asn Asn Gly Lys Thr Glu Leu Asn Tyr Lys 225 230 235 240 Asn Thr Glu Pro Val Leu Asp Ser Asp Gly Ser Tyr Phe Met Tyr Ser 245 250 255 Lys Leu Arg Val Glu Lys Lys Asn Trp Val Glu Arg Asn Ser Tyr Ser 260 265 270 Cys Ser Val Val His Glu Gly Leu His Asn His His Thr Thr Lys Ser 275 280 285 Phe Ser Arg Thr Pro Gly Lys 290 295 <210> 7 <211> 294 <212> PRT <213> Artificial sequence <220> <223> Synthesis: Mutant-2 human BCMA protein-mouse Fc <400> 7 Met Leu Gln Met Ala Gly Gln Cys Ser Gln Asn Glu Tyr Phe Asp Ser 1 5 10 15 Leu Leu His Ala Cys Ile Pro Cys Gln Leu Arg Cys Ser Ser Asn Pro 20 25 30 Pro Gly Thr Cys Gln Arg Tyr Cys Asn Ala Ser Val Thr Asn Ser Val 35 40 45 Lys Gly Thr Asn Ala Gly Leu Gly Gly Leu Val Asp Tyr Lys Asp Asp 50 55 60 Asp Asp Lys Thr His Thr Cys Pro Pro Cys Lys Cys Pro Ala Pro Asn 65 70 75 80 Leu Leu Gly Gly Pro Ser Val Phe Ile Phe Pro Pro Lys Ile Lys Asp 85 90 95 Val Leu Met Ile Ser Leu Ser Pro Ile Val Thr Cys Val Val Val Asp 100 105 110 Val Ser Glu Asp Asp Pro Asp Val Gln Ile Ser Trp Phe Val Asn Asn 115 120 125 Val Glu Val His Thr Ala Gln Thr Gln Thr His Arg Glu Asp Tyr Asn 130 135 140 Ser Thr Leu Arg Val Val Ser Ala Leu Pro Ile Gln His Gln Asp Trp 145 150 155 160 Met Ser Gly Lys Glu Phe Lys Cys Lys Val Asn Asn Lys Asp Leu Pro 165 170 175 Ala Pro Ile Glu Arg Thr Ile Ser Lys Pro Lys Gly Ser Val Arg Ala 180 185 190 Pro Gln Val Tyr Val Leu Pro Pro Pro Glu Glu Glu Met Thr Lys Lys 195 200 205 Gln Val Thr Leu Thr Cys Met Val Thr Asp Phe Met Pro Glu Asp Ile 210 215 220 Tyr Val Glu Trp Thr Asn Asn Gly Lys Thr Glu Leu Asn Tyr Lys Asn 225 230 235 240 Thr Glu Pro Val Leu Asp Ser Asp Gly Ser Tyr Phe Met Tyr Ser Lys 245 250 255 Leu Arg Val Glu Lys Lys Asn Trp Val Glu Arg Asn Ser Tyr Ser Cys 260 265 270 Ser Val Val His Glu Gly Leu His Asn His His Thr Thr Lys Ser Phe 275 280 285 Ser Arg Thr Pro Gly Lys 290 <210> 8 <211> 118 <212> PRT <213> Artificial Sequence <220> <223> Synthesized: BCA7, BCA7 - 2C5, BCA7 - 2E1, BCA7 - 2D11, BCA7 - 2G2, BCA7 - 2D8, BCA7 - 2E8 <400> 8 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Ser Ser Thr Ala 20 25 30 Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Gly Arg Ile Lys Ser Lys Ser Asp Gly Gly Thr Thr Asp Tyr Ala Ala 50 55 60 Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr 65 70 75 80 Leu Phe Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr 85 90 95 Tyr Cys Ala Lys Gly Gly Gly Thr Tyr Gly Tyr Trp Gly Gln Gly Thr 100 105 110 Thr Val Thr Val Ser Ser 115 <210> 9 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> Synthesis: BCA7 <400> 9 Ser Tyr Val Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Val Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30 Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu 35 40 45 Met Ile Tyr Asp Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gly Ser Tyr Thr Ser Ser 85 90 95 Gly Ser Tyr Val Phe Gly Thr Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 10 <211> 113 <212> PRT <213> Artificial sequence <220> <223> Synthesis: BC4C9 <400> 10 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Phe Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Asp Ile Asn Trp Val Arg Gln Ala Thr Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Trp Met Asn Pro Asn Ser Gly Asn Thr Gly Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asn Thr Ser Ile Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Ser Gly Leu Gly Glu Trp Gly Gln Gly Thr Leu Val Thr Val Ser 100 105 110 Ser <210> 11 <211> 111 <212> PRT <213> Artificial sequence <220> <223> Synthesis: BC4C9 <400> 11 Gln Ser Val Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Val Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30 Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu 35 40 45 Met Ile Tyr Asp Val Ser Lys Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ile Ser Tyr Ser Ser Ser 85 90 95 Ser Thr Phe Tyr Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu 100 105 110 <210> 12 <211> 117 <212> PRT <213> artificial sequence <220> <223> Composition: BC5C4 <400> 12 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr 20 25 30 Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Gly Ile Ser Trp Asn Ser Gly Ser Ile Gly Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Thr Ile Asp Asn Val Ala Phe His Ser Trp Gly Gln Gly Thr Leu 100 105 110 Val Thr Val Ser Ser 115 <210> 13 <211> 111 <212> PRT <213> Artificial Sequence <220> <223> Synthesis: BC5C4 <400> 13 Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Val Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Ile Gly Gly Tyr 20 25 30 Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu 35 40 45 Ile Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Asp Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Asp Asn 85 90 95 Gly Ala Leu Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 14 <211> 120 <212> PRT <213> Artificial Sequence <220> <223> Synthesis: BC6G8 <400> 14 Gln Val Gln Leu Gln Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Gln 1 5 10 15 Thr Leu Ser Leu Thr Cys Ala Ile Ser Gly Asp Ser Val Ser Ser Asn 20 25 30 Ser Val Gly Trp His Trp Ile Arg Gln Ser Pro Ser Arg Gly Leu Glu 35 40 45 Trp Leu Gly Arg Thr Tyr Tyr Arg Ser Asn Phe Ala Thr Asp Tyr Ala 50 55 60 Ala Ser Val Arg Gly Arg Met Thr Ile Asn Ala Asp Thr Ser Thr Asn 65 70 75 80 Gln Ile Ser Leu His Leu Asn Ser Leu Thr Pro Glu Asp Thr Ala Val 85 90 95 Tyr Tyr Cys Thr Arg Asp Trp Tyr Gly Val Tyr Asp Phe Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 15 <211> 109 <212> PRT <213> Artificial Sequence <220> <223> Synthesis: BC6G8 <400> 15 Ser Tyr Glu Leu Met Gln Pro Pro Ser Val Ser Val Ala Pro Gly Lys 1 5 10 15 Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys Ser Val 20 25 30 His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr 35 40 45 Tyr Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser 50 55 60 Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu Ala Gly 65 70 75 80 Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ser Ser Ser Asp His 85 90 95 Leu Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 <210> 16 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> Synthesis: BCA7-2C5 <400> 16 Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Val Thr Ile Ser Cys Thr Gly Thr Ser Ser Ala His Gly Gly His 20 25 30 Tyr Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu 35 40 45 Met Ile Tyr Asp Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gly Ser Tyr Thr Ser Ser 85 90 95 Gly Ser Tyr Val Phe Gly Thr Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 17 <211> 110 <212> PRT <213> Artificial sequence <220> <223> Synthesis: BCA7 - 2E1 <400> 17 Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Val Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Gly Gly Gly His 20 25 30 Thr Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu 35 40 45 Met Ile Tyr Asp Val Ser Asn Arg Pro Ser Trp Val Ser Asn Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gly Ser Tyr Thr Ser Ser 85 90 95 Gly Ser Tyr Val Phe Gly Thr Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 18 <211> 110 <212> PRT <213> Artificial sequence <220> <223> Synthesis: BCA7 - 2D11 <400> 18 Ser Tyr Glu Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Val Thr Ile Ser Cys Thr Gly Thr Ser Ser Val Val Gly Gly His 20 25 30 Asp Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu 35 40 45 Met Ile Tyr Asp Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gly Ser Tyr Thr Ser Ser 85 90 95 Gly Ser Tyr Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu 100 105 110 <210> 19 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> Synthesis: BCA7-2G2 <400> 19 Gln Ser Val Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Val Thr Ile Ser Cys Thr Gly Thr Ser Ser Ser Val Gly Gly Arg 20 25 30 Gln Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu 35 40 45 Met Ile Tyr Asp Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gly Ser Tyr Thr Ser Ser 85 90 95 Gly Ser Tyr Val Phe Gly Thr Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 20 <211> 110 <212> PRT <213> artificial sequence <220> <223> Synthesis: BCA7-2D8 <400> 20 Gln Ser Val Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Val Thr Ile Ser Cys Thr Gly Thr Ser Ser Ser Ile Gly Asp Ser 20 25 30 Tyr Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu 35 40 45 Met Ile Tyr Asp Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gly Ser Tyr Thr Ser Ser 85 90 95 Gly Ser Tyr Val Phe Gly Thr Gly Thr Thr Leu Thr Val Leu 100 105 110 <210> 21 <211> 110 <212> PRT <213> artificial sequence <220> <223> synthesis: BCA7-2E8 <400> 21 Gln Ser Val Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Val Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30 Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu 35 40 45 Met Ile Tyr Asp Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gly Ser Leu Arg Ser Asn 85 90 95 Gly Asp Tyr Val Phe Gly Thr Gly Thr Thr Leu Thr Val Leu 100 105 110 <210> 22 <211> 448 <212> PRT <213> Artificial Sequence <220> <223> Synthesis: BCA7 - 2C5 (IgG1 SPPC) <400> 22 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Ser Ser Thr Ala 20 25 30 Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Gly Arg Ile Lys Ser Lys Ser Asp Gly Gly Thr Thr Asp Tyr Ala Ala 50 55 60 Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr 65 70 75 80 Leu Phe Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr 85 90 95 Tyr Cys Ala Lys Gly Gly Gly Thr Tyr Gly Tyr Trp Gly Gln Gly Thr 100 105 110 Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro 115 120 125 Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly 130 135 140 Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn 145 150 155 160 Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln 165 170 175 Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser 180 185 190 Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser 195 200 205 Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr 210 215 220 His Thr Ser Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser 225 230 235 240 Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 245 250 255 Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro 260 265 270 Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 275 280 285 Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val 290 295 300 Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 305 310 315 320 Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr 325 330 335 Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu 340 345 350 Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys 355 360 365 Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 370 375 380 Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 385 390 395 400 Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 405 410 415 Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 420 425 430 Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 435 440 445 <210> 23 <211> 216 <212> PRT <213> artificial sequence <220> <223> synthesis:BCA7-2C5(λ) <400> 23 Gln Ser Val Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Val Thr Ile Ser Cys Thr Gly Thr Ser Ser Ala His Gly Gly His 20 25 30 Tyr Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu 35 40 45 Met Ile Tyr Asp Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gly Ser Tyr Thr Ser Ser 85 90 95 Gly Ser Tyr Val Phe Gly Thr Gly Thr Lys Leu Thr Val Leu Gly Gln 100 105 110 Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu 115 120 125 Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr 130 135 140 Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys 145 150 155 160 Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr 165 170 175 Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His 180 185 190 Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys 195 200 205 Thr Val Ala Pro Thr Glu Cys Ser 210 215 <210> 24 <211> 121 <212> PRT <213> Artificial Sequence <220> <223> Synthesis: J6M0 GSK anti - BCMA Ab <400> 24 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Asn Tyr 20 25 30 Trp Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Ala Thr Tyr Arg Gly His Ser Asp Thr Tyr Tyr Asn Gln Lys Phe 50 55 60 Lys Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Ala Ile Tyr Asp Gly Tyr Asp Val Leu Asp Asn Trp Gly 100 105 110 Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 25 <211> 107 <212> PRT <213> Artificial Sequence <220> <223> Synthesis: J6M0 GSK anti - BCMA Ab <400> 25 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Gln Asp Ile Ser Asn Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Tyr Thr Ser Asn Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Arg Lys Leu Pro Trp 85 90 95 Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 26 <211> 117 <212> PRT <213> Artificial Sequence <220> <223> Synthesis: C11D5 BB anti - BCMA Ab <400> 26 Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu 1 5 10 15 Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr 20 25 30 Ser Ile Asn Trp Val Lys Arg Ala Pro Gly Lys Gly Leu Lys Trp Met 35 40 45 Gly Trp Ile Asn Thr Glu Thr Arg Glu Pro Ala Tyr Ala Tyr Asp Phe 50 55 60 Arg Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr 65 70 75 80 Leu Gln Ile Asn Asn Leu Lys Tyr Glu Asp Thr Ala Thr Tyr Phe Cys 85 90 95 Ala Leu Asp Tyr Ser Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Thr 100 105 110 Leu Thr Val Ser Ser 115 <210> 27 <211> 111 <212> PRT <213> Artificial Sequence <220> <223> Synthesis: C11D5 BB anti - BCMA Ab <400> 27 Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Met Ser Leu Gly 1 5 10 15 Lys Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser Val Ser Val Ile 20 25 30 Gly Ala His Leu Ile His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro 35 40 45 Lys Leu Leu Ile Tyr Leu Ala Ser Asn Leu Glu Thr Gly Val Pro Ala 50 55 60 Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Asp 65 70 75 80 Pro Val Glu Glu Asp Asp Val Ala Ile Tyr Ser Cys Leu Gln Ser Arg 85 90 95 Ile Phe Pro Arg Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 110 <210> 28 <211> 8 <212> PRT <213> Artificial sequence <220> <223> Synthesis: Peptide <400> 28 Glu Tyr Phe Asp Ser Leu Leu His 1 5 <210> 29 <211> 5 <212> PRT <213> Artificial sequence <220> <223> Synthesis: BCA7 (VH CDR1) <400> 29 Thr Ala Trp Met Ser 1 5 <210> 30 <211> 19 <212> PRT <213> Artificial sequence <220> <223> Synthesis: BCA7 (VH CDR2) <400> 30 Arg Ile Lys Ser Lys Ser Asp Gly Gly Thr Thr Asp Tyr Ala Ala Pro 1 5 10 15 Val Lys Gly <210> 31 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Synthesis: BCA7 (VH CDR3) <400> 31 Gly Gly Gly Thr Tyr Gly Tyr 1 5 <210> 32 <211> 14 <212> PRT <213> Artificial sequence <220> <223> Synthesis: BCA7 (VL CDR1) <400> 32 Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser 1 5 10 <210> 33 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Synthesis: BCA7 (VL CDR2) <400> 33 Asp Val Ser Asn Arg Pro Ser 1 5 <210> 34 <211> 10 <212> PRT <213> Artificial sequence <220> <223> Synthetic: BCA7 (VL CDR3) <400> 34 Gly Ser Tyr Thr Ser Ser Gly Ser Tyr Val 1 5 10 <210> 35 <211> 5 <212> PRT <213> Artificial sequence <220> <223> Synthesis: BC4C9 (VH CDR1) <400> 35 Ser Tyr Asp Ile Asn 1 5 <210> 36 <211> 17 <212> PRT <213> Artificial sequence <220> <223> Synthesis: BC4C9 (VH CDR2) <400> 36 Trp Met Asn Pro Asn Ser Gly Asn Thr Gly Tyr Ala Gln Lys Phe Gln 1 5 10 15 Gly <210> 37 <211> 4 <212> PRT <213> Artificial sequence <220> <223> Synthesis: BC4C9 (VH CDR3) <400> 37 Gly Leu Gly Glu 1 <210> 38 <211> 14 <212> PRT <213> Artificial sequence <220> <223> Synthesis: BC4C9 (VL CDR1) <400> 38 Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser 1 5 10 <210> 39 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Synthesis: BC4C9 (VL CDR2) <400> 39 Asp Val Ser Lys Arg Pro Ser 1 5 <210> 40 <211> 11 <212> PRT <213> Artificial sequence <220> <223> Synthesis: BC4C9 (VL CDR3) <400> 40 Ile Ser Tyr Ser Ser Ser Ser Ser Thr Phe Tyr Val 1 5 10 <210> 41 <211> 5 <212> PRT <213> Artificial sequence <220> <223> Synthesis: BC5C4 (VH CDR1) <400> 41 Asp Tyr Ala Met His 1 5 <210> 42 <211> 17 <212> PRT <213> Artificial sequence <220> <223> Synthesis: BC5C4 (VH CDR2) <400> 42 Gly Ile Ser Trp Asn Ser Gly Ser Ile Gly Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 43 <211> 8 <212> PRT <213> Artificial sequence <220> <223> Synthesis: BC5C4 (VH CDR3) <400> 43 Ile Asp Asn Val Ala Phe His Ser 1 5 <210> 44 <211> 14 <212> PRT <213> Artificial sequence <220> <223> Synthesis: BC5C4 (VL CDR1) <400> 44 Thr Gly Thr Ser Ser Asp Ile Gly Gly Tyr Asn Tyr Val Ser 1 5 10 <210> 45 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Synthesis: BC5C4 (VL CDR2) <400> 45 Glu Val Ser Asn Arg Pro Ser 1 5 <210> 46 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Synthesis: BC5C4 (VL CDR3) <400> 46 Glu Val Ser Asn Arg Pro Ser 1 5 <210> 47 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Synthesis: BC6G8 (VH CDR1) <400> 47 Ser Asn Ser Val Gly Trp His 1 5 <210> 48 <211> 18 <212> PRT <213> Artificial sequence <220> <223> Synthesis: BC6G8 (VH CDR2) <400> 48 Arg Thr Tyr Tyr Arg Ser Asn Phe Ala Thr Asp Tyr Ala Ala Ser Val 1 5 10 15 Arg Gly <210> 49 <211> 8 <212> PRT <213> Artificial sequence <220> <223> Synthesis: BC6G8 (VH CDR3) <400> 49 Asp Trp Tyr Gly Val Tyr Asp Phe 1 5 <210> 50 <211> 11 <212> PRT <213> Artificial sequence <220> <223> Synthesis: BC6G8 (VL CDR1) <400> 50 Gly Gly Asn Asn Ile Gly Ser Lys Ser Val His 1 5 10 <210> 51 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Synthesis: BC6G8 (VL CDR2) <400> 51 Tyr Asp Ser Asp Arg Pro Ser 1 5 <210> 52 <211> 12 <212> PRT <213> Artificial sequence <220> <223> Synthesis: BC6G8 (VL CDR3) <400> 52 Gln Val Trp Asp Ser Ser Ser Asp His Leu Val Val 1 5 10 <210> 53 <211> 5 <212> PRT <213> Artificial sequence <220> <223> Synthesis: BCA7-2C5 (VH CDR1) <400> 53 Thr Ala Trp Met Ser 1 5 <210> 54 <211> 19 <212> PRT <213> Artificial sequence <220> <223> Synthesis: BCA7-2C5 (VH CDR2) <400> 54 Arg Ile Lys Ser Lys Ser Asp Gly Gly Thr Thr Asp Tyr Ala Ala Pro 1 5 10 15 Val Lys Gly <210> 55 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Synthesis: BCA7-2C5 (VH CDR3) <400> 55 Gly Gly Gly Thr Tyr Gly Tyr 1 5 <210> 56 <211> 14 <212> PRT <213> Artificial sequence <220> <223> Synthesis: BCA7-2C5 (VL CDR1) <400> 56 Thr Gly Thr Ser Ser Ala His Gly Gly His Tyr Tyr Val Ser 1 5 10 <210> 57 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Synthesis: BCA7-2C5 (VL CDR2) <400> 57 Asp Val Ser Asn Arg Pro Ser 1 5 <210> 58 <211> 10 <212> PRT <213> Artificial sequence <220> <223> Synthesis: BCA7-2C5 (VL CDR3) <400> 58 Gly Ser Tyr Thr Ser Ser Gly Ser Tyr Val 1 5 10 <210> 59 <211> 5 <212> PRT <213> Artificial sequence <220> <223> Synthesis: BCA7-2E1 (VH CDR1) <400> 59 Thr Ala Trp Met Ser 1 5 <210> 60 <211> 19 <212> PRT <213> Artificial sequence <220> <223> Synthesis: BCA7-2E1 (VH CDR2) <400> 60 Arg Ile Lys Ser Lys Ser Asp Gly Gly Thr Thr Asp Tyr Ala Ala Pro 1 5 10 15 Val Lys Gly <210> 61 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Synthesis: BCA7-2E1 (VH CDR3) <400> 61 Gly Gly Gly Thr Tyr Gly Tyr 1 5 <210> 62 <211> 14 <212> PRT <213> Artificial sequence <220> <223> Synthesis: BCA7-2E1 (VL CDR1) <400> 62 Thr Gly Thr Ser Ser Asp Gly Gly Gly His Thr Tyr Val Ser 1 5 10 <210> 63 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Synthesis: BCA7-2E1 (VL CDR2) <400> 63 Asp Val Ser Asn Arg Pro Ser 1 5 <210> 64 <211> 10 <212> PRT <213> Artificial sequence <220> <223> Synthesis: BCA7-2E1 (VL CDR3) <400> 64 Gly Ser Tyr Thr Ser Ser Gly Ser Tyr Val 1 5 10 <210> 65 <211> 5 <212> PRT <213> Artificial sequence <220> <223> Synthesis: BCA7-2D11 (VH CDR1) <400> 65 Thr Ala Trp Met Ser 1 5 <210> 66 <211> 19 <212> PRT <213> Artificial sequence <220> <223> Synthesis: BCA7-2D11 (VH CDR2) <400> 66 Arg Ile Lys Ser Lys Ser Asp Gly Gly Thr Thr Asp Tyr Ala Ala Pro 1 5 10 15 Val Lys Gly <210> 67 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Synthesis: BCA7-2D11 (VH CDR3) <400> 67 Gly Gly Gly Thr Tyr Gly Tyr 1 5 <210> 68 <211> 14 <212> PRT <213> Artificial sequence <220> <223> Synthesis: BCA7-2D11 (VL CDR1) <400> 68 Thr Gly Thr Ser Ser Val Val Gly Gly His Asp Tyr Val Ser 1 5 10 <210> 69 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Synthesis: BCA7-2D11 (VL CDR2) <400> 69 Asp Val Ser Asn Arg Pro Ser 1 5 <210> 70 <211> 10 <212> PRT <213> Artificial sequence <220> <223> Synthesis: BCA7-2D11 (VL CDR3) <400> 70 Gly Ser Tyr Thr Ser Ser Gly Ser Tyr Val 1 5 10 <210> 71 <211> 5 <212> PRT <213> Artificial sequence <220> <223> Synthesis: BCA7-2G2 (VH CDR1) <400> 71 Thr Ala Trp Met Ser 1 5 <210> 72 <211> 19 <212> PRT <213> Artificial sequence <220> <223> Synthesis: BCA7-2G2 (VH CDR2) <400> 72 Arg Ile Lys Ser Lys Ser Asp Gly Gly Thr Thr Asp Tyr Ala Ala Pro 1 5 10 15 Val Lys Gly <210> 73 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Synthesis: BCA7-2G2 (VH CDR3) <400> 73 Gly Gly Gly Thr Tyr Gly Tyr 1 5 <210> 74 <211> 14 <212> PRT <213> Artificial sequence <220> <223> Synthesis: BCA7-2G2 (VL CDR1) <400> 74 Thr Gly Thr Ser Ser Ser Val Gly Gly Arg Gln Tyr Val Ser 1 5 10 <210> 75 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Synthesis: BCA7-2G2 (VL CDR2) <400> 75 Asp Val Ser Asn Arg Pro Ser 1 5 <210> 76 <211> 10 <212> PRT <213> Artificial sequence <220> <223> Synthesis: BCA7-2G2 (VL CDR3) <400> 76 Gly Ser Tyr Thr Ser Ser Gly Ser Tyr Val 1 5 10 <210> 77 <211> 5 <212> PRT <213> Artificial sequence <220> <223> Synthesis: BCA7-2D8 (VH CDR1) <400> 77 Thr Ala Trp Met Ser 1 5 <210> 78 <211> 19 <212> PRT <213> Artificial sequence <220> <223> Synthesis: BCA7-2D8 (VH CDR2) <400> 78 Arg Ile Lys Ser Lys Ser Asp Gly Gly Thr Thr Asp Tyr Ala Ala Pro 1 5 10 15 Val Lys Gly <210> 79 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Synthesis: BCA7-2D8 (VH CDR3) <400> 79 Gly Gly Gly Thr Tyr Gly Tyr 1 5 <210> 80 <211> 14 <212> PRT <213> Artificial sequence <220> <223> Synthesis: BCA7-2D8 (VL CDR1) <400> 80 Thr Gly Thr Ser Ser Ser Ile Gly Asp Ser Tyr Tyr Val Ser 1 5 10 <210> 81 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Synthesis: BCA7-2D8 (VL CDR2) <400> 81 Asp Val Ser Asn Arg Pro Ser 1 5 <210> 82 <211> 10 <212> PRT <213> Artificial sequence <220> <223> Synthesis: BCA7-2D8 (VL CDR3) <400> 82 Gly Ser Tyr Thr Ser Ser Gly Ser Tyr Val 1 5 10 <210> 83 <211> 5 <212> PRT <213> Artificial sequence <220> <223> Synthesis: BCA7-2E8 (VH CDR1) <400> 83 Thr Ala Trp Met Ser 1 5 <210> 84 <211> 19 <212> PRT <213> Artificial sequence <220> <223> Synthesis: BCA7-2E8 (VH CDR2) <400> 84 Arg Ile Lys Ser Lys Ser Asp Gly Gly Thr Thr Asp Tyr Ala Ala Pro 1 5 10 15 Val Lys Gly <210> 85 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Synthesis: BCA7-2E8 (VH CDR3) <400> 85 Gly Gly Gly Thr Tyr Gly Tyr 1 5 <210> 86 <211> 14 <212> PRT <213> Artificial sequence <220> <223> Synthesis: BCA7-2E8 (VL CDR1) <400> 86 Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser 1 5 10 <210> 87 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Synthesis: BCA7-2E8 (VL CDR2) <400> 87 Asp Val Ser Asn Arg Pro Ser 1 5 <210> 88 <211> 10 <212> PRT <213> Artificial sequence <220> <223> Synthesis: BCA7-2E8 (VL CDR3) <400> 88 Gly Ser Leu Arg Ser Asn Gly Asp Tyr Val 1 5 10 <210> 89 <211> 14 <212> PRT <213> Artificial sequence <220> <223> Synthesis: BCA7-2C5 (VL λ CDR1) <400> 89 Thr Gly Thr Ser Ser Ala His Gly Gly His Tyr Tyr Val Ser 1 5 10 <210> 90 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Synthesis: BCA7-2C5 (VL λ CDR2) <400> 90 Asp Val Ser Asn Arg Pro Ser 1 5 <210> 91 <211> 10 <212> PRT <213> Artificial sequence <220> <223> Synthesis: BCA7-2C5 (VL λ CDR3) <400> 91 Gly Ser Tyr Thr Ser Ser Gly Ser Tyr Val 1 5 10 <210> 92 <211> 184 <212> PRT <213> Homo sapiens <220> <221> misc_feature <223> Wild-type human BCMA protein <400> 92 Met Leu Gln Met Ala Gly Gln Cys Ser Gln Asn Glu Tyr Phe Asp Ser 1 5 10 15 Leu Leu His Ala Cys Ile Pro Cys Gln Leu Arg Cys Ser Ser Asn Thr 20 25 30 Pro Pro Leu Thr Cys Gln Arg Tyr Cys Asn Ala Ser Val Thr Asn Ser 35 40 45 Val Lys Gly Thr Asn Ala Ile Leu Trp Thr Cys Leu Gly Leu Ser Leu 50 55 60 Ile Ile Ser Leu Ala Val Phe Val Leu Met Phe Leu Leu Arg Lys Ile 65 70 75 80 Asn Ser Glu Pro Leu Lys Asp Glu Phe Lys Asn Thr Gly Ser Gly Leu 85 90 95 Leu Gly Met Ala Asn Ile Asp Leu Glu Lys Ser Arg Thr Gly Asp Glu 100 105 110 Ile Ile Leu Pro Arg Gly Leu Glu Tyr Thr Val Glu Glu Cys Thr Cys 115 120 125 Glu Asp Cys Ile Lys Ser Lys Pro Lys Val Asp Ser Asp His Cys Phe 130 135 140 Pro Leu Pro Ala Met Glu Glu Gly Ala Thr Ile Leu Val Thr Thr Lys 145 150 155 160 Thr Asn Asp Tyr Cys Lys Ser Leu Pro Ala Ala Leu Ser Ala Thr Glu 165 170 175 Ile Glu Lys Ser Ile Ser Ala Arg 180

Claims

1. A fully human anti-BCMA antibody or an antigen-binding fragment thereof, comprising a heavy chain and a light chain, wherein the heavy chain comprises a heavy chain variable region (VH), and the light chain comprises a light chain variable region (VL), Wherein the VH comprises: a heavy chain CDR1 of the amino acid sequence of SEQ ID NO:53, a heavy chain CDR2 of the amino acid sequence of SEQ ID NO:54, and a heavy chain CDR3 of the amino acid sequence of SEQ ID NO:55; and the VL comprises: a light chain CDR1 of the amino acid sequence of SEQ ID NO:56, a light chain CDR2 of the amino acid sequence of SEQ ID NO:57, and a light chain CDR3 of the amino acid sequence of SEQ ID NO:

58.

2. An anti-BCMA Fab fragment, comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein VH comprises a heavy chain CDR1 of the amino acid sequence of SEQ ID NO: 53, a heavy chain CDR2 of the amino acid sequence of SEQ ID NO: 54, and a heavy chain CDR3 of the amino acid sequence of SEQ ID NO: 55; and the VL comprises a light chain CDR1 of the amino acid sequence of SEQ ID NO: 56, a light chain CDR2 of the amino acid sequence of SEQ ID NO: 57, and a light chain CDR3 of the amino acid sequence of SEQ ID NO:

58.

3. An anti-BCMA single-chain antibody, comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein VH comprises a heavy chain CDR1 of the amino acid sequence of SEQ ID NO: 53, a heavy chain CDR2 of the amino acid sequence of SEQ ID NO: 54, and a heavy chain CDR3 of the amino acid sequence of SEQ ID NO: 55; and the VL comprises a light chain CDR1 of the amino acid sequence of SEQ ID NO: 56, a light chain CDR2 of the amino acid sequence of SEQ ID NO: 57, and a light chain CDR3 of the amino acid sequence of SEQ ID NO:

58.

4. An anti-BCMA antibody or an antigen-binding fragment thereof, comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the amino acid sequence of the VH is SEQ ID NO: 8 and the amino acid sequence of the VL is SEQ ID NO:

16.

5. An anti-BCMA Fab fragment comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the amino acid sequence of the VH is SEQ ID NO: 8 and the amino acid sequence of the VL is SEQ ID NO:

16.

6. An anti-BCMA single-chain antibody comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the amino acid sequence of the VH is SEQ ID NO: 8 and the amino acid sequence of the VL is SEQ ID NO:

16.

7. The antibody or antigen-binding fragment according to claim 1 or 4, which comprises an antibody of the IgG1, IgG2, IgG3 or IgG4 class.

8. The antibody or antigen-binding fragment according to any one of claims 1 to 6, which blocks the binding between APRIL protein and BCMA protein.

9. The antibody or antigen-binding fragment according to any one of claims 1 to 6, which binds to BCMA protein from humans, cynomolgus monkeys and mice.

10. The antibody or antigen-binding fragment of any one of claims 1 to 6, which binds to cells expressing BCMA protein.

11. The antibody or antigen-binding fragment of any one of claims 1 to 6, which binds to human myeloma cells expressing BCMA protein.

12. A pharmaceutical composition comprising the antibody or antigen-binding fragment according to any one of claims 1 to 11 and a pharmaceutically acceptable excipient.

13. One or more nucleic acids encoding the antibody or antigen-binding fragment of any one of claims 1 to 11.

14. A host cell carrying one or more expression vectors according to claim 13.

15. A method for preparing a first polypeptide comprising an antibody heavy chain variable region and a second polypeptide comprising an antibody light chain variable region or an antibody or antigen-binding fragment, the method comprising: The population of host cells according to claim 14 is cultured under conditions suitable for expressing the first polypeptide and the second polypeptide or the antibody or the antigen-binding fragment.

16. The method according to claim 15, further comprising: The expressed first polypeptide and the expressed second polypeptide or the expressed antibody or antigen-binding fragment are recovered.

Citation Information

Patent Citations

  • Polyethylene glycol derivatives, their modified peptides, methods for producing them and use of the modified peptides

    EP0473084A2

  • Direct screening method

    US20030039958A1

  • Concatenated nucleic acid sequence

    US20040009507A1

  • Method to screen phage display libraries with different ligands

    US20040038291A2

  • Nucleic acids, proteins, and screening methods

    US20040202995A1